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T he role of the innate immune system 
in the pathogenesis of IBD
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MC–Sophia Children’s Hospital, Rotterdam, the Netherlands
2. Wilhelmina Children’s Hospital, Utrecht University Medical Center, Utrecht, the 
Netherlands
Parts of this review have been published in:
Van Lierop et al., NtVA 2005, Vol 5. Nr 4. Page 136 – 141
Van Lierop et al., JPGN 2009, Vol 48. Nr 2. Page 142-151
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INTESTINAL HOMEOSTASIS
In 1676 Antonie van Leeuwenhoek discovered small one-cell consisting microorgan-
isms. These “animalcules”, as van Leeuwenhoek called his discovery, are now known 
as bacteria and are as old as 4 billion years. In the human intestine an ecosystem has 
developed in which bacteria and eukaryotic cells live in a mutual benefi cial relationship. 
The intestinal tract is colonized with over 1014 bacteria and over 400 species. These com-
mensal bacteria live in symbiosis with the human species, helping with the extraction of 
nutrients from ingested food and suppressing the growth of pathogenic counterparts.1, 2
In order to maintain intestinal homeostasis, the mucosal immune system plays a 
crucial role. On the one hand the immune system has to recognize invading patho-
genic bacteria and mount appropriate pro-infl ammatory immune responses in order 
to protect the host from these bacteria. On the other hand, extensive pro-infl ammatory 
immune responses have to be restricted to pathogens only. In turn, an aberrant immune 
response upon for example food antigens (celiac disease) or commensal bacteria (In-
fl ammatory Bowel Disease (IBD)) could lead to tissue damage and chronic infl ammation.
INFLAMMATORY BOWEL DISEASE
IBD is described as a chronic infl ammatory response of the gastrointestinal tract with 
a prevalence of roughly 5-15 per 100.000.3 To date IBD includes two disease entities: 
Crohn’s disease (CD) and ulcerative colitis (UC). CD was described for the fi rst time as 
regional ileitis in 1932 by Crohn, Ginzburg and Oppenheimer in New York. Around the 
same time, reports on UC were published by Lockhart-Mummery in London.
CD and UC are distinguished based upon clinical and histopathological diff erences. 
Although these two entities diff er in multiple ways (e.g. phenotype and drug respon-
siveness) both diseases are thought to result from an aberrant immune response to 
commensal bacteria. Therefore CD and UC could well be part of a broad spectrum of 
intestinal infl ammatory conditions.
Traditionally, exaggerated responses by mucosal T- and B-cells (the adaptive immune 
system) have been regarded as the key contributors to the pathogenesis of IBD.4 The 
recent discovery however, of innate defects that are associated with IBD have refocused 
the attention to this arm of the immune system.5, 6 The innate immune system plays a 
crucial role in the development of IBD. Cells of this immune system are the fi rst that 
come in contact with the microbiota in the intestinal lumen.
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MICROBIOTA:
Bacterial host cross-talk
The human intestine contains about 1014 micro-organisms that critically contribute to 
tissue homeostasis, host metabolism and other benefi cial processes. On the other hand, 
it has been shown that IBD may, in contrast, result from aberrant cross talk between the 
mucosal immune system and this vast population of commensal bacteria.7
IBD as infectious disease
The fi rst reports of diseases suggestive of IBD contained descriptions of a condition 
named hyperplastic tuberculosis of the intestine. Subsequently, various case reports 
were published on patients suff ering from what was believed to be intestinal tubercu-
losis, but acid-fast organisms could not be isolated.8 To date, stating that IBD is caused 
by a pathogenic microorganism is at least controversial. Amongst the many proposed 
pathogens, Mycobacterium avium paratuberculosis (MAP) has gained some support.9-11 
MAP was originally identifi ed in cows suff ering from an intestinal infl ammation called 
Johne’s disease that shows histopathological similarities with Crohn’s disease. Although 
the association of MAP with CD has gained support, a causative role for MAP in the 
CD pathogenesis has not been established. Specifi cally, it can be argued that MAP is a 
secondary invader rather than a true pathogen.12-14
Along the same lines, other microorganisms such as paramyxovirus (measles), Chla-
mydia spp., Escherichia coli, Saccharomyces cerevisiae, Listeria monocytogenes and Helico-
bacter spp. have been implicated in part, based on the detection of specifi c antibodies 
(Table 1).15-30 More in particular, an increase of adhesive and invasive of E. coli strains has 
been associated with CD.21, 31, 32 Enhanced invasiveness may result from the expression 
of certain microbial components such as fl agellin.33 Moreover, fl agellin has been identi-
fi ed as a microbially derived immunodominant antigen that is associated with CD and 
is involved in intestinal infl ammation in various mouse models.34-38 In analogy with the 
distinct association between Helicobacter pylori and peptic ulcer disease, many attempts 
have been made to establish a similar mucosal paradigm for IBD. Based on the available 
data however, it seems more likely that these diseases do not result from primary infec-
tions but that microbial invasion and subsequent immune responses are secondary to 
infl ammation and intestinal barrier disruption.39
A role for non-pathogenic luminal microbiota
It has been widely accepted that luminal microbiota play an important role in the 
pathogenesis of IBD (fi gure 1). Substantiation comes from various IBD-animal models 
that are dependent on intestinal colonization.40-43 In humans, surgical deviation of in-
fl amed intestine has shown to ameliorate infl ammation that is thought to result from 
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diminished microbial exposure.44 Further support comes from the apparent effi  cacy of 
certain antibiotics in the treatment of IBD.45-48
Colitogenic vs. protective microbial strains
Although no specifi c pathogens have been isolated and mucosal responses seem to be 
directed towards a wide range of microbial antigens, the question remains whether spe-
cifi c groups of bacteria are still important in the pathogenesis of IBD. On the other hand, 
it seems likely that certain bacteria or bacterial factors are important for the induction of 
tolerance and therefore protection from infl ammation. In certain animal models, various 
segmented fi lamentous bacteria fail to induce colitis whereas in contrast, colonization 
with Helicobacter muridarum results in an accelerated development of IBD.49 In other 
models it was shown that the phenotype of intestinal infl ammation depends on the 
species of commensal bacteria that were used. Furthermore, it was shown that the loca-
tion of disease depends on the specifi c bacterial strain that is used for colonization.50 
Table 1, IBD associated microbiota and antibodies
Partly adapted from 173
Bacteria Reference:
Mycobacterium avium paratuberculosis 9-11, 174, 175
Listeria monocytogenes 23, 176
Escherichia. Coli 20-27, 177 
Enterotoxigenic Bacteroides fragilis 178-180
Klebsiella oxytoca 181
Pseudomonas maltophilia 182, 183
Chlamydia spp. 17-19, 184
Streptococci spp. 23
Helicobacter spp 30, 49
Yersinia pseudotuberculosis 185
Cytomegalovirus 28
Saccharomyces cerevisiae 29
Paramyxovirus 15, 16
Mycoplasma pneumoniae 17
Coxiella burnetii 17
Antibodies: Reference:
Saccharomyces cerevisiae (gASCA) 186-188
Klebsiella pneumoniae 189, 190
Outer membrane porins (OmpC) 186, 191, 192
Pseudomonas
fl uorescens-associated sequence I2 (anti-I2)
193, 194
Flagellin (CBir1) 34-38
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Molecular techniques now enable us to characterize microbiota in fecal streams and 
colonic biopsy specimens. New fi ndings however, have greatly complicated this fi eld of 
research; as such, it has been established that bacteria are very capable of altering the 
expression of capsule polysaccharides that are directly associated with immunogenic-
ity.51, 52 In other words, a specifi c microbe may suppress the immune system under certain 
conditions53, 54, while a genetically identical microorganism may lead to infl ammation in 
other circumstances.46,  55 The driving force behind this microbial adaptation may well 
be the host immune system itself as has been shown recently.46 In these mouse studies, 
luminal microbes attained a colitogenic phenotype in a genetically susceptible host. 
Intriguingly, these bacteria could now provoke colitis in naïve animals.46 These studies 
may in fact suggest that in IBD patients, we should treat the microbes along with the 
immune system.
Finally, there is the issue of the use of probiotics as IBD treatment, based on the con-
cept that the assumed disbalance between pathogenic and commensal bacteria could 
be restored with the administration of these bacteria. Although some progress has been 
made into understanding the working mechanisms56 and some effi  cacy has been seen 
in certain IBD patients.57-60 Much more research is needed before these interventions can 
be applied in large patient cohorts. The fact that certain microbial fermentation prod-
ucts such as butyrate can suppress infl ammation through inhibition of NF-кB activation, 
may eventually lead to the discovery of certain specifi c benefi cial microbial species.61-64
Figure 1. The role of the microbiota and the innate immune system in the pathogenesis of IBD
Commensal bacteria can evoke immune responses via TLR or NOD signaling. Innate cells respond 
through the production of cytokines and chemokines to attract other immune cells (e.g. neutrophils, 
macrophages). Dendritic cells can sample bacteria and activate T and B cells. For each level of this 
paradigm both protective as well as contributive mechanisms are discussed.
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PATTERN RECOGNITION RECEPTORS
Sensing luminal microbes
Pattern recognition receptors (PRR) such as toll-like receptors (TLR) continuously rec-
ognize bacteria (fi gure 1). Subsequently, activation of PRR mediated pathways leads to 
chemokine and cytokine production by immune cells or production of antimicrobial 
molecules by Paneth cells.
TLR are transmembrane proteins which contain a leucine-rich domain and a conserved 
cytoplasmic domain.65 TLR activation results in nuclear translocation and activation of 
the pro-infl ammatory transcriptionfactor NF-κB that is associated with the production 
of mediators. 66-68 Moreover, in antigen presenting cells (e.g. dendritic cells), TLR signal-
ing leads to the induction of co-stimulatory molecules and subsequent activation of 
adaptive immune cells such as T-lymphocytes.65 In turn, activated T cells can exert their 
function e.g. cytokine production.
Nucleotide-binding oligomerization domain (NOD) or Catterpillar receptors are intra-
cellular receptors that can trigger similar NF-κB dependent pathways. Microbial muramyl 
dipeptide (MDP), the smallest bioactive component of peptidoglycan (PGN) that is a 
component of all bacteria, has been identifi ed as the specifi c ligand for NOD2.69, 70 Diff er-
ent mutations in the NOD2 gene, located on chromosome 16q12, have been shown to 
associate with CD. Specifi cally, NOD2-mutations are thought to alter the susceptibility 
and location of the disease.5, 6, 71-73
Recently, a third class of PRRs has been identifi ed: the infl ammasome. The infl amma-
some is an intracellular protein complex that initiates the release of caspase-1. In con-
cert with NF-κB phosphorylation upon TLR signaling, activation of the infl ammasome 
will result in secretion of the pro-infl ammatory cytokines IL-1β and IL-18.74, 75 One of the 
key constituents of the infl ammasome is the NALP3 molecule and NALP3-mutations 
are associated with infl ammatory disease.76, 77 Interestingly, fl agellin was identifi ed as a 
specifi c ligand for NALP3 reiterating the potential importance of this specifi c microbial 
ligand for infl ammation.
The exact function and interactions of all these PRRs, and how signaling through 
these receptors eventually leads to an increased and chronic infl ammatory responses 
is strongly debated.78 In short, it is not known how these ligands actually reach their 
respective PRRs and what would be the net eff ect of activation of various receptors at 
the same time. A fi rst step will be the identifi cation of specifi c cellular receptors and 
transporters that mediate the uptake of the microbial ligands and assess if they are 
involved in the IBD pathogenesis.
Pieter BW.indd   13 15-Jul-10   16:49:03 PM
14 Chapter 1
LOSS OR GAIN OF INNATE IMMUNE FUNCTION:
To date, two main hypotheses address how defects in the innate immune system could 
contribute to the IBD pathogenesis:
I: Loss of function: upon recognition of microbial ligands there is a diminished respon-
siveness, i.e. less production of mediators such as chemokines and cytokines. In turn, 
this will lead to suboptimal recruitment and function of innate cells such as neutrophils 
and macrophages. In this condition, otherwise harmless commensal microbiota will 
increasingly penetrate and translocate the intestinal mucosa. Finally, this will lead to 
chronic attraction and activation of adaptive immune cells e.g. B- and T-lymphocytes, 
thus chronic infl ammation.
II: Gain of function: defects in innate cells will lead to hyper-responsiveness upon 
microbial stimulation. In this case, despite normal levels of ligand availability, excessive 
chemokine production will directly cause infl ammation by recruited innate (e.g. neutro-
phils and macrophages) and adaptive cells (e.g. B and T cells).
Before assessing the actual contribution of these two functional innate defects to the 
IBD pathogenesis we will fi rst address the principles of microbial sensing:
Regulating PRR sensitivity: ligand exposure and PRR expression
Theoretically, activation of PRRs depends on the availability of ligands and can be con-
trolled by altering receptor expression or through the induction of various intracellular 
regulators.79 Intestinal epithelium expresses low amounts of TLR at the apical surface 
under healthy conditions.80-86 An altered expression of TLR3 and 4 has been suggested 
in IBD and for some murine colitis models. As such, TLR4 was described to be upregu-
lated, whereas cytoplasmic TLR3 was downregulated in active CD.81, 87 As TLR5 is mainly 
expressed at the basolateral side of colonic epithelial cells, activation of this receptor 
may depend on regulation of the exposure to its ligand fl agellin. Indeed, expression 
of TLR5 by the IEC seems to remain unchanged in IBD but disruption of the integrity 
of the epithelial barrier during IBD can lead to an enhanced translocation of fl agellin 
and subsequent cellular activation. In addition, fl agellin exposure after disruption of the 
epithelial barrier in murine models indeed results in an exacerbation of colitis.85, 88-92
Regulating PRR sensitivity: expression of regulators
A next step for the regulation of PRR sensitivity is through the production of intracellular 
regulators. Induction of colitis in mice that lack SIGIRR, an intracellular inhibitor in the 
TLR–NF-κB pathway, results in excessive epithelial damage and increased severity of an 
experimental colitis.93-95 GRIM-19 is another regulator of NOD2 dependent NF-κB acti-
vation. A recent study suggested that infl amed mucosa of IBD patients expresses less 
GRIM-19 in comparison to mucosa of non-IBD patients.96 To date, no mutations in the 
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GRIM-19 gene have been linked to IBD.97 Finally, CD patients have been found to have 
an increased number of mutations in the gene encoding for PPARγ that is implicated in 
regulation of TLR signalingγ.98, 99 Furthermore, PPARγ expression seems to be reduced in 
UC patients.100
Notably, even well controlled animal models seem to yield confl icting results; some 
recent studies mention enhanced susceptibility to infl ammation in the absence of TLR 
signaling,101-103 while other studies establish a contributive role for TLR signaling.104,  105 
Recently, various novel regulatory mediators and associated mechanisms have been 
described: Tollip, sTLR2, IRAK-M, A20 and SLPI.85, 106-113
In summary of this part, it is important to stress that to date, it has been impossible 
to estimate the relative contribution of each of these regulatory mechanisms. The com-
plexity of this innate network, with the wide range of ligands and increasing number of 
TLRs, NODs, infl ammasome components and regulators may in fact need computational 
analyses to establish its contributions to health and infl ammation.
Diminished PRR signaling in IBD, loss of function
The association between mutations in the intracellular microbial pattern receptor NOD2 
and Crohn’s disease (CD) have been attributed to a loss of function of the innate immune 
system in these patients. NOD2 is expressed by monocytes and epithelial cells such as 
the Paneth cells (Pc).114, 115 Pc are predominantly located in the terminal ileum, within the 
crypts of Lieberkühn. Upon microbial stimulation, PC produce mediators such as anti-
microbial molecules, e.g. α-defensins (cryptdins in mice).116-121 A defective PC function 
in NOD2 mutated patients could contribute to the IBD through a failure of microbial 
regulation at the mucosal surfaces. Patients with CD were found to have a diminished 
expression of α-defensins that was most pronounced in CD patients with a NOD2 muta-
tion.122, 123 As PC are mainly found in the terminal ileum it is not surprising that genotypic 
defects in NOD2 seem to be linked to a disease phenotype with severe infl ammation at 
that specifi c location.
Substantiation for this concept comes from animal models; NOD2 defi cient mice 
show impaired PC responses upon challenge with the NOD2 ligand MDP and a failure to 
eradicate certain pathogens.124 These studies explain how a defect in clearance of cer-
tain bacteria may lead to a perpetuative, albeit insuffi  cient, mucosal immune response 
and therefore chronic infl ammation.
Recently, other epithelial derived anti-microbial products such as β-defensins and 
cathalicidin have been suggested to protect the host from the enhanced microbial pres-
sure that occurs during mucosal infl ammation. Indeed, local administration of cathali-
cidin was shown to ameliorate colitis in mice.125 Anti-microbials could therefore provide 
new therapeutic options in the IBD treatment.
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A second innate cell type that may contribute to the chronic infl ammation in IBD is 
the mucosal macrophage (fi gure 1). Similar to the mechanism for Paneth cells, a loss 
of function in macrophages has been described.126 Furthermore, monocyte-derived 
macrophages from CD patients with a NOD2 mutation produced less of the chemo-
attractant IL-8 upon stimulation with the NOD2 ligand MDP. In turn, this could lead to a 
reduced and delayed recruitment of neutrophils, and suboptimal clearance of bacteria 
from the intestine, again leading to chronic infl ammation. Similar mechanisms have 
been proposed for macrophages that are defi cient in the expression of other PPRs such 
as TLR4.127, 128
Enhanced PRR signaling in IBD, gain of function
Chemokines are among the fi rst mediators that innate cells produce upon stimulation. 
Various researchers have been able to link the expression of various chemokines (ENA-
78, CXCL-8, MCP-1, MCP-2, MCP-3, MIP1α, MIP1β, MIP-3α) in colonic epithelium to the 
severity of the infl ammation in IBD, that is suggestive of enhanced innate responsive-
ness.129-134
A strong case for enhanced PRR signaling in IBD was off ered by research performed 
in NOD2 defi cient mice. Microbial peptidoglycan (PGN) can be recognized by the ex-
tracellular receptor TLR2 as well as the intracellular NOD2 protein. When macrophages 
derived from NOD2 defi cient mice were stimulated with PGN, this resulted in an over-
expression of pro-infl ammatory cytokines compared to wild-type macrophages.135 It 
was suggested that NOD2 may act as a negative regulator for TLR2 signaling. This way, 
defective signaling through NOD2 may lead to exaggerated TLR2 sensitivity through the 
absence of dampening mechanisms. In humans, in was confi rmed that in the absence of 
NOD2 signaling, TLR2 activation can result in enhanced expression of pro-infl ammatory 
cytokines upon stimulation.135-138
Finally, Damen et al. showed that buccal epithelial cells derived from pediatric Crohn’s 
disease patients secrete higher amounts of CXCL-8, MIG, and IP-10 in comparison to adult 
Crohn’s patients or age-matched UC patients.139 From these studies it was concluded that 
pediatric CD may represent a specifi c subset of patients that is incapable of maintaining 
a physiological state of epithelial hyporesponsiveness to microbial stimulation.140
BRIDGING INNATE AND ADAPTIVE:
Next to aberrant innate immune responses to luminal bacteria by epithelial cells, Pan-
eth cells and macrophages, other non-adaptive cells have been implicated in the IBD 
pathogenesis: goblet cells141, 142, neutrophils143, eosinophils144, mast cells145 and NKT cells 
(fi gure 1).146-149
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All these immune-cells seem to play a signifi cant role in maintaining the typical non-
infl ammatory state of the healthy intestinal mucosa but consequently contribute to 
infl ammation in susceptible hosts.
Dendritic cells
Dendritic cells (DC) are key innate immune cells that play a crucial role in the recognition 
and processing of microbial and viral products. These cells are highly capable of picking 
up antigens via PRR, leading to activation of these cells. Activation leads to a functional 
maturation of the DC and migration to the draining lymph node. Next, antigens are 
presented to the cells of the adaptive immune system leading to a consequent adaptive 
immune response.
Intestinal DC can contribute to infl ammation through the production of pro-infl am-
matory cytokines such as TNF-α.46 Next, DC are involved in antigen presentation and 
activation of B- and T-lymphocytes e.g. through the production of specifi c cytokines.150 
Mucosal dendritic cells are present within the isolated follicles of the gut and the lamina 
propria where they can sample bacteria in the lumen.151,  152 In human IBD and diff er-
ent IBD models, DC have been shown to display a more activated phenotype and an 
enhanced production of pro-infl ammatory cytokines.87, 139, 153-159 It is believed that activa-
tion of intestinal DC is a prerequisite for the activation of the pathogenic T cells that 
are key to the pathogenesis of IBD (fi gure 1). Next, it is the type of mediators that DC 
produce that will determine the subtype of eff ector T cell, e.g. Th1, Th2 or Th17. Each 
of these specifi c T cell subsets has been implicated in specifi c IBD types.160 As such, Th1 
and Th17 cells are thought to play a role in CD, whereas UC is associated with a mixed 
Th1/Th2 profi le.147 Whether the required activated DC phenotype for specifi c Th subset 
diff erentiation results from particular microbial exposure or is associated with genetic 
defects that directly aff ect DC function remains to be elucidated. One of the determin-
ing factors could be Thymic stromal lymphopoietein (TSLP) that is produced by the IEC 
upon TLR activation and gives rise to Th2 diff erentiation.161-164 As such, CD could result 
from an impaired TSLP production by the IEC.165
The capacity to serve as innate cells as well as initiators of adaptive responses have 
emphasized the role of DC in the immunological cascade that contributes to mucosal 
tolerance as well as infl ammation.
GENETICS
Genetic involvement in the pathogenesis of IBD fi rst came from epidemiological studies. 
First-degree relatives from IBD patients have a 2-5 times increased risk in developing CD 
or UC. In monozygotic twins the rate of concordance increases up to 60% for CD and 
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almost 20% for UC. As the rate of concordance is not 100% in monozygotic twins, this 
indicates that IBD is inherited as a complex genetic basis.4
Multiple genes have been linked to IBD over the years. These genes were associated 
with activity of disease, disease phenotype or were specifi cally associated with either 
adult or pediatric IBD.166-171 Prominent was the discovery of IBD associated genetic 
variability in NOD2 (CARD15), which directed research to the interaction between mi-
crobiota and the innate immune system.5,  6,  71-73 Although these genetic studies have 
brought great discoveries regarding heritability and genetic risk factors the functional 
immunological consequences of genetic variability is diffi  cult to establish.
Furthermore, it is becoming clear that IBD patients represent a very heterogeneous 
group that may need a novel classifi cation beyond that of CD and UC. Given the distinct 
disease phenotype and associated immune pathology in children for example, it seems 
warranted that early onset infl ammatory bowel disease can be seen as a specifi c disease 
entity.172
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OUTLINE OF THIS THESIS
Infl ammatory bowel disease (IBD) is thought to result from an aberrant intestinal im-
mune response to commensal bacteria in a genetically susceptible host. In this thesis 
we investigated the interaction between the innate immune system and the microbiota 
at various levels.
As described in chapter 1, loss of function as well as gain of function of the innate im-
mune system has been suggested to result in intestinal infl ammation. Whether loss of 
function or gain of function is detectable in an individual will depend on the disease 
type, duration and state of disease, cell type and other factors. Due to this complexity, 
we argued in chapter 2 that results regarding the function of immune cells in patients 
from one study cannot be extrapolated to IBD in general.
In chapter 3 we fi rst assessed the interaction between the innate and the adaptive im-
mune system in a mouse model for IBD. Innate immune cells are crucial in the establish-
ment of colitis. Here we showed that inhibition of T-cell function by tacrolimus results 
in a diminished recruitment of neutrophils and monocytes that is associated with lower 
colitis scores.
Dendritic cells (DC) play a key role in the recognition of various microbial products in the 
intestine. In chapter 4 we assessed the origin and phenotype of the pro-infl ammatory 
DC in the pathogenesis of colitis. For this purpose we studied the phenotype of the DC 
during the diff erent phases of colitis development in a mouse model for Crohn’s disease, 
TNBS colitis.
In chapter 5 we further investigated the role of DC in the pathogenesis of IBD. We stud-
ied the intrinsic capacity of DC of pediatric IBD patients to secrete the pro-infl ammatory 
cytokines Interleukin (IL)-12 and IL-23 upon specifi c microbial stimulation. We assessed 
whether the cytokine production was related to the phenotype of IBD, duration of 
disease and treatment of disease.
Paneth cells (Pc) play an important role in the protection against microbial invasion into 
the intestinal crypts and in the regulation of microbial intestinal composition in general. 
In chapter 6 we assessed the role of PC derived TNF-α, a key innate pro-infl ammatory 
cytokine, in intestinal infl ammation in pediatric IBD patients and celiac disease patients. 
We further investigated the regulation of the pro-infl ammatory cytokine TNF-α in Pc in 
mice and in vitro.
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Aberrant tolerance to microbial products has been proposed in the pathogenesis of 
multiple infl ammatory conditions. In chapter 7 we investigated the acquisition of innate 
microbial tolerance in IBD patients and healthy controls by analyzing responsiveness of 
monocytes upon repetitive LPS stimulation. This process of endotoxin tolerance is an 
important protection mechanism to handle continuous microbial triggers, as seen in 
the intestine.
Optimal treatment of IBD aims at the induction and preservation of clinical remission. 
However, drug responsiveness varies between patients. In chapter 8 we analyzed im-
mune processes and drug responsiveness by investigating RNA gene expression profi les 
of pediatric IBD patients with inactive disease and control individuals.
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D EFECTIVE ACUTE INFLAMMATION IN CROHN’S DISEASE
Daniel Marks and colleagues1 suggest that patients with Crohn’s disease have a general 
defect in the innate mucosal immune response, including diminished interleukin 8 pro-
duction. We are not convinced.
Various studies show an increased number of neutrophils—probably associated with 
the respective induction of specifi c chemokines, such as interleukin 8—rather than a 
diminished neutrophilic infl ux.2 Moreover, intestinal epithelial cells are an important 
source of interleukin 8, in ulcerative colitis as well as in Crohn’s disease.3 Taken together, 
these data indicate a limitation to the general constitutional abnormality in Crohn’s 
disease as postulated by Marks and colleagues.
By contrast with Marks and colleagues’ fi ndings, we have shown increased release of 
interleukin 8 (on stimulation and at basal levels) by buccal epithelial cells derived from 
children with Crohn’s disease when compared with healthy controls and children with 
ulcerative colitis.4 Furthermore, monocyte-derived dendritic cells from our children with 
infl ammatory bowel disease did not show this striking diff erence in chemokine produc-
tion. Whether epithelial cells represent a cell type with a particular responsiveness that 
might not be seen in myeloid cells such as macrophages remains to be clarifi ed. Finally, 
childhood Crohn’s disease might represent a specifi c disease entity. Indeed, reports sug-
gest that, in comparison with adults, children with the disease have a higher number of 
associated mutations, diff erent kinetics, and diff erences in location of infl ammation and 
responsiveness to immunosuppression.5
Therefore, we suggest that the diff erences in immune responses found by Marks and 
colleagues do not necessarily represent a general mucosal paradigm for Crohn’s disease. 
We argue that their results cannot be extrapolated to other involved immune cells or to 
specifi c patients such as children with Crohn’s disease.
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ABSTRACT
Background & Aims: T-cells are a main target for anti-infl ammatory drugs in infl am-
matory bowel disease. As the innate immune system is equally implicated in the 
pathogenesis of these diseases, T-cell suppressors may not only inhibit T-cell-dependent 
production of pro-infl ammatory mediators but also aff ect innate immune cell function. 
Specifi cally, these drugs may impair innate immune cell recruitment and activation 
through inhibition of T-cells or act independent of T-cell modulation. We explored the 
extent of immune modulation by the T-cell inhibitor tacrolimus in a murine colitis model.
Methods: We assessed the eff ects of tacrolimus on TNBS colitis in wild type and Rag2-
defi cient mice. Severity of colitis was assessed by means of histological scores and 
weight loss. We further characterized the infl ammation using immunohistochemistry 
and by analysis of isolated intestinal leukocytes at various stages of disease.
Results: Tacrolimus treated wild type mice were less sensitive to colitis and had fewer 
activated T-cells. Inhibition of T-cell function was associated with strongly diminished 
recruitment of infi ltrating neutrophils in the colon at the early stages of this model. In 
agreement, immunohistochemistry demonstrated that tacrolimus inhibited produc-
tion of neutrophil chemo-attractants CXCL1 and CXCL2. Rag2-defi cient mice displayed 
enhanced baseline levels of lamina propria neutrophils that was moderately increased 
in TNBS colitis and remained unaff ected by tacrolimus.
Conclusion: Both the innate and the adaptive mucosal immune system contribute to 
TNBS colitis. Tacrolimus suppresses colitis directly through inhibition of T-cell activation 
and by suppression of T-cell-mediated recruitment of neutrophils.
Pieter BW.indd   42 15-Jul-10   16:49:04 PM
T-cell regulation of neutrophil infi ltrate at the early stages of a murine colitis model 43
INTRODUCTION
Inhibition of T-cell mediated pro-infl ammatory immune responses has been a success-
ful strategy in the treatment of infl ammatory bowel disease (IBD).1-3 However, various 
defects in the function of innate immune cells have been implicated in the pathogenesis 
of these diseases as well. As such, a lack of responsiveness to bacterial stimuli of macro-
phages and Paneth cells has been linked to a failure of microbial eradication at the mu-
cosal surfaces.4-6 In contrast to this lack of responsiveness, it has been established that 
innate immune cells may instead display exaggerated responses to bacterial stimuli.7-11
Innate responsiveness is tightly regulated through the control of expression of innate 
receptors such as Toll-like proteins and nucleotide-binding oligomerization domain 
containing 2 (NOD2) is strongly dependent on the presence of a range of both extracel-
lular as well as intracellular mediators.12 In addition, interactions between adaptive and 
innate immune cells have been shown to regulate innate sensitivity that is crucial to 
maintain the physiological non-infl ammatory state of the intestinal mucosa. Specifi cally, 
activation of lamina propria (LP) CD4+ T lymphocytes regulate epithelial integrity and 
functions e.g. susceptibility to microbial stimulation.13-16 Moreover, activated T-cells 
regulate recruitment of innate cells through the production of chemokines such as 
CXCL8 (IL-8) or the murine analogues CXCL1 (KC) and CXCL2 (MIP-2) and through 
interactions with other chemokine producing immune cells such as macrophages and 
epithelial cells.14, 17
To specifi cally address the interplay between innate and adaptive cells in colitis we 
applied a classical T-cell dependent mouse model. Trinitro-benzene sulphonic acid 
(TNBS) induced colitis has been widely used as a murine model for Crohn’s disease.18, 19 
The occurrence of hapten-specifi c antibodies, the effi  cacy of anti-IL-12 treatment and 
studies of TNBS colitis in mouse models that are defi cient at certain checkpoints of T-cell 
activation have established a contributive role for T- and B-cells.20-24 Further substantia-
tion for a crucial contribution of T-cells to this colitis model was established by showing 
the disease was transferable by injection of T-cells derived from colitic mice into WT 
recipients.25, 26 The fact that TNBS induced intestinal infl ammation is diminished in Rag-
defi cient mice may suggest the involvement of the adaptive immune system in regulat-
ing innate immune cells in TNBS colitis.27 In all cases, TNBS colitis has been associated 
with neutrophil infi ltration in the early phases of disease.24, 28
Tacrolimus (FK506) has strong T-cell inhibiting capacities and was originally used in the 
prevention of allograft rejection in tissue transplantation.29 The main working mecha-
nism is closely related to that of cyclosporin A. Through the inhibition of calcineurin, the 
phosphatase activity of the transcription factor ‘nuclear factor of activated T-cells’ (NFAT) 
is reduced, resulting in the inhibition of T-cell activation.2, 30, 31 Tacrolimus has been used 
as treatment of IBD and effi  cacy has been shown in various colitis models.2, 32-40
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To specifi cally address T-cell mediated control of innate infi ltration in TNBS colitis, we 
applied tacrolimus in wild type (WT) and Rag2-defi cient mice (Rag-/-). Pathways of T-cell 
activation were further explored by using a mouse model for diphtheria toxin (DT) - 
inducible short-term depletion of dendritic cells (CD11c-DTR).
MATERIALS AND METHODS
Animals
All animal procedures and protocols were performed with the approval of local institu-
tional animal studies ethics committee.
Male 6-8 week old BALB/c mice were purchased from Charles River (Maastricht, 
The Netherlands). BALB/c Rag-/- mice were generated from BALB/c Rag2/Il2rg double-
knockout mice on a mixed background by outcrossing (10X) Rag-/- onto a BALB/c back-
ground. BALB/c Rag2/Il2rg double-knockout mice were generated at the Erasmus MC, 
Rotterdam, The Netherlands.
BALB/c CD11c-DTR transgenic mice have been reported previously.41 DO11.10 mice 
were obtained from Charles River. All animals were housed in isolator cages with water 
and a standard pellet diet ad libitum (Hope Farms, Woerden, The Netherlands).
Induction of colitis
Colitis was induced as previously described.42 In brief, mice were sensitized with 2,5% 
TNBS (Sigma-Aldrich, Zwijndrecht, The Netherlands) in 50% EtOH by skin painting (100 
μl). At day seven after sensitization 100 μl containing 2.5 mg of TNBS in 50% ethanol was 
administered intrarectally (i.r.) under Isofl urane anesthesia. Control mice received 100 
μl of 50% EtOH. Body weight, stools and general health status were monitored daily. 
At indicated time points, mice were sacrifi ced and the colon was removed for further 
analyses. Severity of colitis was scored using parameters as described in table 1.
Table 1. Criteria for microscoping scoring of severity of colitis.*
Score Symptom
0-1-2 Hyperaemia
0-1-2 Bowel wall thickening
0-1-2 Destruction of normal architecture
0-1-2 Goblet cell depletion
0-1-2 Ulceration
0-1-2 Mononuclear cell infl ux / celllar infi ltration
Distal colonic sections were scored for the listed parameters and scores were summed.
*Adapted from Mc Caff erty et al. with minor modifi cations.57
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Inhibition of T-cell function
To establish the appropriate dose of tacrolimus (Astellas Pharma, Leiderdorp, The 
Netherlands), the drug was tested in an ovalbumin (OVA)-specifi c T-cell system.43 WT 
mice received 1x107 CD4+ DO11.10 T-cells, labeled with 5,6-carboxysuccinimidyl-
fl uoresceine-ester (CFSE) (Molecular Probes, Leiden, The Netherlands), by intravenous 
(i.v.) injection. After 24 hours, mice were treated with 70 mg OVA protein grade V (Sigma 
Aldrich) per intragastric gavage (i.g.). T-cell divisions were assessed on cells isolated from 
the draining mesenteric lymph node using fl ow cytometry at 72 hours. A daily dose of 
0.125 mg/ml, 200 μl intra-peritoneally (i.p.) of tacrolimus dissolved in NaCl 0.9% resulted 
in complete inhibition of T-cell proliferation.
Depletion of dendritic cells
Dendritic cell (DC) depletion was achieved by intra-peritoneal (i.p.) injection of trans-
genic (Tg) CD11c-DTR mice with 200 μl of diphtheria toxin (DT) at 4 ng/g body weight41 
one day prior to colitis induction. As a control, non-Tg littermates received an equal dose 
of DT.
Isolation and characterization of colonic leukocytes
Complete colon including the caecum was resected for isolation of lamina propria 
mononuclear cells (LPMC) as described.44 To characterize lamina propria leukocytes, 
cells were incubated with anti-CD16/CD32 (2.4G2). Cells were stained with PE/Texas Red 
labeled anti-CD45 (30-F11) (Invitrogen), FITC-labeled anti-Ly6C (AL-21), PerCP-labeled 
CD11b (MAC-1α), APC-labeled CD11c (HL3) (BD Pharmingen, Breda, The Netherlands), 
Alexa700-labeled anti-MHC-II (M5/114.15.2), PE-Cy7-labeled anti-CD8α (53-6.7) (Biole-
gend, Uden, The Netherlands) and APC-Cy7-labeled anti-GR-1 (RB6-8C5) (e-Bioscience) 
for 30 minutes at 4°C. Cells were measured on a FACS Canto II cytometer with FACS Diva 
software (BD). Data were analyzed using Flowjo software (Tree Star).
Histology
Distal colon sections (5 mm) were fi xed in 4% PFA in PBS and embedded in paraffi  n. Four 
μm sections were stained with hematoxylin (Vector Laboratories, Burlingame, CA) and 
eosin (Sigma-Aldrich). For immunohistochemistry (IHC), sections were deparaffi  nized 
and endogenous peroxidases were quenched with 3% H2O2 in methanol for 20 min. 
Antigen retrieval was achieved by microwave treatment in citrate buff er (10 mM pH 
6.0). Sections were blocked for 1 hour in either 1% blocking reagent (Roche, Almere, 
The Netherlands) in PBS or 10 mM Tris, 5mM EDTA, 0.15M NaCl, 0.25% gelatine, 0.05% 
Tween-20, 10% normal mouse serum, 10% normal rabbit serum, pH 8. Antibody incuba-
tion was performed overnight at 4°C with rabbit anti-myeloperoxidase (MPO; Rockland, 
Gilbertsville, PA) diluted 1: 1000, anti-mouse CXCL1, anti-mouse CXCL2 (R&D systems, 
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Abingdon, United Kingdom) using a concentration of 2μg/ml and biotinylated anti-TNP 
(BD Pharmingen) diluted 1:500. Immunoreactions were detected using respectively bio-
tinylated secondary goat-anti-rabbit or rabbit-anti-goat serum with the Vectastain ABC 
Elite Kit (Vector Laboratories) and 3,3’-diaminobenzidine tetrahydrochloride (Sigma-
Aldrich). Sections were counterstained with Hematoxylin.
Immuno-fl uorescence microscopy
Cytospins of isolated colonic LP leukocytes were fi xed for 10 min in 100% methanol. 
Antibodies for CD3 (rabbit anti-human CD3; Dako, Heverlee, Belgium) and CXCL1 or 
CXCL2 (goat anti-mouse chemokine, R&D Abingdon, UK) were incubated overnight. 
Secondary antibodies anti-rabbit Alexa fl uochrome 555 and anti-goat Alexa fl uochrome 
488 (Invitrogen) were used to detect CD3 and CXCL1 or CXCL2 respectively. Cytospins 
were incubated with Prolong gold (Vector) containing DAPI (Sigma).
RNA isolation, reverse transcription and Real Time quantative PCR
RNA was isolated from colonic tissue with RNeasy midi kit (Qiagen #75144) according to 
the manufacturers’ instructions. Messenger RNA expression was analyzed in duplicate, 
normalized against cyclophilin as an internal control gene. Results are expressed as rela-
tive messenger RNA expression using the ΔCt method.45 Sequences of the IFNγ primer: 
forward primer: 5’-CAAAAGGATGGTGACATGA-3’, reverse primer: 5’-GGGTTGTTGACCT-
CAAACT-3’. Sequences used of the cyclophilin primer: forward primer: 5’-AACCCCACC-
GTCTTCT-3’, reverse primer: 5’-CATTATGGCGTGTAAAGTCA-3’.
T-cell stimulation assay
Human whole blood was centrifuged (10 min, 260g) and serum was removed. Using 
a Lymphopreptm gradient (Axis-Shield, Oslo, Norway) lymphocytes were isolated. CD4+ 
T-cells were isolated using negative depletion for CD4+ cells using a CD4+ T-cell isolation 
kit (MACS, Miltenyi Biotec, Utrecht, The Netherlands). Cells were incubated in 96 wells 
plates (2*105 cells / 200 μl) in IMDM medium containing 10% human serum, 100 U/ml 
penicillin and 100 μg/ml streptomycin with 1 μg/ml CD3/CD28 T-cell expander Dynal 
beads (Invitrogen) for 72 hours with various concentrations of tacrolimus as indicated. 
CXCL8 concentrations were determined in the supernatant by ELISA (BD Biosciences).
Statistical analysis
Changes in weight, histology score, cell numbers and cytokines levels were statistically 
analyzed using an unpaired Student’s t-test when appropriate. A p-value of <0.05 was 
considered statistically signifi cant. Data are presented as the mean ± standard error 
of the mean (SEM) of n=5 to 8 mice per group (as indicated). Experiments have been 
performed at least twice.
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RESULTS
TNBS colitis development is associated with colonic neutrophil infl ux
We characterized the involvement of adaptive and innate immune cells in TNBS colitis 
during the fi rst days of disease. Induction of TNBS colitis resulted in a decrease of body-
weight within 24 hours and reached maximum levels at 72 hours (p<0.001) (fi gure 1a). 
Histology showed maximum colonic infl ammation (Table 1) within 24 hours after colitis 
induction compared to EtOH controls (p<0.01) and remained at constant levels during 
the fi rst three days (fi gure 1b). The rapid development of colitis strongly implicated 
involvement of innate immune cells. Therefore, we assessed MPO expression on co-
lonic sections to evaluate neutrophil infi ltration into the intestinal tissues. TNBS treated 
animals showed neutrophils in the colon LP at 24 hours, suggesting the involvement of 
these cells in the development of TNBS colitis (fi gure 1c).
To characterize the infi ltrating cells in more detail, we isolated whole leukocyte popu-
lations from the colonic LP at indicated time points for analysis by fl owcytometry. Total 
numbers of neutrophils (CD45+GR1+) and monocytes (CD45+CD11b+CD11c-) in the LP 
increased compared to EtOH controls at day 1 and day 3 (p<0.01) (fi gure 1d,e). Total 
numbers of eosinophils (CD45+CD11b+GR1intFSClowSSChigh), DCs (CD45+CD11c+MHC-II+) 
and T- (CD45+CD3+) and B-cells (CD45+CD19+) did not diff er compared to control animals 
(data not shown). However, we detected increased percentages of CD3+CD4+CD25+ 
(activated) T-cells in the mesenteric lymph nodes of TNBS treated mice (fi gure 1f ). 
Percentages of CD3+CD4+CD25+FoxP3+ regulatory T-cells did not increase during TNBS 
colitis (data not shown).
These data show that TNBS colitis development is associated with neutrophil infl ux 
within 24 hours in the colonic LP and an increase of activated eff ector T-cells within the 
draining lymph node.
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Adaptive immune cells are essential for colonic neutrophil recruitment
We next investigated the involvement of adaptive immune cells in the recruitment of 
neutrophils by applying TNBS colitis in Rag-/- mice. Numbers of colonic LP neutrophils 
were increased in untreated Rag-/- mice compared with WT animals (p<0.05) (fi gure 2a). 
Upon TNBS colitis induction, Rag-/- mice develop a mild colitis (fi gure 2b) that is associ-
A B
C D
E F
Figure 1.  TNBS colitis development is associated with colonic neutrophil infl ux.
(A) Weight loss and (B) severity of colitis in TNBS colitic WT mice. (C) MPO staining, indicating neutrophils 
in colonic tissue at 24 hours after TNBS colitis induction (left) en EtOH control (right). (D,E) Total number 
of infi ltrating neutrophils (D) and monocytes (E) in the colonic LP after TNBS administration, analysed 
by fl owcytometry. (F) Percentages of activated T-cells (CD4+CD25+) of total CD4+ T-cell in the mesenteric 
lymph node. 
(A-F) n=7 per group, **p<0.01, *p<0.05, error bars represent SEM.
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ated with a moderate increase of lamina propria neutrophils (19.6%) in comparison with 
WT animals (65.8%) (fi gure 2c).
Tacrolimus reduces severity of colitis in WT mice
To specifi cally address the eff ect of T-cell inhibition on innate infl ammation, we analyzed 
the eff ect of the T-cell inhibitory drug tacrolimus on colitis development. To this aim, 
we fi rst established a model for tacrolimus mediated T-cell suppression. The optimum 
dose of 0.125 mg/ml for T-cell inhibition was established as described in materials & 
methods (fi gure 3a). Mice were injected daily with 200 μl 0.125 mg/ml tacrolimus i.p. 
starting one day prior to colitis induction. Tacrolimus administration did not aff ect TNBS 
associated weight loss (fi gure 3b). However, histology scores were markedly decreased 
in the tacrolimus treated animals at 24 and 72 hours (p<0.01; p<0.05) (fi gure 3c).
A B
C
Figure 2. Adaptive immune cells are essential for colonic neutrophil recruitment
(A) Absolute numbers of neutrophils in the colonic LP under baseline conditions in WT and Rag-/- mice. (B) 
Colitis score of TNBS colitic Rag-/- mice as compared to WT mice. (C) Mean increase of neutrophils in the 
colonic LP in TNBS colitis as compared with EtOH controls in WT and Rag-/- mice.  (A) n=4 per group. (B,C)  
n=7 for TNBS, n=3 for EtOH, *p<0.05, error bars represent SEM.
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Tacrolimus inhibits neutrophil infl ux and pro-infl ammatory cytokine 
production in TNBS colitis
To assess whether suppression of T-cell proliferation by tacrolimus aff ected the infi ltra-
tion of innate cells during TNBS colitis, we performed immunohistological staining for 
MPO. Colon sections of tacrolimus treated colitic animals showed a decrease in MPO 
positive cells in the LP compared to controls (fi gure 4a). In agreement, the number of 
neutrophils in the LP was reduced in tacrolimus treated mice at 24 hours after colitis 
induction (p=0.01) (fi gure 4b). Numbers of other immune cells (monocytes, eosinophils, 
DCs, T- and B-cells) were not aff ected by tacrolimus treatment (Supplementary fi gure 1). 
However, tacrolimus treatment was associated with a lack of increase of activated T-cells 
within the mesenteric lymph nodes at 24 and 72 hours of disease induction (fi gure 4c).
To further explore the immunosuppressive eff ects of tacrolimus in TNBS colitis we de-
termined expression of the pro-infl ammatory cytokine IFN-γ in colonic tissue by qPCR. 
Expression of IFN-γ was diminished upon tacrolimus treatment at 24 hours after colitis 
induction (p<0.05) (fi gure 4d).
BA
C
Figure 3. Tacrolimus reduces severity of colitis in WT mice.
(A) Proliferation of OVA-specifi c T-cells (CD3+CD4+KJ1-26+) in the mesenteric lymph node of control (top) 
and tacrolimus treated WT mice (bottom). (B,C) Weight loss (B) and severity of colitis (C) of tacrolimus 
treated mice upon TNBS administration. 
(A-C) n=7 for TNBS, n=5 for EtOH. (D,E) n=5, **p<0.01, *p<0.05, error bars represent SEM. 
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Tacrolimus has no direct eff ect on neutrophils in moderate colitis in Rag-/- 
animals
To exclude a direct eff ect of tacrolimus on innate cell function, we investigated whether 
tacrolimus could directly aff ect neutrophil infl ux in mice in the absence of a functional 
adaptive immune system. Therefore, we applied tacrolimus in TNBS colitic Rag-/- mice. 
Tacrolimus treatment had no eff ect on the mild form of colitis that occurs in Rag-/- mice 
after TNBS induction (fi gure 5a). In addition, numbers of colonic neutrophils were not 
aff ected by tacrolimus in Rag-/- colitic mice, indicating that tacrolimus does not directly 
inhibit neutrophil infl ux in TNBS colitis (fi gure 5b).
A
B C
D
Figure 4. Tacrolimus inhibits neutrophil infl ux and pro-infl ammatory cytokine production in TNBS colitis.
(A) Representative colonic section obtained at 24 hours after TNBS induction in tacrolimus treated (left) 
and control (right) animals. Brown staining indicates MPO positive cells. (B) Total number of neutrophils 
in the colon during TNBS colitis in tacrolimus treated and control animals. (C) Percentages of activated 
T-cells in mesenteric lymph nodes of tacrolimus treated and control animals. (D) Colonic levels of IFNγ 
determined by qPCR. (A-D) n=7 per group, **p<0.01, *p<0.05, error bars represent SEM.
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As tacrolimus has also been suggested to inhibit dendritic cell antigen presentation46 we 
fi rst explored contributions of DCs to TNBS colitis using CD11c-DTR mice. To this aim, DCs 
were depleted 24 hours prior to colitis induction by i.p. injections of DT. This treatment 
resulted in a 90% reduction of MLN DCs and a ~70% reduction of DCs in the colonic LP 
(fi gure 5c). This level of DC reduction had no eff ect on histological colitis scores (fi gure 
5d). We next stained colonic tissue with antibodies directed to the trinitrophenyl (TNP)-
hapten modifi ed self–antigen complex.20 At 24 hours after TNBS colitis induction, the 
hapten was detected in epithelial cells (Supplementary fi gure 2). As such, other antigen 
presenting cells, such as IEC, could well be involved in the initial antigen presentation to 
T-cells. Together with the DC depletion data, this suggests that tacrolimus may not have 
inhibited colitis through suppression of DC mediated antigen presentation.
A B
C D
Figure 5. Tacrolimus has no eff ect on colitis severity and neutrophil numbers in Rag-/- mice. 
(A,B) Eff ects of tacrolimus on severity of colitis (A) and on the number of neutrophils in the colonic LP (B) 
in TNBS colitic Rag-/- mice. (C) Percentage of DCs (CD11c+MHC-II+) in the MLN and colonic LP of total CD45+ 
cells in Tg (DT sensitive) and non-Tg (DT non-sensitive) CD11c-DTR mice at 24 hours after DT i.p. injection. 
(D) Severity of colitis determined by histological scores of Tg TNBS treated animals compared with non-Tg 
TNBS treated animals at 72 hours post TNBS induction. 
(A,B) n=7 per group (C,D) n=5 per group, **p<0.01, *p<0.05, error bars represent SEM.
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Tacrolimus aff ects innate recruitment through T-cell suppression
As the recruitment of neutrophils is regulated via chemo-attractants we performed IHC 
staining for the neutrophil chemo-attractants CXCL1 (KC) and CXCL2 (MIP-2), mouse 
equivalents of CXCL8. Both chemokines were abundantly present in leukocytes within 
the LP and within the intestinal epithelial cells (IEC) of TNBS colitic WT mice (fi gure 6a). 
The expression of CXCL1 and CXCL2 was almost completely absent in tacrolimus treated 
animals (fi gure 6b). Immune fl uorescence staining for CXCL1 or CXCL2 and T-cells (CD3) 
on isolated LP leukocytes from TNBS treated mice confi rmed that T-cells are capable of 
producing neutrophil attracting chemokines (fi gure 6c).
Next, we assessed in vitro whether tacrolimus could aff ect chemokine production by 
T-cells. Hereto, we analyzed chemokine production of stimulated human peripheral T-
cells in the presence of a dose range of tacrolimus. The production of CXCL8 diminished 
by tacrolimus in a dose dependent manner (p<0.001) (fi gure 6d).
DISCUSSION
T-cell activation has been regarded as a crucial contribution to the pathogenesis of IBD 
through the release of various mediators e.g. cytokines that are implicated in mucosal 
infl ammation. Furthermore, these cells may also contribute through regulating recruit-
ment and activation of other immune cells such as neutrophils. We explored the eff ects 
of the T-cell inhibitor tacrolimus on innate infi ltration in a murine colitis model. First, we 
established that the early phases of TNBS colitis are characterized by an infl ux of mainly 
MPO positive cells. Further analysis by fl owcytometry of colonic LP leukocytes identifi ed 
neutrophils and monocytes as the main infi ltrating populations (fi gure 1).
To address the contribution of adaptive immune cells to colitis, we decided to induce 
TNBS colitis in Rag2-defi cient mice. We show that Rag-/- mice develop only a moderate 
TNBS colitis that is accompanied by reduced neutrophil recruitment in comparison to WT 
mice. As we found that Rag-/- mice exhibit enhanced baseline levels of neutrophils within 
the lamina propria we were unable to properly compare these mice to WT animals. We 
therefore explored T-cell mediated control of innate infl ammation, by treating WT mice 
with the T-cell inhibiting drug tacrolimus starting one day prior to TNBS colitis induction. 
These experiments revealed that T-cell inhibition by tacrolimus results in diminished 
severity of colitis that is accompanied by a strong reduction in neutrophil infi ltration 
and diminished pro-infl ammatory cytokine levels (fi gure 3,4). These data indicate that 
T-cells contribute to mucosal infl ammation through recruitment of innate cells.
To exclude a direct suppressive eff ect of tacrolimus on innate cells,47, 48 we treated TNBS 
colitic mice Rag-/- mice with tacrolimus, as these mice are not capable of mounting adap-
tive immune responses. Treatment of these Rag-/- mice with tacrolimus did not result in 
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A
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D
C
D
Figure 6. Tacrolimus aff ects neutrophil attracting chemokine production through T-cell suppression. 
Representative example of expression of neutrophil attracting chemokines CXCL1 (A) and CXCL2 (B) 
on colonic sections of TNBS treated mice at 24 hours after tacrolimus treatment (left) and NaCl controls 
(right). (C) Immuno-fl uorescence staining of CXCL1 (left) or CXCL2 (right) in red and CD3 in green 
on isolated colonic LP leukocytes from colitic mice. (D) Production of CXCL8 by human CD4+ T-cells 
after αCD3-αCD28 stimulation with various concentrations of tacrolimus. CXCL8 is determined in the 
supernatant at 72 hours (A,B,C) n=7 per group (D) n=3 per variable, ND:non detected, *p<0.001, error bars 
represent SEM.
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any reduction of colitis severity or inhibition of neutrophil infi ltration (fi gure 5). These 
data indicate that -at this dose- tacrolimus does not inhibit neutrophil recruitment in the 
absence of adaptive immune cells.
Chemokines involved in neutrophil recruitment, e.g. CXCL1 and CXCL2, can be pro-
duced by diff erent cells that are present within the intestinal tract.7,  49-51 We detected 
CXCL1 and CXCL2 within LPMC and within the IEC. Double staining of CD3 (T-cells) and 
these chemokines identifi ed T-cells as a potential source of these neutrophil attracting 
chemokines.
Tacrolimus treatment was associated with a robust down-regulation of the produc-
tion of these chemokines in colitis on histology. These analyses suggest that tacrolimus 
treatment inhibits neutrophil recruitment through suppression of T-cell mediated che-
mokine production. Indeed, similar mechanisms for tacrolimus have been proposed in 
a model of acute lung injury, where neutrophil recruitment in lung tissue could be ef-
fectively inhibited by tacrolimus.52 Moreover, it has been shown that T-cells can produce 
substantial amounts of CXCL2 or CXCL8 in mice and humans respectively.14,17 Our in vitro 
experiments confi rm a dose dependent suppression by tacrolimus of CXCL8 production 
by human T-cells.
Next, T-cells can induce chemokine production by other cells as well. For example, 
it has been shown that primed T-cells are capable of inducing chemokine production 
by epithelial cells.14 We show that tacrolimus treatment is associated with diminished 
expression of CXCL1 and CXCL2 both in cells that are present within the LP and in the 
IEC (fi gure 6). These data establish that tacrolimus suppresses chemokine production by 
T-cells and, indirectly, by other cells such as IEC and macrophages.
As tacrolimus has also been suggested to inhibit dendritic cell antigen presentation46 
we explored contributions of DCs to TNBS colitis. DC depletion by diphteria toxin in 
CD11c-DTR mice resulted in a 90% reduction of MLN DCs and a ~70% reduction of DCs in 
the colonic LP that is comparable to recent reports using similar interventions in another 
experimental colitis model.53 This level of DC reduction had no eff ect on histological 
colitis scores (fi gure 5). As it has been suggested that the intestinal epithelial cells may 
act a potent antigen presenting cells54, 55 we next stained colonic tissue with antibod-
ies directed to the trinitrophenyl (TNP)-hapten modifi ed self–antigen complex.20 At 24 
hours, the hapten was strongly detected in epithelial cells. These data suggest that IEC 
could be involved in the initial antigen presentation to T-cells. Given the strong inhibi-
tion of tacrolimus on TNBS colitis development, this suggests that this drug may not 
have inhibited colitis through suppression of DC mediated antigen presentation. Future 
studies may therefore aim at assessing whether tacrolimus has direct immunosuppres-
sive eff ects on antigen presenting cells other than classical CD11c+ DC.
Next to adaptive immune cells e.g. T-cells, neutrophils have been identifi ed as eff ector 
cells in IBD, responsible for epithelial injury and dysfunction leading to tissue damage. 
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This mechanism is supported by reports that describe successful treatment of murine 
colitis by chemokine inhibitors.56 In accordance, T-cell inhibition in IBD patients may not 
only result in inhibition of the release of cytotoxic mediators by these cells, but also from 
diminished T-cell dependent neutrophil recruitment to the infl amed intestine. Given the 
broad spectrum of action of such T-cell inhibitors, one could argue that these drugs may 
be a fi rst choice during fulminant infl ammation in IBD.
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SUPPLEMENTARY FIGURES
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1. Tacrolimus does not aff ect total numbers of monocytes, eosinophils, DCs, T-cells or B-cells in the colonic 
LP.
(A-E) Number of monocytes (A), eosinophils (B), DCs (C), T-cells (D) and B-cells (E) in the colonic LP during 
TNBS colitis in tacrolimus treated mice, determined by fl owcytometry. n=7 per group, error bars represent 
SEM.
2. TNP is present throughout the intestinal epithelial layer and the LP after TNBS administration.
Representative example of TNP (brown) stained colonic section at 24 hours after TNBS induction (left) and 
ethanol control (right).
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SUMMARY
Resident lamina propria dendritic cells play an important role in maintenance of toler-
ance to harmless antigens. Recent new insights have revealed that in such steady-state 
conditions resident lamina propria DC can be divided into non-overlapping subtypes 
with distinct functions on the basis of surface marker expression. However, it is unclear 
whether a subtype of these DC or newly recruited infl ammatory antigen presenting 
cells drive intestinal infl ammation upon loss of tolerance. To determine which DC are 
predominantly involved in antigen presentation during colonic infl ammation, we have 
characterized the role of DC subtypes during hapten-induced colitis. Within 1 day post 
colitis induction and infl ux of Ly6c+ monocytes occurred in the lamina propria. On day 
3 of infl ammation an increase in the percentage of monocyte-derived Ly6c+ CD11b+ DC 
in the mucosa draining lymph nodes occurred. Transient depletion of resident CD11c+ 
cells in CD11c-DTR mice eff ectively reduced CD11c+ DC in the mucosa draining LN 
on day 3 of colitis but did not aff ect Ly6c+ CD11b+ DC nor infl uenced the severity of 
disease. Mucosal administration of fl uorescently labeled ovalbumin on day 2 of colitis 
established that Ly6c+ CD11b+ DC were associated with antigen and eff ectively drove 
proliferation of OVA specifi c D011.10 cells. These data infer that monocyte infi ltration 
during intestinal infl ammation gives rise to a new subtype of monocyte-derived DC that 
can present antigen and may support T-cell division.
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INTRODUCTION
Mononuclear phagocytes including macrophages and dendritic cells (DC) are highly 
abundant in the lamina propria of the intestine. These cells exert a broad range of im-
mune functions in both innate and adaptive immunity ranging from phagocytosis and 
killing, stimulation and recruitment of other immune cells1,  2 to antigen presentation 
and T cell diff erentiation after migration to the local lymph nodes (LN).3-5 Recent iden-
tifi cation of non-overlapping subtypes of antigen presenting cells (APC) with distinct 
functions has led to pivotal progress in understanding the intricacies of APC function 
in lamina propria. Three major subsets of intestinal lamina propria APC can be distin-
guished; the CD11c+ DC that are divided into CD11c+ CD103+ CD11b- CX3CR1- DC and 
CD11c+ CD103- CD11b+ CX3CR1+ DC as well as the macrophage like CD11c-low CD11b+ 
CX3CR1+ F4-80+ cells.6-8
CD11c+ CD103+ CD11b- CX3CR1- DC which originate from a common DC progenitor 
migrate from the lamina propria to the draining mesenteric lymph nodes (MLN) during 
normal steady state conditions.4, 9 These CD103+ DC induce the expression of gut hom-
ing receptors CCR9 and α4β7 on adaptive T-cells, and are involved in immune regulation 
via the induction TGF-β and retinoic acid dependent induction of FOXP3+ Tregs.10-12 In 
contrast, CD11c+ CD103- CD11b+ CX3CR1+ DC which originate from Ly6C+ monocytes fail 
to migrate to MLN.4, 9 Instead these DC are closely associated with the epithelium and are 
capable of extending processes across the epithelium into the intestinal lumen.13, 14 As 
such, CD11c+ CD103- CD11b+ CX3CR1+ DC may play an important role in local sampling 
and uptake of luminal microbes and stimulate T cell responses to a lesser extent.
CD11clow CD11b+ CX3CR1+ F4-80+ lamina propria macrophages also originate from 
Ly6C+ monocytes.9 These macrophages spontaneously secrete IL-10 and are hypore-
sponsive to TLR stimulation.6 Furthermore, they were reported to induce FOXP3+ Tregs 
in the presence of TGF-β, and suppress the action of the CD11b+ lamina propria DC.6
Epithelial cell derived factors are suggested to steer DC diff erentiation and condition 
their acquisition of particular functions.3 For example, epithelial cells imprint the ability 
to metabolize vitamin-A, which allows these cells to generate gut tropic CCR9+ Foxp3+ 
cells.15, 16 CD11c+ CD103- CD11b+ CX3CR1+ DC may escape conditioning or be insensitive 
to this imprinting and instead have the ability to drive infl ammatory T-cell responses. 
These CD103- cells could act as sentinels for the presence of pathogenic antigens or 
bacteria.4, 17
Dysregulation of intestinal homeostasis, as occurs in infl ammatory bowel disease, may 
be associated with shifts in balance between these populations of APC. As such, infl am-
mation could be induced by pro-infl ammatory APC that are already present at steady 
state but become dominant and are activated after contact with microbial patterns 
and pro-infl ammatory cytokines. For example, genetically engineered mice transiently 
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lacking CX3CR1- lamina propria APC were found to be more sensitive to DSS colitis due 
to a predominance of TNF secreting CX3CR1+ DC.7 Alternatively, new subpopulations of 
infl ammatory DC could be recruited to the intestine during infl ammation. Here we re-
port that infi ltrating Ly6c+ monocytes critically predominate in lamina propria and give 
rise to a new subtype of monocyte derived DC that can present antigen and supports 
T-cell division in the mucosal draining MLN during trinitrobenzene sulfonic acid (TNBS) 
colitis in WT mice.
MATERIALS & METHODS
Animals
Specifi c pathogen-free BALB /c mice (8 – 10 weeks) were purchased from Charles River 
(Maastricht, The Netherlands). DO11.10 transgenic (Tg) mice, which have a Tg TCR spe-
cifi c for the ovalbumin (OVA) 323 – 339 peptide, and CD11c-DTR transgenic mice on a 
BALB/c background18 were bred at our own facility. All mice were kept under routine 
animal housing conditions and experiments were approved by the animal experimental 
committee of the Erasmus MC.
Induction of colitis
Colitis was induced as previously described.19 In brief, mice were sensitized with 2.5% 
TNBS (Sigma-Aldrich, The Netherlands) in 50% ethanol (EtOH) by skin painting (100 
μl). At day seven after sensitization 100 μl of 2.5% TNBS in 50% EtOH was administered 
intrarectally (i.r.) under isofl urane anesthesia. Control mice received 100 μl of 50% EtOH. 
Body weight, stools and general health status were monitored daily. At indicated time 
points, mice were sacrifi ced and the colon and draining lymph nodes were removed for 
further analyses.
Isolation and purifi cation of lymph node and colonic APC
At various time points after colitis induction the MLN and iliac lymph nodes (ILN) were 
isolated and digested using Liberase Blenzyme 3 (Roche, The Netherlands) in the pres-
ence of DNAse I (Roche) for 30 – 35 min at 37°C. At the same time colonic lamina propria 
mononuclear cells (LPMC) were isolated as previously described.20
Depletion of dendritic cells
Two days after colitis induction CD11c+ DC were depleted in CD11c-DTR mice by an 
intra-peritoneal (i.p.) injection of 200 μl of diphtheria toxin (DT) at 4 ng/g body weight 
in 0.9% saline. As a control, non-Tg or wildtype (WT) littermates were treated with an 
equal dose of DT.
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Flow cytometry
To characterize lamina propria, MLN- and ILN-derived leukocytes, cells were fi rst incu-
bated with anti-CD16/CD32 (2.4G2) (a kind gift of Bioceros, The Netherlands) to block 
non-specifi c binding of antibodies. Next, cells were stained with PE labeled anti-CD45 
(30-F11), PE-Cy7-labeled anti-F4-80 (BM8), Alexa700-labeled anti-MHCII (M5/114.15.2), 
PE-Cy7-labeled anti-CD8 (53-6.7) (Biolegend, Uden, The Netherlands), FITC-labeled 
anti-Ly6C (AL-21), PerCP-labeled anti-CD11b (MAC-1), APC-labeled anti-CD11c (HL3), 
PE-labeled anti-CD103 (M290) (BD Parmingen), PE-labeled anti-CCR7 (4B12), APC-Cy7-
labeled anti-GR-1 (RB6-8C5) or APC-Cy7-labeled anti-F4-80 (BM8) (e-Bioscience, Frank-
furt, Germany) for 30 minutes at 4°C. Cells were measured on a FACS Canto II cytometer 
with FACS Diva software (BD). Data were analyzed using Flowjo software (Tree Star Inc, 
Ashland, OR).
OVA-tracking
OVA (Calbiochem, San Diego, CA) was coupled with alexa-647-conjugated carboxylic 
acid succinimidylester (Invitrogen, The Netherlands) according to manufacturers’ in-
structions. Two days after colitis induction mice received 100 μl (17 mg/ml) alexa-647-
labeled OVA i.r. or 300 μl intragastrically (i.g.). Presence of OVA-alexa-647 was studied 
in the diff erent DC subsets from the MLN by comparison with cells from MLN of mice 
treated with non-labeled OVA.
Histology
Distal colon sections (5 mm) were fi xed in 4% PFA in PBS and embedded in paraffi  n. 
Four μm sections were stained with hematoxylin (Vector Laboratories, Burlingame, CA) 
and eosin (Sigma-Aldrich). Severity of colitis was scored using parameters as previously 
described.21
Adoptive transfer and CFSE labeling
Lymph nodes and spleens were isolated from DO11.10 mice and single-cell suspen-
sions were prepared, enriched for CD4+ T cells as described earlier22 and labeled with 
CFSE (Molecular Probes, Invitrogen) to follow their division profi les in vivo. Each mouse 
received 1.107 CD4+ KJ1.26+ cells in 100 μl saline by intravenous injection one day after 
induction of colitis. The next day mice were treated i.r. with 35 mg in 100 μl or i.g. with 
70 mg in 200ul PBS. OVA-induced proliferation was studied in the ILN and MLN four days 
after colitis induction.
Statistical analysis
Changes in weight, histology score, cell numbers and cytokines levels were statistically 
analyzed using an unpaired Student’s t-test when appropriate. A p-value of < 0.05 was 
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considered statistically signifi cant. Data are presented as the mean ± standard error 
of the mean (SEM) of n=5 to 8 mice per group (as indicated). Experiments have been 
performed at least twice.
RESULTS
Increased numbers of CD11b+ Ly6c+ APC in lamina propria and MLN during 
TNBS colitis
In order to investigate whether shifts in predominance of diff erent APC populations 
occur during TNBS colitis in mice, we characterized APC subsets based on expression of 
CD11c and CD11b in the colonic lamina propria as well as the draining lymph nodes at 
various time points after induction of TNBS colitis.
I.r. administration of TNBS in pre-sensitized mice causes an acute colitis characterized 
by weight loss and a high disease activity score (fi gure 1a). This colitis peaks at day 3 af-
ter induction, and mice slowly recovered showing only minimal signs disease activity at 
day 10. Within one day after induction of colitis a strong increase in the CD11c- CD11b+ 
cells accounting for up to 50% of the CD45+ lamina propria cells was observed (fi gure 
1b). By comparison, in EtOH controls this CD11c- CD11b+ APC population consisted of 
approximately 5% of the CD45+ lamina propria cells. Further characterization of the 
CD11c- CD11b+ APC population revealed that the majority of the cells are Ly6c+, sug-
gesting that these cells derive from recently migrated monocytes (fi gure 1c). During the 
course of disease this CD11c- CD11b+ APC population remained signifi cantly increased 
as illustrated by elevated levels at day 3 and returned to normal levels at day 10 after 
TNBS challenge (fi gure 1b).
To see how the intestinal infl ammation aff ects APC subsets in the draining lymph 
nodes, we isolated and analyzed the MLN at diff erent time points after colitis induction. 
Three days after colitis induction the percentage of CD11c+ MHCII+ DC within the total 
CD45+ leukocyte population was signifi cantly increased in the MLN (fi gure 1d). This 
coincided with strong increase in the percentage of CD11c+ CD11b+ DC population, 
which could already be detected at day 1. Similarly to the cells in the lamina propria, 
the majority of the CD11c+ CD11b+ DC subset expressed Ly6c suggesting these cells 
are monocyte-derived DC. To corroborate that the CD11c+ MHCII+ CD11b+ Ly6C+ DC are 
monocyte-derived DC, surface expression of known mo-DC markers was performed.23 
Flow cytometry of the CD11c+ MHCII+ CD11b+ Ly6C+ DC population in the MLN of TNBS 
colitis mice revealed that the cells were negative for CD103 and positive for F4-80. More-
over, a small percentage of cells was CCR7 positive, indicative of recent migration into 
the node (fi gure 1e). The same phenotype was detected when Ly6C+ DC were studied in 
the ILN (data not shown).
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Figure 1. TNBS colitis is associated with monocyte infl ux into the lamina propria and DC into the LN. 
A: Weight loss and severity of colitis were determined at 1, 3 and 10 days after induction of colitis. B: 
CD45+ leukocytes were isolated from colon lamina propria and the changes in APC subsets characterized 
using fl owcytometric analysis of CD11b and CD11c expression. C: Expression of Ly6C was used to 
discriminate between resident macrophages and recruited monocytes within the CD11c- CD11b+ 
population of lamina propria cells. D: Changes in CD11c+ MHCII+ DC in MLN and the DC subpopulation 
expressing CD11b were determined during the course of colitis. E: The population of Ly6C+ CD11b+ 
CD11c+ MHCII+ DC detected in the MLN at day 3 was analyzed for the expression of CCR7, F4-80 and 
CD103. * Statistically signifi cant (P < 0.05)
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On day 10 the percentage of CD11c+ CD11b+ DC in MLN of TNBS colitis mice was simi-
lar to the percentage in control EtOH mice although the percentage of CD11c+ MHC-II+ 
DC within the total CD45+ leukocyte population remained higher than in EtOH controls.
From these data we conclude that CD11c- CD11b+ Ly6c+ monocytic cells infi ltrate the 
lamina propria within one day after TNBS colitis induction. Moreover, at day 3 there is a 
strong increase in the proportion of CD11C+ CD11b+ Ly6c+ DC in the MLN.
Depletion of CD11c+ cells does not aff ect the course of TNBS colitis
To assess the contribution of the CD11c+ DC in TNBS colitis a transient depletion of the 
cells was performed by i.p. injection of DT in CD11c-DTR mice. Previously we reported 
that CD11c+ DC depletion with DT injection before TNBS colitis induction did not aff ect 
disease severity.21 As the peak increase of CD11c+ MHCII+ DC in MLN occurred at 3 days 
post TNBS challenge the DT treatment was now performed on day 2 after TNBS chal-
lenge. As shown in fi gure 2a, the depletion of CD11c+ cells did not aff ect disease severity 
and progression.
DT injection on day 2 after TNBS challenge was eff ective as, on day 3, the CD11c+ cells 
in the MLN were reduced by 50% in CD11c-DTR transgenic mice when compared to 
non-transgenic controls, (fi gure 2b). In the colonic lamina propria complete depletion 
of the CD11c+ CD11b- DC was obtained (fi gure 2c). Crucially, in both lamina propria and 
MLN the majority of the residual CD11c+ DC were CD11b+ Ly6C+ suggesting that this 
population of DC was not aff ected by DT injections. Possibly, these cells have escaped 
depletion because they were monocytes that were CD11c- at the time of DT injection. 
In agreement, analysis of the lamina propria after DT treatment revealed that on day 3 
after colitis induction the monocyte infl ux was not aff ected by CD11c-depletion in the 
CD11c-DTR mice (fi gure 2c). These data revealed that CD11c+ DC depletion did not aff ect 
severity TNBS colitis. However, as CD11c+ Ly6c+ CD11b+ cells were not depleted these 
monocyte-derived DC may play a crucial role in the disease.
 Ly6C+ DC are the main population containing mucosally administered antigen 
in colitic mice
To see whether the Ly6C+ DC could be involved in the presentation of antigens we 
administered OVA-alexa-647 i.g. on day 2 of colitis. On day 3 of colitis OVA-647 positive 
CD11c+ MHCII+ DC were detected in the MLN. Moreover, the majority of OVA-647 positive 
DC had the Ly6C+ phenotype (fi gure 3). Similarly, i.r. administration of OVA-647 on day 
2 led to OVA-647+ Ly6C+ CD11c+ MHCII+ DC in the colon draining ILN (data not shown).
In sum, CD11c+ MHCII+ CD11b+ Ly6C+ DC in MLN of TNBS colitis mice can contain 
mucosally administered antigen.
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Figure 2. DC depletion did not aff ect severity of TNBS colitis and did not deplete Ly6C+ cells. 
A: CD11c+ DC were depleted in CD11c-DTR mice using an i.p. injection of DT 2 days after the induction 
of colitis. The course of TNBS colitis was assessed using weight loss and colitis score. B: The CD11c+ 
MHCII+ DC and the CD11b+ Ly6C+ subpopulation were analyzed in the MLN of mice one day after the DC 
depletion (3 days after colitis induction) using fl ow cytometry. C: The eff ect of DC-depletion on the lamina 
propria APC subsets was studied using the expression of CD11c and CD11b. In addition the expression of 
Ly6c within the CD11b+ populations (I+II) was assessed (C). * Statistically signifi cant (P < 0.05)
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Mucosal administration of antigen induces enhanced Ag-specifi c T-cell 
proliferation
To see how the presence of this subset within the lymph node aff ects the adaptive T-
cell response during TNBS colitis, it was determined whether colonic OVA application 
induced diff erential proliferation of OVA-specifi c T-cells in TNBS colitis mice versus EtOH 
controls. Thereto, an adaptive transfer of CFSE-labeled DO11.10 T-cells was performed 
on day 1 of TNBS colitis. On day 2 of colitis mice were given OVA i.r. and the OVA-specifi c 
T-cell response was analyzed on day 3 of colitis. As depicted in fi gure 4A, the percentage 
of proliferating OVA specifi c T-cells is strongly increased compared to that seen in EtOH 
controls in the ILN and MLN 3 days after antigen exposure (fi gure 4a). In agreement 
with their vigorous proliferation profi le, the cells expressed high levels of the activation 
marker CD25+ and low levels of the lymph nodes homing receptor CD62L (fi gure 4b).
These data show that the predominance of OVA-containing Ly6C+ CD11b+ DC in the 
MLN is associated with enhanced T-cells proliferation and activation.
DISCUSSION
In this study we show that within one day after induction of TNBS colitis Ly6c+ monocytes 
infi ltrate the intestinal lamina propria followed by a Ly6c+ CD11b+ DC increase in the 
draining lymph nodes. As the Ly6C+ DC are the major population containing mucosally 
delivered antigen and support T-cell division in vivo these cells have the capacity to 
contribute to the adaptive infl ammatory T-cell response. In agreement, upon depletion 
Figure 3. Ly6C+ DC are the main population containing mucosally administered antigen in colitic mice
Mice received OVA-labeled with Alexa Fluor-647 (or non-labeled OVA as control) in 200 μl saline i.g. 2 days 
after induction of colitis. One day after antigen administration the MLN were isolated and the expression 
Ly6C and CD11b was studied within the CD11c+ MHCII+ OVA-Alexa-647+ population. 
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of classical CD11c+ DC while maintaining Ly6c+ DC the course of colitis was unaff ected 
arguing that this new population of infl ammatory APC has an essential function in 
disease development.
Our data show that a new subpopulation of Ly6c+ infl ammatory DC is recruited to the 
MLN during TNBS colitis. Under steady state conditions these monocyte-derived DC are 
not detectable in lymphoid organs.24 Instead, these cells require infl ammatory signals 
for their recruitment.25 Our observation that the Ly6C+ DC were the major population 
containing mucosally administered OVA-antigen, combined with the enhanced prolif-
eration of OVA-specifi c T-cells in mice suff ering from colitis, argue that these Ly6C+ DC 
have a role in antigen presentation. This is in line with the function of protein presenting 
Ly6C+ DC that arise after vaccination with protein in the presence of alum.26 On the 
other hand, Ly6C+ DC are often referred to as infl ammatory DC or TNF/iNOS-producing 
(Tip)-DC that arise during infections.1,  23 Tip-DC are generally poor antigen presenters 
and contribute to immune responses through the production of antimicrobial media-
tors and by providing help to B cells for antibody production.27 Further experiments are 
currently performed to assess the innate and adaptive function of the Ly6C+ MLN-DC in 
our TNBS colitis model.
Figure 4. TNBS colitis is associated with increased DO11.10 proliferation after mucosal delivery of OVA.
Mice received 1 x107 CSFE-labeled CD4+ KJ1.26+ DO11.10 T-cells i.v. one day after colitis induction. 
The next day OVA was administered to the mucosa either i.r (ILN) or i.g. (MLN). Three days after OVA 
administration the ILN and MLN were isolated and single-cell suspensions were stained for the presence 
of CD4+ KJ1.26+ DO11.10 T-cells. A: CFSE profi les of CD4+ KJ1.26+ T cells were used to determine the 
percentage of proliferating cells in ILN and MLN. B: The expression of activations markers CD25 and the 
lymph node homing receptor CD62L in the ILN were studied within the CD4+ KJ1.26+ DO11.10 T-cell 
population.
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Indirect evidence for the role of the Ly6C+ DC in TNBS colitis comes from our obser-
vation that depletion of classical DC in CD11c-DTR mice while maintaining Ly6c+ DC 
did not aff ect the severity of disease. This is in contrast to the recent observation that 
depletion of classical DC could enhance DSS colitis severity.28 The diff erences between 
these fi ndings could not be attributed to the timing of depletion as neither depletion 
before challenge nor depletion on day 2 aff ected disease severity.21 Diff erences in the 
mechanisms of colitis induction between the hapten TNBS and the toxic DSS polymer, 
location and chronicity of the infl ammation between DSS and TNBS colitis may be the 
cause for diff erential eff ects in these models.
Although the Ly6C+ MLN-DC are likely to be derived from a Ly6C+ monocyte population 
it is questionable whether these cells have migrated from the lamina propria as only a 
very small proportion of the cells expressed the chemokine receptor CCR7. Alternatively, 
the Ly6+DC have diff erentiated locally from monocytes that are recruited to the LN as 
has been described for infl uenza infection.29
The strong increase in the number of Ly6C+ monocytes in lamina propria TNBS colitis 
agrees with previous reports that CD11b+ macrophages infi ltrate the lamina propria 
during chronic colitis in IL-10 defi cient mice.30 This monocytic infi ltration is likely to be 
chemokine dependent as CCL2 is increased in laminia propria after colitis induction.31 
Similarly, infection with Toxoplasma gondii leads to a strong CCR2 dependent recruit-
ment of Ly6C+ monocytes32 and oral infection with Salmonella induces recruitment of 
Ly6C+ monocytes that produce high levels of TNF and iNOS.33
Interestingly, multiple studies have shown that depletion of macrophages eff ectively 
inhibit colitis induction.30, 34 However, as the depleting agents MS-Cl2MDP and saporin-
conjugated anti-CD11b are likely to also aff ect both monocytes and monocyte-derived 
DC these studies should be re-evaluated.
In conclusion, our fi ndings that intestinal infl ammation during TNBS colitis is asso-
ciated with a newly recruited subset of monocyte-derived DC have important conse-
quences for understanding the mechanisms that lead to loss of tolerance to bacterial 
fl ora as seen in infl ammatory bowel disease.
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INTRODUCTION
In the past, analysis of the mucosal T cell phenotype largely supported the concept of 
Crohn’s disease (CD) as a T helper 1 (Th1) disease, driven by interleukin-12 (IL-12) and 
characterized by the production of the signature cytokine interferon (IFN)-gamma, and 
ulcerative colitis (UC) as an atypical Th2 disease characterized by production of cyto-
kines such as IL-13.1 The antigen presenting dendritic cells have been identifi ed as key 
players in their capacity to drive this T cell polarization (Rescigno).2,3
The discovery of the Th17 lineage, driven by IL-23 (as well as IL-6 and transforming 
growth factor-β) and characterized by IL-17 production has led to re-evaluation, and 
the realization that a number of infl ammatory conditions including CD, may actually be 
Th17 dependent.2,3
While re-examining the concepts of the various T cell phenotypes in infl ammatory 
bowel disease (IBD), it has become apparent that our understanding of the complex 
cytokine networks regulating these cells is far from complete. Overall, we are unable to 
determine the relative contribution of each cytokine to the initiation and perpetuation 
of infl ammation in IBD.2 We know that IL-12 (containing a p35 and a p40 subunit) and 
IL-23 (containing a p19 and a p40 subunit) are both produced in large quantities, along 
with other cytokines, by activated antigen-presenting cells (APCs), such as dendritic 
cells (DCs). In vitro, their secretion can be studied using artifi cial innate ligands, which 
activate receptors such as Toll-like receptors (TLRs) and Nod2-receptors. It is evident 
that there are signifi cant diff erences in the regulation of transcription of the component 
subunits (p19, p35 and p40), and indeed the kinetics and time-course of secretion diff er, 
raising the possibility that they act diff erentially in acute and chronic infl ammation.7
In addition, the promiscuity of p40 is far from unique in the IL-12 family of cytokines; 
the recent demonstration of the combination of p35 with EBI-3 (itself a component 
of IL-27) to form the regulatory cytokine IL-35 illustrates how much more we have to 
learn in the fi eld of cytokine regulation.8 The activation status of the immune cells and 
the relative synergy between multiple TLR signals determine how diff erent pathogen-
associated molecular patterns (PAMPs) elicit diff erent cytokine-driven T lymphocyte 
phenotypes.
The ability of an APC to secrete a cytokine does not confi rm a relevant biological 
role, as postsecretory eff ects are modifi ed by the relative expression of the appropriate 
receptor on the target cell, and by the local presence of other cytokines and regulatory 
T cells, which are capable of modifying T cell responses to cytokines.2 Kugathasan et al. 
compared T cell clones derived from the colonic mucosa of pediatric patients with newly 
diagnosed CD with those from patients with established disease or infective colitis.9 
They were able to examine the relative secretion of T cell cytokines, and the susceptibil-
ity to modulation by APC-derived cytokines. Overall, they found signifi cant diff erences 
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between T cells from early and late disease. Early disease was characterized by a strongly 
polarized Th1 response indistinguishable from that evoked in infective colitis, express-
ing high levels of the specifi c IL-12 receptor β2 subunit and IFN-γ, and sensitivity to 
cytokine modulation. In contrast, clones from established disease produced more IL-4 
and IL-10, and demonstrated relative insensitivity to the eff ects of modulation when 
cultured with cytokines. Of note, clones derived from early disease had the ability to 
upregulate markedly the secretion of the immunoregulatory cytokines IL-10 and IL-4 in 
response to the appropriate stimulus.
This study raises a number of important questions regarding the role of cytokines in 
shaping the mucosal infi ltrate in IBD, and the potential for disease modifying therapies. 
In particular, given the apparent insensitivity of T cells in established disease (at least to 
the cytokines used), it will be important to establish the additional mechanisms active in 
controlling the mucosal adaptive response, such as co-stimulatory molecules, microbial 
antigens and the eff ects of regulatory T cells.10 Perhaps the most intriguing question is 
whether targeting the disease early (in immunological terms), when cytokines are still 
dominant players in shaping the immune response and establishing chronicity, might 
off er greater potential to modify the course of disease than intervening late with anti-
cytokine therapy.2
This concept is supported by clinical observations of greater effi  cacy with biological 
therapies when used in early IBD. Further studies looking at the earliest immunological 
events in IBD are needed to guide the rational selection of the most appropriate cyto-
kine target, as are longitudinal studies of the balance of cytokines in the evolution of 
chronic IBD.
One of the remaining questions is, what will determine the development of these 
typical eff ector T cells: the expression of specifi c T cell receptors or the production of dif-
ferentiating cytokines by antigen presenting cells? In this chapter, we directly addressed 
whether the capacity of dendritic cells to produce IL-12 and/or IL-23 could be linked to 
a specifi c subset of pediatric IBD patients.
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PRODUCTION OF IL-12P70 AND IL-23 BY MONOCYTE-DERIVED DENDRITIC 
CELLS IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE
Infl ammatory bowel disease (IBD) patients represent a heterogeneous group of patients 
that may need novel classifi cation beyond just Crohns’ disease (CD) and ulcerative colitis 
(UC). Notably, based on patient specifi cs such as genetics, disease location, immune 
responses and drug responsiveness it seems likely that early onset infl ammatory bowel 
diseases represents a specifi c disease entity.1 Consequently, various disease associated 
eff ector T cells have been identifi ed, likely generated under the control of cytokines that 
are produced by antigen-presenting cells. In their recent publication, Kugathsan et al. 
demonstrate that the level of IL12β2 (IL-12 receptor) expression by mucosal T cells may 
be a major determinant during the initial manifestations of the CD for the development 
of the typically associated mucosal Th1 cytokine profi le.2 In this case, the presence of a 
specifi c T cell receptor correlated with the development of early CD. Similar mechanisms 
have been proposed for another recently discovered eff ector T cell subset. As such, T 
cell diff erentiation into interleukin-17 producing cells (Th17) may, in part, depend on 
T cell expression of the IL-23 receptor.3 Specifi cally, germline variations of IL23R have 
been implicated in conferring protection to ileal CD.4 The question now is, what will 
determine the development of these typical eff ector T cells; the expression of specifi c T 
cell receptors or the production of diff erentiating cytokines by antigen presenting cells? 
In our studies we directly addressed whether the capacity of dendritic cells to produce 
IL-12 and/or IL-23 could be linked to a specifi c subset of pediatric IBD patients.
To this aim, we cultured monocyte-derived dendritic cells (MoDC) obtained from 17 
children with Crohn’s disease (age 6.9–18 yrs, median 14.1 yrs) and 18 children with 
ulcerative colitis (age 3.2–17.2 yrs, median 13.3 yrs).5 After harvesting, the moDCs (2x105 
cells per well, 200 μl) were stimulated overnight with various microbial ligands at diff er-
ent concentrations: lipopolysaccharide (E.Coli, serotype 055:B5 L-4005, Sigma-Aldrich, 
Schnelldorf, Germany), zymosan (Sigma-Aldrich) and pam3cys (EMC Microcollections 
GmbH, Tubingen, Germany). Cell supernatants were collected and the production of 
IL-12p70 and IL-23 was determined by means of Cytometric Bead Array (BD Biosciences, 
San Jose, USA) and enzyme-linked immunoabsorbent assay (coating Affi  nity Purifi ed 
anti-human IL-23p19 [clone eBio473P19], detection anti-human IL-12p40/70 [clone 
C8.6; eBioscience]) respectively. For statistical analyses, Pearson correlation coeffi  cients 
and Spearman rank-correlation coeffi  cients were calculated both for the original values 
and the logarithmic transformed values. Furthermore, Analysis of Variance (Anova) and 
Linear Mixed Models with a unstructured correlation matrix for the residuals to account 
for dependencies (due to repeated measurements) were used.
Within the two patient groups, there was a high variability in IL-12p70 and/or IL-23 
production upon microbial stimulation (fi gure 1a and b). The levels of either IL-12 or 
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IL-23 could not be related to disease activity (expressed by pediatric Crohn’s disease 
activity index [PCDAI] or Lightiger colitis activity index [LCAI] respectively), disease loca-
tion, or medication. There was no diff erence in cytokine production by moDCs when we 
compared early to late IBD (for CD as well as for UC). There was a clear dose dependent 
relation between the production of IL-12 or IL-23 and for all the used microbial ligands. 
As such, we could subcategorize the patient moDCs into high, intermediate, or low 
responders, irrespective of the used microbial ligand (data not shown).
These data indicate that neither of the specifi c IBD subsets (CD or UC) may be as-
sociated with a ‘’hardwired’’ predisposition for IL-12 or IL-23 production. We did not fi nd 
any relation between IL-12p70 and IL-23 levels (fi gure 2), confi rming recent reports that 
the production of these two cytokine family members is diff erentially regulated. We 
conclude that the intrinsic capacity of MoDC to produce IL-12p70 and/or IL-23 is not 
associated with a specifi c subtype or stage of infl ammatory bowel disease. We therefore 
Figure 1a: High variability in the production of IL-12p70 by moDCs derived from children with Crohn’s 
disease (CD) vs. ulcerative colitis (UC). moDCs were stimulated overnight with LPS at 0.1 μg/ml. 
Figure 1b:  High variability in the production of IL-23 by moDCs obtained from children with Crohn’s 
disease (CD) vs. ulcerative colitis (UC). moDCs were stimulated with LPS 0.1 at μg/ml. 
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hypothesize that the presence of specifi c mucosal T eff ector cells that have been identi-
fi ed in CD or UC results from the local amount of particular microbial ligands and T-cell 
expression of specifi c receptors such as IL-12β2 and IL-23R.
Figure 2: No relation between the production of IL-12p70 and IL-23 by moDCs. moDCs were derived from 
children with Crohn’s disease and stimulated with LPS at 0.1 mg/ml. 
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ABSTRACT
Background: Intestinal Paneth cells (Pc) produce anti-microbial defensins, lysozyme 
and pro-infl ammatory TNF-α. Impaired Pc defensin production has been associated with 
intestinal infl ammation. Elucidation of the mechanisms that regulate TNF-α production 
by Pc may identify a novel contributive pathway of mucosal infl ammation.
Methods: With immunohistochemistry, we determined lysozyme and TNF-α expres-
sion by Pc of 74 pediatric Infl ammatory Bowel Disease (IBD) patients, 20 celiac disease 
patients and 27 healthy controls.
Next, we explored diff erences in the regulation of lysozyme and TNF-α production in 
an in vitro model using a human monocyte cell-line.
Finally, we examined jejunal segments derived from IL-10-/- mice in SPF and germ-free 
conditions and LPS-insensitive mice (CH3/HeJ) for TNF-α and lysozyme expression.
Results: Lysozyme was equally expressed by Pc in all patients and controls. In contrast, 
45% of the Crohn’s disease patients, 37% of the ulcerative colitis patients and 35% of the 
celiac disease patients expressed TNF-α in Pc. 19% of healthy duodenum was positive 
for TNF-α in Pc.
In vitro analysis showed that TNF-α production by a monocyte cell line could be in-
duced by LPS and suppressed by IL-10 and not by IL-22. Under similar conditions, LPS, 
IL-10 and IL-22 had no eff ect on lysozyme expression as determined by quantitative PCR.
In line with this fi nding, we observed enhanced expression of TNF-α in Pc of IL-10-/- 
mice compared to WT mice that was absent in germ-free IL-10-/- mice. Finally, CH3/HeJ 
LPS-insensitive mice expressed less Pc-derived TNF-α compare to CH3/HeN LPS sensitive 
mice.
Conclusion: In humans, Pc TNF-α levels are associated with mucosal infl ammatory 
diseases. In mice, TNF-α production by Pc is dependent on microbial stimulation and 
regulated by IL-10. Under comparable conditions, Pc lysozyme levels remain unaff ected. 
These data indicate diff erential regulation of TNF-α and lysozyme production by Pc.
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INTRODUCTION
Paneth cells (Pc) play an important role in the regulation of intestinal microbial homeo-
stasis in the small intestine. Pc release anti-microbial peptides such as lysozyme and 
defensins, in order to prevent bacterial invasion into the intestinal crypts.1-4 Impaired 
production and release of these peptides has been associated with bacterial overgrowth 
and infl ammatory intestinal diseases such as Crohn’s disease (CD).5, 6
Next to lysozyme and defensins, tumor necrosis factor-α (TNF-α) is also produced 
by Pc.7 Augmented production of TNF-α by hematopoietic cells has been associated 
with multiple infl ammatory conditions including infl ammatory bowel disease (IBD). 
Over-expression of Pc-derived TNF-α has been suggested to contribute to necrotizing 
enterocolitis.8
Production of TNF-α in hematopoietic cells can be inhibited by interleukin (IL)-10.9, 10 
Along these lines, IL-10 knock-out mice spontaneously develop colitis that is thought 
to depend on increased levels of TNF-α.11,  12 Furthermore, polymorphisms in the IL-10 
promotor and IL-10 receptor have been associated with IBD in humans, indicating an 
important regulatory and anti-infl ammatory role for IL-10.13-15 To date, it is not known 
how induction and control of TNF-α by Pc is regulated.
To identify a potential role for Pc derived TNF-α in mucosal infl ammation we deter-
mined expression of both lysozyme and TNF-α in intestinal biopsies from pediatric 
patients with IBD or celiac disease and controls. Next, we studied various transgenic 
mice to determine the relative contribution of microbial signaling and IL-10 to Pc TNF-α 
production and regulation.
MATERIALS & METHODS
Patients
Biopsies of 44 pediatric Crohn’s disease patients and 30 ulcerative colitis patients were 
included in this study, as well biopsies derived from 20 patients with celiac disease and 27 
controls. All biopsies were performed for diagnostic purposes and none of the patients 
received medication at the time of biopsy. IBD patients were diagnosed by endoscopy, 
histo-pathological and clinical characteristics according to the Porto criteria.16 Biopsies 
of celiac disease patients were all scored Marsh III.17, 18 Control biopsies showed no sign 
of infl ammation. All biopsies were fi xed in paraformaldehyde and embedded in paraffi  n. 
Histological scores and pathological characteristics of the sections were performed by 
a blinded pathologist.
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Animals
Specifi c pathogen-free (SPF) 10-week-old female BALB/c mice were purchased from 
Charles River (Saint Aubin Lee´s Elbeuf, France). SPF 10-week-old female LPS-unrespon-
sive C3H/HeJ mice and LPS-responsive C3H/HeN mice19,  20 were purchased from CLEA 
Japan, Inc. (Tokyo, Japan). SPF 8-to 10-week old IL-10-defi cient C57BL/6 mice, formally 
designated ‘IL-10tm1Cgn’ (I. J. Bristol, M. Mähler, E. H. Leiter, J. P. Sundberg: IL-10tm1Cgn, 
an IL-10 gene-targeted mutation; JAX notes 471, The Jackson Laboratory, Bar harbor, 
ME, USA, 1997) (obtained from M. Mähler, Hanover, Germany), and their wild-type (WT) 
littermates were bred at the animal facility of the Erasmus MC (Rotterdam, the Neth-
erlands) and maintained in isolator cages with water and a standard pellet diet (Hope 
Farms, the Netherlands) ad libitum.
Immunohistochemistry
Sections (4mm) were routinely stained with hematoxylin (Vector Laboratories, CA) and 
eosin (Sigma-Aldrich, The Netherlands) to study morphological alterations.
For immunohistochemistry sections were dewaxed and endogenous peroxidases 
were quenched with 3% H2O2 in methanol for 20 min. Antigen retrieval for lysozyme 
P (for human and mouse sections) was obtained after microwave treatment in citrate 
buff er (10 mM pH 6.0) and for TNF-α after treatment with 0.1 % pepsin in 0.01 N HCl for 7 
minutes at 37°C. Sections were blocked for 1 hour in either 1% blocking reagent (Roche, 
The Netherlands) in PBS or 10 mM Tris, 5mM EDTA, 0.15M NaCl, 0.25% gelatine, 0.05% 
Tween-20, supplemented with either 10% normal mouse plus normal rabbit serum or 
10% normal human serum, pH 8. Antibody incubation was performed overnight at 4°C 
with rabbit anti-lysozyme P (DakoCytomation, Denmark) diluted 1:50, goat anti-mouse 
TNF-α (Santa Cruz Biotechnology, CA) diluted 1:200, mouse anti-human TNF-α (Immu-
noTools, Germany) diluted 1:100. Immunoreactions were detected using respectively 
biotinylated secondary goat anti-rabbit, rabbit anti-goat or horse anti-mouse serum 
with the Vectastain ABC Elite Kit (Vector Laboratories) and 3,3’-diaminobenzidine tetra-
hydrochloride (Sigma-Aldrich).
Alls sections were counterstained with Hematoxylin (Vector Laboratories) and pictures 
were taken by a Leica DM 5500 microscope with 40x and 100x lens.
In vitro assays
THP-1 cells were maintained in RPMI1640 medium (Gibco) containing 10% heat inacti-
vated fetal calf serum in 5% CO2 at 37°C. For each experiment, THP-1 cells were seeded 
in 96-well fl atbottom plates at a density of 2x105 cells/well. THP-1 cells were treated with 
1μg/ml LPS (E.coli 055:B5, Sigma) alone or in combination with either 10ng/ml rhIL10 
(ImmunoTools, Germany) or 10ng/ml rhIL22 (ImmunoTools). Supernatant and cells were 
harvested after 6h of stimulation. TNF-α production was measured by ELISA (hTNF-α, 
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BD) and lysozyme expression was analyzed by qPCR on RNA that was isolated using a 
RNA isolation kit (Qiagen). cDNA was generated by standard methods and amplifi ed 
using an ABI Prism 7700 Sequence detector in the presence of SYBR Green according to 
manufacturer’s protocol (DyNAmo HS SYBR Green qPCR kit, New England Biolabs). We 
used GAPDH primers as an internal control and specifi c primers for hLysozym. Primer 
sequences: hGAPDH-F: GTCGGAGTCAACGGATT, hGAPDH-R: AAGCTTCCCGTTCTCAG, 
hLysozym-F: ACCCCAGGAGCAGTTAAT and hLysozym-R: GCCACCCATGCTCTAAT.
Statistical analysis
Production of TNF-α and lysozyme was statistically analyzed using an unpaired Student’s 
t-test when appropriate. A p-value of < 0.05 was considered statistically signifi cant. Data 
are presented as the mean ± standard error of the mean (SEM).
RESULTS
Human Pc express higher levels of TNF-α in infl ammatory conditions
To investigate whether Pc-derived TNF-α is involved in human intestinal infl ammation, 
we obtained biopsies from duodenum, terminal ileum and the distal part of the colon 
of newly diagnosed IBD patients. Next to H&E staining, these biopsies were stained for 
lysozym and TNF-α. We observed PC metaplasia in 65% of the IBD patients (CD 66%, 
ulcerative colitis (UC) 63%), confi rming earlier reports (Table 1).21
We found that all Pc from IBD patients as well as controls expressed lysozyme at similar 
levels (fi gure 1a). Immunohistochemical staining for TNF-α showed that 42% of the IBD 
Table 1. TNF-α expression in Pc of IBD patients, celiac disease patients and controls
Total Metaplasia %
IBD 74 48 64.8
CD 44 29 65.9
UC 30 19 63.3
Total TNF-α %
IBD 74 31 41.9
CD 44 20 45.5
UC 30 11 36.7
Celiac disease 20 7 35.0
Control 27 5 18.5
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Figure 1. Paneth cells express TNF-α irrespective of location
(A-C) Representative examples of immunohistochemical staining for lysozyme (A) and TNF-α (B) on 
intestinal sections of pediatric IBD patients. (A) Paneth cells (Pc) are present in small intestinal (left) and 
colonic (right) sections from pediatric IBD patients. Brown staining indicated lysozyme expression. (B) 
TNF-α (brown) in the Pc is expressed in a subset of patients. (C) Representative small intestinal section of a 
celiac disease patient. Brown staining indicates lysozyme (left) and TNF-α (right) expression.
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patients contained TNF-α expressing Pc (Table 1). Within the group of IBD patients, Pc 
of CD and UC patients displayed equal positivity for TNF-α (45% and 37%, respectively, 
Table 1). Examples of immunohistochemical staining for TNF-α are shown in fi gure 1b. 
Intriguingly, TNF-α positivity in the Pc was irrespective of the location of the Pc. Patients 
with colonic metaplastic Pc showed similar expression (on / off ) for TNF-α as compared 
with Pc in the small intestine. In contrast, only 19% of healthy controls showed TNF-α 
expression in the Pc of duodenal biopsies, indicating that increased TNF-α expression in 
Pc is associated with mucosal infl ammatory diseases.
To determine whether the induction of TNF-α expression in the Pc was specifi c for IBD, 
we analyzed duodenal biopsies from celiac disease patients with high level of intestinal 
infl ammation (Marsh III score). We found that in 35% of these celiac disease patients, 
duodenal biopsies contained TNF-α expressing Pc (fi gure 1c, Table 1). These results 
showed that Pc-derived TNF-α was irrespective of intestinal location and not specifi c for 
IBD, but rather associated with intestinal infl ammation in general. In contrast to TNF-α, 
lysozyme was constitutively expressed in Pc of both patients and controls, suggesting 
diff erential regulation of lysozyme and TNF-α in the Pc.
Lysozyme and TNF-α are diff erentially regulated in vitro
Our fi nding that lysozyme was constitutively expressed in all Pc and TNF-α expression 
was only observed in Pc of a subset of patients, suggests that lysozyme and TNF-α ex-
pression are diff erentially regulated in the Pc.
As there is no Pc cell line available, we determined lysozym and TNF-α expression in 
the human monocytic cell line THP-1. THP-1 cells have been shown to produce lysozyme 
as well as TNF-α upon lipo-polysaccharide (LPS) stimulation.22 Furthermore, it has been 
shown that IL-10 can downregulate TNF-α production in hematopoietic cells.9, 10
We stimulated THP-1 cells with LPS alone (1μg/ml) or in addition of recombinant hu-
man (rh) IL-10 or, as a negative control, the IL-10 family member rhIL-22 (each 10ng/
ml). Supernatant and cells were harvested after 6h of stimulation. TNF-α production 
was measured by ELISA and lysozyme expression was analyzed by qPCR. We found 
that stimulation with LPS induced the expression of TNF-α, while expression of lysozym 
remained stable. Addition of rhIL-10 partially inhibited the induction of TNF-α but did 
not aff ect lysozyme expression. As expected, the addition of rhIL-22 did not have any 
eff ect on either TNF-α or lysozyme expression (fi gure 2). These data confi rm that TNF-α 
production is induced by LPS and down-regulated by IL-10, whereas lysozym expression 
is constitutive.
Lysozyme and TNF-α are diff erentially regulated in vivo
Our in vitro experiment indicated a direct role for IL-10. As we were unable to stain IL-10 
or its receptor on our human biopsies, we further expanded on our in vitro data by exam-
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ining IL-10-defi cient mice. In our facility these mice spontaneously develop colitis at 20 
weeks of age. To compare expression of Pc-derived TNF-α and lysozyme in non-infl amed 
mice, we used 9 weeks old IL-10-/- mice and age-matched WT mice.
We found strong TNF-α staining in Pc of IL-10-/- mice compared to WT controls (fi gure 
3a,b,c). In contrast, both type of mice expressed similar levels of lysozyme (fi gure 3d,e). 
These results confi rm that, also in an in vivo model, IL-10 inhibits TNF-α expression in Pc 
and has no eff ect on the expression of lysozyme under similar conditions.
It has been well established that microbial exposure stimulates production of TNF-α 
in various immune cells. To investigate potential microbial regulation of TNF-α in the Pc 
in vivo, we analyzed the expression of TNF-α in IL10-/- mice that were maintained under 
germ-free conditions. In sharp contrast with IL10-/- mice that were maintained under spf 
conditions, these mice did not express TNF-α in the Pc (fi gure 3f ) indicating a role for 
microbial stimulation in Pc TNF-α production.
We found similar expression levels of lysozyme when comparing germ-free IL10-/- 
mice to IL10-/- mice that were kept at SPF conditions (fi gure 3g). Together with the data 
shown in fi gure 3a and 3b, these data confi rm that microbial exposure is crucial for the 
expression of Pc-derived TNF-α, whereas lysozyme is constitutively expressed.
TNF-α expression is dependent on LPS signaling
Next, we determined lysozyme and TNF-α expression in Pc within the terminal ileum of 
LPS-insensitive mice (CH3/HeJ) and controls (CH3/HeN) kept under spf conditions. CH3/
HeJ mice are defi cient for toll-like receptor 4 (TLR4), the specifi c receptor for LPS, and are 
therefore insensitive to LPS stimulation.
By counting TNF-expressing Pc in both type of mice we determined that Pc from 
CH3/HeJ mice expressed less TNF-α compared to CH3/HeN controls, indicating that the 
$ %
Figure 2. Lysozyme and TNF-α are diff erentially regulated in vitro
(A,B) TNF-α and lysozyme production by THP-1 cells 6 hours after stimulation with LPS (1μg/ml) alone or 
in addition of recombinant human IL-10 or the IL-10 family member IL-22 (each 10ng/ml). Production of 
TNF-α was measured by ELISA (A), whereas lysozyme was analyzed by qPCR (B). Error bars represent SEM, 
*p<0.05
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Figure 3. Lysozyme and TNF-α are diff erentially regulated in vivo
(A-E) Representative examples of immunohistochemical staining for TNF-α (brown, A,B) and lysozyme 
(brown, D,E) on small intestinal sections of wild type (WT) mice (A,D) and interleukin (IL)-10-defi cient 
mice (B,E) in SPF conditions. (C) Quantifi cation of TNF-α expression in the crypts of WT and IL-10-/- mice 
depicted as number of TNF-α positive crypts per section. (F,G) Expression of TNF-α (F) and lysozyme (G) in 
small intestinal sections of IL-10-/- mice that were kept under germ-free conditions. 
Error bars represent SEM, *** p<0.001, ** P<0.01, ND = not detected, n=9 mice per group for mice in SPF 
conditions. N=3 mice per group in germ free conditions.
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production of TNF-α in the Pc is at least partially regulated by LPS (p<0.05) (fi gure 4). This 
confi rms the observation that Pc-derived TNF-α production is driven by TLR4 signaling.
DISCUSSION
We found enhanced levels of Pc TNF-α in patients with mucosal infl ammatory diseases. 
In order to explore the regulation of Pc derived TNF-α, we analyzed the expression of 
TNF-α in vitro and in vivo. In mice, TNF-α production by Pc was dependent on microbial 
stimulation and regulated by IL-10. Under comparable conditions, Pc lysozyme levels 
remained unaff ected, indicating diff erential regulation of TNF-α and lysozyme produc-
tion by Pc.
IL-10 plays an important role in the regulation of TNF-α in hematopoietic cells. Binding 
of IL-10 to its receptor leads to the phosphorylation of suppressor of cytokine signal-
ing-3 (SOCS3) via activation of signal transducer and activator of transcription-3 (STAT3). 
This in turn leads to the inhibition of pro-infl ammatory genes expression. Whether IL-10 
exerts a comparable function in the Pc is unknown. However, as epithelial cells express 
STAT3, a similar mechanism could be responsible for the regulation of TNF-α expression 
by Pc.23-25
+H1+H-
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Figure 4. Impaired LPS signaling results in aberrant TNF-α expression in the Pc
(A,B) Representative examples of TNF-α expression in TLR4-defi cient CH3/HeJ (A) and CH3/HeN controls 
(B). (C) Number of TNF-α positive crypts per section in LPS insensitive (CH3/HeJ) and controls (CH3/HeN). 
Error bars represent SEM, * p<0.05, n=5 mice per group.
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Although we were unable to detect IL-10 or the IL-10 receptor by immunohistochem-
istry on our human biopsies, insuffi  cient IL-10 expression, as has been found in a subset 
of IBD patients15, could result in augmented production of TNF-α by Pc. Nonetheless, 
these polymorphisms are rare in IBD and not identifi ed in celiac disease patients. There-
fore, aberrant IL-10 signaling may partly explain the diff erence in TNF-α expression by Pc 
between controls and patients with mucosal infl ammatory diseases.
Microbial exposure was crucial for the induction of TNF-α in the Pc in our mouse 
experiments.
Even in IL10-/- mice, colonization with SPF microbiota is required for Pc TNF-α produc-
tion. By showing that TLR4-defi cient CH3/HeJ mice express diminished levels of TNF-α 
we established a role for LPS-TLR4 signaling as a prerequisite for Pc TNF-α production 
(fi gure 3,4). Indeed, toll-like receptor stimulation by microbial products has been shown 
to initiate pro-infl ammatory immune responses in epithelial cells that may include Pc.26 
Interestingly, we observed no diff erence between Pc derived TNF-α expression in the 
small intestine as compared with metaplastic Pc in the colon. As the bacterial load varies 
widely in these two locations, diff erences in microbial stimulation are not a suffi  cient 
explanation for the enhanced expression of TNF-α in Pc of these patients. Moreover, in 
celiac disease patients, all patients had a Marsh III score but clearly diff ered in Pc TNF-α 
expression, thereby excluding local mucosal infl ammation as a dominant determinant. 
These fi ndings indicate that the expression of TNF-α by Pc is in part intrinsically regu-
lated. In this model, host genetics, systemic conditions e.g. infl ammation as well as local 
factors may determine this Pc function. In this small patient cohort, we were not able 
to establish diff erences in local infi ltrations or systemic infl ammation (data not shown).
In contrast to TNF-α, lysozyme was constitutively expressed under all tested condi-
tions. A lack of IL-10 or absence of microbial stimulation had no eff ect on the expression 
of lysozyme in the Pc, suggesting diff erential regulation of TNF-α and lysozyme. As lyso-
zyme was constitutively expressed in germ free mice, this suggests that the production 
of lysozyme is largely independent of microbial triggers. However, release of lysozyme 
has been shown to be dependent on interactions with glycolipid and independent 
on LPS stimulation.4, 27 The exact role of microbial induced lysozyme production by Pc 
therefore remains to be elucidated.
Finally, diff erences in the regulation of TNF-α expression and lysozyme in the Pc could 
be explained by potential diff erences in epigenetic control of the genes encoding for 
these proteins. A recent paper established the existence of tolerazible genes (including 
genes encoding for TNF-α) and non-tolerazible genes (e.g. anti-microbial genes).28 These 
fi ndings can explain how TNF-α production may become down-regulated under condi-
tions that do not aff ect lysozyme translation. Although enhanced TNF-α expression is 
associated with mucosal infl ammatory diseases as IBD, celiac disease (this study) and 
necrotizing enterocolitis8, it remains to be explored whether Pc derived TNF-α contrib-
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utes to intestinal infl ammation. A contributing role is supported by our fi nding that Pc 
express enhanced levels of TNF-α prior to the development of colitis in IL-10-/- mice. Fu-
ture studies are needed to expand on our fi ndings and the potential pro-infl ammatory 
role of Pc in mucosal infl ammation.
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ABSTRACT
Introduction: Despite continuous microbial exposure within the intestine, the mucosal 
immune system is able to maintain a state of tolerance to the resident microbiota. Im-
paired immune responses to intestinal microbial products are thought to contribute to 
infl ammatory bowel disease (IBD). Repetitive microbial stimulation of monocytes from 
healthy individuals leads to tolerance evidenced by a reduced release of infl ammatory 
cytokines. We assessed whether acquisition of innate microbial tolerance in IBD patients 
diff ers from healthy controls by analyzing responsiveness of monocytes upon repetitive 
lipopolysaccharide (LPS) stimulation.
Materials & Methods: Blood-derived monocytes of 20 pediatric patients with inactive 
IBD (10 Crohn’s disease, 10 ulcerative colitis) and 14 pediatric controls were stimulated 
with various doses of LPS. After 18h the cells were re-stimulated with 10ng/ml LPS to 
assess the reduction in LPS responsiveness. The production of the pro-infl ammatory 
cytokine TNF-α was determined.
Results: Monocytes from patients with inactive IBD and controls produced comparable 
levels of TNF-α upon initial LPS stimulation. However, when cells from Crohn’s disease 
and ulcerative colitis patients were primed with low-dose LPS, LPS re-stimulation re-
sulted in considerably lower levels of TNF-α compared to controls.
Conclusion: This study shows that blood-derived monocytes from pediatric IBD patients 
become more tolerant to LPS upon repetitive stimulation. This intrinsic immune defect 
may contribute to the etiopathogenesis of IBD.
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INTRODUCTION
Innate immune defects have been implicated in the pathogenesis of infl ammatory bowel 
disease (IBD).1-5 We have shown that in pediatric Crohn’s disease patients, epithelial cells 
derived from the buccal mucosa display enhanced responsiveness to microbial stimula-
tion.4 On the other hand, dendritic cells derived from the same group of patients did not 
show any diff erences in immune responses compared to controls.6 Similar to most of 
the published studies, these experiments involved the use of a single microbial stimulus 
but not repetitive stimulation. As such, it remains unclear whether these experiments 
represent the more physiological situation of chronic microbial exposure within the 
intestinal mucosa.
Furthermore, while the cytokine production by immune cells upon microbial stimula-
tion varies widely in controls and IBD patients, absolute concentrations of cytokines 
are not directly associated with disease activity.6 Therefore it seems more likely that 
altered cytokine responses within patients determine the outcome of following immune 
responses, rather than the absolute value upon a single microbial stimulus.
It is well established that repetitive microbial stimulation of innate cells can lead to a 
state of non-responsiveness denoted as microbial tolerance.7-9 Innate defects in IBD may 
be accounted for by this mechanism of impaired microbial tolerance.
We assessed sensitivity to the induction of lipopolysaccharide (LPS)-tolerance in 
blood-derived monocytes of IBD patients with inactive disease by applying repetitive 
LPS stimulation Our data indicate that monocytes from IBD patients display enhanced 
unresponsiveness to repetitive LPS stimulation compared to controls.
MATERIAL AND METHODS
Patients
A cohort of 19 pediatric IBD patients, containing 10 Crohn’s disease (CD) patients and 9 
ulcerative colitis patients (UC), was included in this study, as well as 14 healthy control 
donors (Table 1). The control group consisted of age-matched orthopedic patients in 
the same age group with no underlying infl ammatory or intestinal diseases. The patients 
were diagnosed with IBD by endoscopy, histo-pathological and clinical characteristics 
according to the Porto criteria.10 Disease activity was determined using the PCDAI and 
PUCAI indexes for Crohn’s disease and ulcerative colitis, respectively.11, 12 Only patients 
with inactive or mild active disease (PCDAI / PUCAI < 30) and with written parental in-
formed consent were included. Approval for this study was obtained by the local ethics 
committee.
Pieter BW.indd   107 15-Jul-10   16:50:11 PM
108 Chapter 7
Isolation of peripheral blood monocytes
Venous blood was collected in EDTA-tubes and peripheral blood mononuclear cells 
(PBMC) were isolated by centrifugation over a Lymphoprep density gradient accord-
ing to standard protocols. First, 20 ml of whole blood was centrifuged (450G, 10 min, 
room temperature) to remove plasma. The remaining blood was diluted 1:1 with PBS, 
placed over 15 ml Lymphoprep, centrifuged (1140G, 20 min, room temperature, without 
brake) and the lymphocyte-containing interface was collected. After washing with 
PBS, PBMC were incubated with MACS CD14+ separation beads (Miltenyi) according to 
manufacturer’s protocol. CD14 positive cells were isolated by magnetic separation and 
washed several times with PBS before use. Purity of monocytes (~95%) was analyzed by 
fl owcytometry.
Flowcytometry
To assess cell purity and viability, cells were incubated with anti-CD16/CD32 (2.4G2) 
to block FC-receptors, stained with CD14-Fitc (BD) and 7AAD and measured on a FACS 
Canto II cytometer with FACS Diva software (BD). Data were analyzed using Flowjo 
software (Tree Star).
Desensitization assay
After isolation, CD14+ cells were incubated in a fl atbottom 96-well plate (Falcon, 2x105 
cells / 200 ml) in Iscove’s Modifi ed Dulbecco’s Media (IMDM, Gibco) containing 10% Hu-
man serum, 100 U/ml penicillin and 100 μg/ml streptomycin. The cells were incubated at 
37°C /5% CO2 to adhere for 18 hours. Next, adherent monocytes were washed once with 
medium and stimulated in triplo with or without 0.1 or 10 ng/ml LPS (E.coli, serotype 
055:B5, Sigma) for 6h (sensitization phase). Supernatant was collected and stored at 
-80°C until further analysis. Monocytes were then incubated in fresh medium for another 
Table 1, Patient characteristics
Crohn’s disease Ulcerative Colitis Controls
Number of patients 10 9 14
Male (n) 6 3 9
Age of Diagnose (y) 13,3 (9-16) 10,3 (3-15)
Age (y) 15,1 (11-17) 15,2 (15-16) 13,7 (10-18)
PCDAI 6,5 (0-30)
PUCAI 5,5 (0-20)
Azathioprine 7 3 0
Mesazaline 0 7 0
Prednisolone 0 1 0
Infl iximab 1 0 0
Methotrexate 2 0 0
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18h at 37°C, washed and either or not re-stimulated for 6h with a second dose of LPS 
(10 ng/ml).
Level of tolerance
Production of TNF-α in the supernatant was determined by means of ELISA (BD) accord-
ing to manufacturer’s protocol. The assay has a detection limit of 10 pg/ml. To quantify 
the level of LPS tolerance, TNF-α production of unprimed monocytes was compared to 
primed cells by calculating the slope of the TNF-α concentrations in the supernatant 
after re-stimulation with LPS. We used LOG10 transformed values in order to correct for 
the variance of TNF-α production.
The slope for each individual was calculated using the formula: y=ax, in which ‘a’ 
stands for the slope. Y equals the diff erence in TNF-α production (LOG10) of unprimed 
and primed samples. For X the arbitrary value of 2 was used. A steeper slope indicated 
enhanced LPS tolerance.
Statistical analysis
LPS responses were statistically analyzed with a non-parametric T-test. Correlations 
between data sets were analyzed with Spearman correlation coeffi  cients. P-values <0.05 
were considered signifi cant.
RESULTS
Monocytes from IBD patients and healthy controls respond similar to primary 
LPS stimulation
We investigated the primary response to LPS stimulation of monocytes from IBD pa-
tients and controls. Monocytes were either unprimed or primed with 0.1 or 10 ng/ml LPS 
for 6 hours and production of TNF-α was determined by means of ELISA. The majority 
of unprimed monocytes did not produce detectable levels of TNF-α within this time 
frame (fi gure 1a). Cells that were primed with LPS showed a range of TNF-α produc-
tion, confi rming earlier reports (fi gure 1b,c).2, 5, 6 We conclude that monocytes from IBD 
patients and controls produced similar amounts of TNF-α upon priming with high- or 
low-dose LPS.
Monocytes produce low levels of TNF-α upon re-stimulation with LPS
In order to investigate the eff ect of chronic LPS stimulation on the innate immune re-
sponse, LPS-primed monocytes from patients and controls were re-stimulated with high-
dose LPS (10ng/ml). Monocytes that were unprimed produced high levels of TNF-α upon 
stimulation with LPS (fi gure 2a), comparable to levels of TNF-α as shown in fi gure 1c.
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In UC patients, priming with low-dose LPS resulted in signifi cantly reduced TNF-α 
production by monocytes compared to controls (p<0.05), whereas TNF-α production 
in CD patients was not signifi cantly diff erent from controls, although a trend could be 
observed (p=0.06, fi gure 2b).
In contrast, monocytes that were primed with high-dose LPS were almost insensitive 
to re-stimulation with LPS, refl ected by the lack off  or very low amounts of TNF-α pro-
duction (fi gure 2c).
These results indicate that priming with LPS of monocytes from patients as well as 
controls results in a diminished secondary response upon re-stimulation. This eff ect was 
most prominent when cells were primed with a high concentration of LPS. Responses 
to priming with low-dose LPS diff ered between IBD patients and controls, suggesting 
enhanced responsiveness upon low-dose LPS in IBD patients.
Monocytes from IBD patients display enhanced LPS-tolerance
The level of TNF-α production by monocytes showed ample variation upon initial LPS 
stimulation as well as upon re-stimulation. Therefore, comparing the average responses 
Figure 1. Monocytes from IBD patients and healthy controls respond similar to initial LPS-stimulation
TNF-a production of peripheral blood-derived monocytes of controls (Co), Crohn’s disease (CD) and 
ulcerative colitis (UC) patients. TNF-α was determined in the supernatant 6 hours after stimulation without 
LPS (A), 0.1 ng/ml LPS (B) and 10 ng/ml LPS (C).
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per group is not suffi  cient to elucidate diff erences between individuals. In order to 
quantify the level of tolerance for each individual, we determined the relative reduction 
in TNF-α production by calculating the slope between unprimed and primed monocytes 
(see Materials and Methods). Steeper slopes represent more robust LPS tolerance. We 
compared the secondary response upon priming with low- or high-dose LPS, respec-
tively (fi gure 3).
Cells of CD as well as UC patients that were primed with low-dose LPS, displayed 
steeper slopes compared to controls (p<0.01, fi gure 3a). However, when cells were 
primed with high-dose LPS, all individuals displayed comparable slopes and therefore 
comparable levels of LPS-tolerance (fi gure 3b).
This indicates that – depending on the dose of LPS at priming – monocytes from IBD 
patients are less responsive to a secondary LPS stimulus compared to controls.
Figure 2. Monocytes produce low levels of TNF-α upon re-stimulation with LPS
TNF-α production of peripheral blood-derived monocytes of controls (Co), Crohn’s disease (CD) and 
ulcerative colitis (UC) patients upon re-stimulation with high-dose LPS. Cells were primed without LPS (A), 
0.1 ng/ml LPS (B) and 10 ng/ml LPS (C) for 6 hours. Cells were washed, incubated with fresh medium for 
18 hours and re-stimulated in fresh medium for 6 hours with 10 ng/ml LPS. TNF-α was measured in the 
supernatant 6 hours after the last stimulation with LPS.
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DISCUSSION
Defective interactions between the innate immune system and the intestinal micro-
biota are strongly implicated in the pathogenesis of IBD.13,  14 Both augmented as well 
as diminished responsiveness of innate hematopoietic and non- hematopoietic cells 
have been proposed as contributors to this mucosal infl ammation.1-5 Interpretation of 
this apparent paradoxical data is even more complex as most studies concern single 
cell stimulation assays that seem to overlook the mechanism of innate tolerance that 
is induced by repetitive stimulation. For example, tolerance to LPS is long known as a 
physiological strategy to limit infl ammatory responses and involves a complex network 
of regulatory proteins that interfere with pro-infl ammatory gene expression.7, 9
Figure 3. Monocytes from IBD patients display enhanced LPS-tolerance
The level of LPS tolerance was determined by quantifying the extent of diminished TNF-α production.  
The slope was calculated between TNF-α levels of un-primed and primed cells with low-dose LPS (0.1 ng/
ml) (A, left panel) and high-dose LPS (10 ng/ml) (B, left panel) for each patient. All cells were re-stimulated 
with high-dose LPS (10 ng/ml). The level of tolerance was determined by the steepness of the slope (right 
panels). 
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To address a possible contribution of altered innate tolerance to the IBD pathogenesis 
we developed a tolerization assay using peripheral blood-derived monocytes. Here we 
show that monocytes of pediatric IBD patients produce comparable levels of TNF-α 
upon initial LPS stimulation (priming). Depending on the dose of LPS at priming, the 
production of TNF-α is diminished in IBD patients as well as in controls upon a secondary 
stimulus (fi gure 2). In short, higher doses of LPS in the priming phase led to a steeper 
decline in TNF-α production upon a secondary challenge.
TNF-α production upon low-dose LPS exposure by monocytes was comparable 
between the three groups, ranging from 60 to 1300 pg/ml. To be able to quantify the 
degree of tolerance induction (i.e. desensitization) for LPS on secondary challenge we 
calculated the slope between the level of TNF-α production of unprimed and primed 
monocytes for each individual patient. In this way we determined signifi cant diff erences 
in LPS responsiveness of individual patients compared to controls, while the average 
responsiveness was not signifi cantly diff erent. Pediatric IBD patients displayed a steeper 
slope compared to controls when cells were primed with low-dose LPS (fi gure 3). These 
data reveal the subtle diff erences that may be overlooked in more robust experimental 
set-up e.g. by using a higher dose of LPS at the sensitization phase. Indeed, when cells 
were primed with high-dose (10 ng/ml) LPS, monocytes became equally tolerized in 
both IBD patients and controls.
The patients we included in this study had a disease activity ranging from inactive 
to mildly active disease based upon PCDAI and PUCAI scores. Most of the patients had 
inactive disease (Table 1), indicating that the diff erences in tolerization between IBD 
patients and controls represent an intrinsic defect. Furthermore, the level of tolerance 
was irrespective of PCDAI or PUCAI score, IBD subtype (CD vs UC) or clinical infl amma-
tory parameters (CRP and ESR), suggesting that defects are independent of disease 
activity (data not shown). Within our cohort, patients were treated with diff erent drugs 
(Table 1). Azathioprine was used in the majority of CD patients, whereas mesazaline 
was mainly used in UC patients. In our studies we could not associate slopes, which 
represent individual levels of tolerance, to specifi c drugs used.
IBD has been associated with various mutations in genes that play a particular role in 
innate microbial sensing. Intriguingly, monocytes have been shown to become tolerant 
to TLR2 stimulation by peptidoglycan upon stimulation with the NOD2 ligand muramyl 
dipeptide. Consequently, defective tolerance to specifi c TLR2 stimulation was detected 
in monocytes from CD patients with a homozygous mutation in the CD-associated 
molecule NOD2 that seems to be in contrast with our fi ndings.2 Of note, NOD2 mutated 
cells are incapable of responding to MDP. Furthermore, patients with a homozygous 
NOD2 mutation are very rare (2%) in our hospitalized pediatric IBD population. We 
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therefore hypothesize that yet unidentifi ed other gene-defects may be involved in the 
mechanisms involved in this enhanced LPS tolerance in our tested population.
In this study we showed enhanced tolerance upon repeated LPS stimulation in pediatric 
IBD patients. Augmented tolerance could potentially lead to a net defi cit in antimicrobial 
defense upon chronic exposure. We hypothesize that this condition may result in dis-
turbed homeostatic interactions between the commensal microbiota and the mucosal 
immune system.14 Subsequently, this may result in enhanced local microbial pressure 
and the activation of adaptive immune cells, including T- and B-lymphocytes, ultimately 
leading to chronic infl ammation.
Interestingly, a recent study showed a similar increased LPS-tolerance in peripheral-
derived monocytes from patients with cystic fi brosis. These cells displayed an impaired 
pro-infl ammatory immune response, a high phagocytic phenotype and diminished 
capacity of antigen presentation upon tolerization. The authors speculate that this 
locked-up tolerance contributes to the high level of recurrent infections associated with 
this disease.15 In contrast with these fi ndings, we did not fi nd diff erences in the primary 
response to LPS stimulation (fi gure 1).
Given the clear diff erences between these two disease entities we speculate that 
enhanced ability to become tolerant may represent a broad paradigm that can be as-
sociated with various chronic diseases. Although similar (unidentifi ed) gene mutations 
within these diseases may play a role, it seems more likely that this enhanced tolerance 
may result from shared elements of these two pathologies. As such, IBD as well as CF 
may be associated with enhanced and chronic exposure of immune cells to microbes.16
Endotoxin tolerance is regulated through the production of a range of regulatory 
proteins that are produced upon stimulation and interfere with the pro-infl ammatory 
cascade. Other mechanisms of control include epigenetic modifi cations of genes in-
volved in cellular activation upon microbial stimulation.17 Future studies in well-defi ned 
cellular subsets, derived from specifi c cohorts of IBD patients, may help elucidate the 
mechanisms underlying enhanced tolerance in IBD.
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ABSTRACT
Introduction: To date, optimal treatment of infl ammatory bowel disease aims at the in-
duction and preservation of clinical remission. Establishment of remission is confi rmed 
by clinical and laboratory parameters as described in scoring systems both for pediatric 
ulcerative colitis and pediatric Crohn’s disease. A detailed analysis of the immune status 
during this inactive state of disease may provide a useful tool to subcategorize this 
phase of the of disease and to potentially refi ne maintenance treatment in the future.
Methods: By using aff ymetrix GeneChips, we analysed gene expression profi les of pe-
ripheral blood leucocytes from pediatric quiescent infl ammatory bowel disease patients 
and control individuals. We performed (un)supervised clustering analysis of infl amma-
tory bowel disease-associated genes applying Ingenuity® pathway software to identify 
specifi c molecular profi les that may enable patient stratifi cation.
Results: Pediatric infl ammatory bowel disease patients with inactive disease display 
heterogeneously distributed gene expression profi les that are signifi cantly distinct 
from controls. Diff erent clusters of IBD patients displayed specifi c immunological gene 
expression profi les and pathways, which were not correlated to medication, diagnosis 
of ulcerative colitis or Crohn’s disease or disease activity. Furthermore, in depth analysis 
of medication (azathioprine and mesalazine) associated gene profi les revealed distinct 
response patterns between individual patients.
Conclusion: This study indicates that the immune status of clinical remission in infl am-
matory bowel disease can be diff erentiated from that of healthy controls. Moreover, 
medication associated genetic profi ling of infl ammatory bowel disease patients 
reveals diff erences in expression between patients despite comparable infl ammatory 
parameters. Future analyses may thus allow for patient subcategorization for tailored 
maintenance therapy.
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INTRODUCTION
Infl ammatory bowel disease (IBD) is known as a chronic infl ammatory disease of the 
intestine. Although multiple treatment options have been used to diminish infl amma-
tion, to date no curative interventions have been described. Therefore, the major aim 
of treatment is the induction and preservation of clinical remission. Furthermore, it is 
becoming clear that IBD patients represent a heterogeneous group that may need a 
novel classifi cation beyond that of Crohn’s disease (CD) and ulcerative colitis (UC). As 
such, disease location, RNA expression, genotype and demographic parameters may 
help discriminating subsets within this patient population. Given the distinct disease 
phenotype and associated pathological changes in children compared to adults, pediat-
ric onset disease can be seen as such a specifi c subset of IBD.1-4.
Clinical remission in IBD is defi ned as the absence of symptoms of disease, that is 
expressed as the pediatric crohn’s disease activity index (PCDAI) or pediatric ulcerative 
colitis activity index (PUCAI). PCDAI or PUCAI scores <10 defi nes remission and scores 
from 10-30 represent mild active disease.5,6 The PCDAI describes the overall disease 
activity and includes laboratory fi ndings and overall wellbeing, whereas the PUCAI only 
involves clinical parameters. During remission, infl ammatory processes can still be pres-
ent on a macroscopic as well as a microscopic level.12 Specifi cally, subclinical immune 
activation might still be present despite the absence of clinical symptoms. A detailed 
analysis of the immune status during quiescent disease may provide a useful tool to 
subcategorize the type of disease and to potentially refi ne maintenance treatment in 
the future.
Infl ammation in IBD results from an aberrant immune responses to harmless antigens, 
including the intestinal microbiota, resulting in mucosal infl ammation.7 In the IBD 
pathogenesis, defects have been identifi ed ranging from initial microbial recognition 
by innate immune cells to aberrant activation of T lymphocytes.8-10 As a consequence, 
remission may involve various immune mechanisms, such as diminished T helper cell 
activation and suppressed microbial stimulation of innate cells.11
Next, various drugs are prescribed in order to maintain remission. For example, 
azathioprine is widely used in CD and mesalazine in UC. However, drug responsiveness 
diff ers widely between patients. Mutations in the genes encoding for the enzymes that 
metabolize these drugs have been shown to predict drug responsiveness and toxicity.13 
Consequently, due to diff erences in drug responsiveness as well as the heterogeneity of 
the IBD subtypes, it is diffi  cult to identify patients that will or will not respond to specifi c 
medication. Although enhanced general infl ammatory markers (e.g. CRP and ESR) are 
associated with imminent exacerbations14, and severity of disease may be predicted 
based upon a panel of genetic polymorphisms15, the usefulness of these parameters for 
individual patients seems limited.16
Pieter BW.indd   121 15-Jul-10   16:50:15 PM
122 Chapter 8
As such, in depth analysis of the overall RNA expression profi les of the specifi c genes 
involved in specifi c drug responses may help predict drug responsiveness in IBD.
To assess the immune status during remission in pediatric IBD, we analyzed RNA gene 
expression profi les of peripheral blood leucocytes (PBL) obtained from pediatric IBD pa-
tients with inactive to mild active disease and control individuals. By using unsupervised 
clustering analysis, supervised analysis of expression of IBD-associated genes as well as 
Ingenuitiy® pathway analysis, we detected marked diff erences in immunological gene 
expression when comparing pediatric IBD patients with inactive disease compared to 
healthy controls. These data indicate that the immune status during clinical remission 
diff ers from that of healthy controls. Moreover, detailed analysis of the genetic pathways 
involved in azathioprine and mesalazine responses revealed two distinct profi les. Ex-
pression of associated genes revealed diff erences between the two groups, suggesting 
diff erences in medication responsiveness for each group.
MATERIAL AND METHODS
Patients
A cohort of 45 pediatric IBD remission patients containing 25 Crohn’s disease patients 
and 20 ulcerative colitis patients were included in this study, as well as 14 age matched 
controls (table 1 patient characteristics). The control group consisted of age-matched 
orthopedic patients with no underlying infl ammatory or intestinal diseases. All IBD 
patients were diagnosed by endoscopy, histo-pathological and clinical characteristics 
according to the Porto criteria.17 Disease activity was determined using the PCDAI and 
PUCAI indexes for Crohn’s disease and ulcerative colitis, respectively.5,  6 Only patients 
with inactive or mild active disease (PCDAI / PUCAI < 30) and with a written parental 
informed consent were included. The majority of patients had a score below 10 (Table 1). 
Patient approval for this study was obtained by the local ethics committee.
Isolation and Quality Control of RNA
Venous blood (2ml) was collected in PAXgene tubes (PreAnalytiX, Hombrechtikon, 
Switzerland) and stored at –20°C until RNA extraction. Total cellular RNA was extracted 
using the PAXgeneTM blood RNA kit (Qiagen, Mississauga, Canada) according to the 
manufacturer’s protocol. RNA levels, quality and purity were assessed with the RNA 6000 
Nano assay on the Agilent 2100 Bioanalyzer (Agilent). The samples did not show RNA 
degradation or contamination with DNA.
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Table 1 Patient characteristics
IBD IBD (n=45) % Control (n=14) %
total 45 14
male 19 42.2 8 57.1
female 26 57.8 6 42.9
Crohn’s disease 25 55.6
Colonic involvement 18 72.0
Ulcerative colitis 20 44.4
Mean Range SD Mean Range SD
Age (years) 15.7 11-18 1.2 13.7 10-18 2.3
Age CD 15.8 11-18 1.5
Age UC 15.6 14-17 0.9
Age of onset (years) 12.1 3-16 3.1
Age of onset CD 13.1 9-16 2.2
Age of onset UC 11.2 3-15 3.6
PCDAI 5.7 0-30 8.8
PUCAI 5.2 0-30 9.0
ESR 12.4 2-55 11.2
ESR CD 14.2 2-55 12.8
ESR UC 10.7 2-35 9.4
CRP 2.9 0-17 3.3
CRP CD 3.7 0-17 4.0
CRP UC 2.1 1-8 1.9
Medication CD # %
Azathioprine 15 65.2
Infl ixmab 2 8.7
Prednisolone 3 13.0
Mesalazine 4 17.4
Methotrexate 5 21.7
None 1 4.3
Medication UC # %
Azathioprine 5 23.8
Infl ixmab 0 0.0
Prednisolone 1 4.8
Salazopurine 3 14.3
Mesalazine 16 76.2
Methotrexate 0 0.0
None 1 4.8
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Gene Expression Profi ling and Quality Control
Samples were analyzed by Aff ymetrix U133 2.0 plus GeneChips as described in.18 The 
GeneChip contains 54,675 probe sets, representing approximately 39,000 genes. 
We used 10 μg of total RNA to prepare antisense biotinylated RNA. Single-stranded 
complementary DNA (cDNA) and double-stranded cDNA was synthesized accord-
ing to the manufacturer’s protocol (Invitrogen Life Technologies) with the use of the 
T7-(deoxythymidine)24-primer (Genset). In vitro transcription was performed with 
biotin-11-cytidine triphosphate and biotin-16-uridine triphosphate (Perkin–Elmer) and 
the MEGAScript T7 labeling kit (Ambion). Double-stranded cDNA and complementary 
RNA (cRNA) was purifi ed and fragmented with the GeneChip Sample Cleanup Module 
(Aff ymetrix). Biotinylated RNA was hybridized to the GeneChip (45°C for 16 hours). 
Staining, washing, and scanning procedures were carried out according to the manu-
facturer’s protocol (Aff ymetrix). All GeneChips were visually inspected for irregularities. 
The R package aff yQCreport was used for quality control and indicated high quality and 
overall comparability of samples.
Data Normalization, Statistical Analysis, and Visualization
Data was normalized as previously described.18 In short, scanned array images of all 
samples were normalized. To visualize the clustering of the samples principal compo-
nent analysis (PCA) was used. The normalized datafi le was transposed and imported into 
Biowisdom/OmniViz version 6.0.3 (Biowisdom, Inc) for further analysis.
Group analysis was performed using Pearsons Rank correlation, student’s T-test, One 
–way ANOVA and Chi-square test when appropriate. A p value <0.05 was considered 
signifi cant.
Unsupervised cluster analysis was performed in Biowisdom/Omniviz using Pearson’s 
correlation in the Correlation View. Supervised analysis was based on SAM (Signifi cance 
Analysis of Microarrays).19 Cut-off s values for signifi cantly expressed genes were chosen 
based on the false discovery rate (FDR) and the fold change (FC). Functional annotation 
of the SAM results was done using Ingenuity® Pathway Analysis (Ingenuity, Mountain 
View, CA)
RESULTS
Gene expression profi les of quiescent pediatric IBD patients are 
heterogeneously distributed and independent of CD or UC diagnosis
We analyzed the overall gene expression profi les of PBL using PCA. Samples that display 
comparable expression profi les show clustering in the PCA. Figure 1 illustrates the PCA 
of controls and pediatric IBD patients, in which control samples appear in a separate 
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cluster (blue) and IBD patients show heterogeneous distribution. CD (red) and UC 
(green) patients with quiescent disease did not cluster separately based on overall gene 
expression profi les.
These results indicate that, based upon overall gene expression profi les, IBD patients 
show distinct profi les compared to controls. Although the phenotype of CD and UC 
patients diff ered, sub-classifi cation between CD and UC was not seen, indicating overlap 
in gene expression profi les between these two subsets.
IBD patients can be stratifi ed based on 3-fold diff erence in gene expression 
level relative to average levels
With the use of unsupervised ordering, samples were classifi ed into subgroups that iden-
tifi ed subsets of IBD patients. We generated a Pearson’s correlation plot that included 
Figure 1. Gene expression profi les of quiescent pediatric IBD patients 
General gene expression profi le of PBL was analyzed using principal components analysis (PCA). Samples 
that display a comparable expression profi le show clustering on the PCA. Control samples appear in a 
separate cluster (blue), whereas IBD study patients appear in a heterogeneous distribution. CD (red) and 
UC (green) patients with quiescent disease could not be separated based on overall gene expression 
profi les. 
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probe sets with a 3-fold diff erence in gene expression level relative to the geometric 
mean, refl ecting up- or down-regulation (fi gure 2). In total, 2957 records met these crite-
ria and correlation between the samples was analyzed on the basis of similarities in gene 
expression profi les. Samples that show positive correlation in gene expression profi ling 
are indicated in red, whereas negative correlation between samples are illustrated in 
blue. This Pearson’s correlation plot revealed three distinct groups, which we annotated 
as group A, B and C. All control samples were located in group A, whereas IBD patients 
were heterogeneously distributed over all three groups. The clustering of patients was 
not due to a specifi c disease-related parameter as we did not observe any correlation 
with diagnosis of CD or UC, severity of disease as determined by PCDAI or PUCAI, age of 
Figure 2. Correlation view of quiescent IBD patients involving 2957 probe sets.
The correlation visualization displays pair wise correlations between the samples. The colors of the cells 
relate to Pearson’s correlation coeffi  cient values, with deeper colors indicating higher positive (red) and 
negative (blue) correlations. This Pearson’s correlation plot revealed three distinct groups (A, B, C). Group 
A, containing controls and IBD patients, and group B and C, which both contain solely IBD patients. 
Pieter BW.indd   126 15-Jul-10   16:50:23 PM
Subcategorization of quiescent pediatric IBD patients by immune gene expression analysis of peripheral cells 127
onset, CRP, ESR, or medication. However, group C contained signifi cantly more women 
compared to groups A and B (p=0.018, Suppl. table 1).
These results indicate that the IBD population of patients with clinically inactive 
disease can be subdivided into three groups with distinct gene expression profi les. This 
distinction of groups A,B and C is made on expression of genes irrespective of func-
tion. CD and UC patients are equally distributed and only part of the IBD patients are 
comparable to controls.
Diff erent clusters of quiescent IBD patients display specifi c immunological 
gene expression profi les
As quiescent IBD patients displayed diff erential gene expression profi les compared to 
non-diseased controls and the immune system has been shown to play an essential role 
in IBD pathogenesis, we analyzed the expression of IBD-related immune genes (suppl 
table 2) in the three groups in a supervised manner.
First, we determined for each group probe sets diff erences with a >1.5 fold higher or 
lower expression compared to controls. Next we determined which of these probes sets 
were signifi cantly diff erent between IBD patients and controls by SAM analysis. The IBD 
patients in group A displayed signifi cantly diff erent expression for 31 immune-associated 
probe sets, whereas group B and C contained 151 and 161 probe sets, respectively. Table 
2 shows the immune-related genes that were SAM signifi cant for each group compared 
to controls.
This analysis indicates that within the three selected groups there is a distinction from 
controls on the basis of immune profi le. Although the majority of IBD patients are in 
clinical remission, IBD associated genes were found to be active and diff ered signifi -
cantly from controls.
In order to investigate which immunological genes were signifi cantly expressed for 
each group, we analyzed signifi cant diff erences in the immunological gene expression 
between all groups and controls. We found that for group A, only two immunological 
probe sets were diff erentially expressed compared to controls and the two other groups. 
Group B displayed specifi c gene expression for 75 probe sets, whereas in group C 26 
probe sets were distinct from controls as well as from the two other groups (table 3).
These results indicate that although the clinical phenotype of IBD patients and controls 
is comparable, there are still signifi cant diff erences in immunological gene expression 
between IBD patients and controls as well as among IBD patients. The correlation plot 
as depicted in fi gure 2 identifi ed three groups based upon diff erences in overall gene 
expression profi les. Further supervised analysis demonstrated that these groups also 
diff ered in the expression of immunological genes that are associated with IBD.
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Table 2A, Top up-regulated genes IBD vs Control
Top Up-regulated
A vs Control Symbol Entrez Gene Name Log Ratio
 BCL2L1  BCL2-like 1  1,122
 FCGR1A  Fc fragment of IgG, high affi  nity Ia, receptor (CD64)  0,799
 MUC5AC  mucin 5AC, oligomeric mucus/gel-forming  0,716
 SOD2  superoxide dismutase 2, mitochondrial  0,715
 CSTA  cystatin A (stefi n A)  0,634
 PIK3C3  phosphoinositide-3-kinase, class 3  0,631
 SOS2  son of sevenless homolog 2 (Drosophila)  0,620
Top Up-regulated
B vs Control Symbol Entrez Gene Name Log Ratio
 POLR2K  polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa  2,424
 IL8  interleukin 8  2,352
 IFI44  interferon-induced protein 44  2,254
 FCGR1A  Fc fragment of IgG, high affi  nity Ia, receptor (CD64)  2,062
 CSTA  cystatin A (stefi n A)  2,018
 IFNGR1  interferon gamma receptor 1  1,857
 ANXA1  annexin A1  1,815
 HMGB1 
(includes 
EG:3146)  high-mobility group box 1  1,786
 NAT1  N-acetyltransferase 1 (arylamine N-acetyltransferase)  1,752
 PIK3C2A  phosphoinositide-3-kinase, class 2, alpha polypeptide  1,665
 LRRK2  leucine-rich repeat kinase 2  1,526
 TGFBR1  transforming growth factor, beta receptor 1  1,515
 IL15  interleukin 15  1,510
 ATP2B1  ATPase, Ca++ transporting, plasma membrane 1  1,460
 JAK2  Janus kinase 2  1,440
 TAF7
 TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
55kDa  1,428
 TLR4  toll-like receptor 4  1,390
 PTPN22  protein tyrosine phosphatase, non-receptor type 22 (lymphoid)  1,388
 NRIP1  nuclear receptor interacting protein 1  1,372
 PRKACB  protein kinase, cAMP-dependent, catalytic, beta  1,336
 MAP3K7  mitogen-activated protein kinase kinase kinase 7  1,332
 HSP90AA1  heat shock protein 90kDa alpha (cytosolic), class A member 1  1,308
 TAF9
 TAF9 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
32kDa  1,295
 ZNF91  zinc fi nger protein 91  1,287
 SRGN  serglycin  1,263
 MAPK6  mitogen-activated protein kinase 6  1,248
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Table 2A (continued)
 SLC26A2  solute carrier family 26 (sulfate transporter), member 2  1,246
 S100P  S100 calcium binding protein P  1,209
 NR3C1
 nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor)  1,202
 NRAS  neuroblastoma RAS viral (v-ras) oncogene homolog  1,197
 LYZ  lysozyme (renal amyloidosis)  1,191
 KAT2B  K(lysine) acetyltransferase 2B  1,171
 HSPA14  heat shock 70kDa protein 14  1,139
 STAT1  signal transducer and activator of transcription 1, 91kDa  1,124
 CREB1  cAMP responsive element binding protein 1  1,122
 HLTF  helicase-like transcription factor  1,119
 GTF2B  general transcription factor IIB  1,050
 SLPI  secretory leukocyte peptidase inhibitor  1,001
 TAF2
 TAF2 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
150kDa  0,953
 ACAT1  acetyl-Coenzyme A acetyltransferase 1  0,948
 NCOA2  nuclear receptor coactivator 2  0,947
 PTGER4  prostaglandin E receptor 4 (subtype EP4)  0,934
 RRAS2  related RAS viral (r-ras) oncogene homolog 2  0,912
 GTF2H5  general transcription factor IIH, polypeptide 5  0,910
 GTF2A1  general transcription factor IIA, 1, 19/37kDa  0,909
 POLR2B  polymerase (RNA) II (DNA directed) polypeptide B, 140kDa  0,897
 MAPK8  mitogen-activated protein kinase 8  0,887
 PPP3CA  protein phosphatase 3 (formerly 2B), catalytic subunit, alpha isoform  0,887
 SMAD4  SMAD family member 4  0,862
 MED14  mediator complex subunit 14  0,838
 GTF2E1  general transcription factor IIE, polypeptide 1, alpha 56kDa  0,831
 TAF5
 TAF5 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
100kDa  0,827
 PTPN2  protein tyrosine phosphatase, non-receptor type 2  0,826
 TAF9B
 TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 31kDa  0,826
 SOD2  superoxide dismutase 2, mitochondrial  0,809
 TAF1
 TAF1 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
250kDa  0,796
 HIF1A
 hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix 
transcription factor)  0,749
 C13ORF31  chromosome 13 open reading frame 31  0,748
 TLR1  toll-like receptor 1  0,738
 HLA-DRA  major histocompatibility complex, class II, DR alpha  0,728
 S100A9  S100 calcium binding protein A9  0,723
 ISG15  ISG15 ubiquitin-like modifi er  0,721
 FEZ2  fasciculation and elongation protein zeta 2 (zygin II)  0,715
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Table 2A (continued)
 WDR92  WD repeat domain 92  0,712
 SRI  sorcin  0,711
 MAP2K4  mitogen-activated protein kinase kinase 4  0,704
 PIK3CA  phosphoinositide-3-kinase, catalytic, alpha polypeptide  0,701
 IFI16  interferon, gamma-inducible protein 16  0,699
 SMAD2  SMAD family member 2  0,697
 BTN2A1  butyrophilin, subfamily 2, member A1  0,690
 GTF2H2  general transcription factor IIH, polypeptide 2, 44kDa  0,687
 SLC22A4 
(includes 
EG:6583)
 solute carrier family 22 (organic cation/ergothioneine transporter), 
member 4  0,681
 SOS2  son of sevenless homolog 2 (Drosophila)  0,665
 TAF12 
(includes 
EG:6883)
 TAF12 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 20kDa  0,664
 FOS  v-fos FBJ murine osteosarcoma viral oncogene homolog  0,661
 SUMO1  SMT3 suppressor of mif two 3 homolog 1 (S. cerevisiae)  0,655
 HLA-DRB1  major histocompatibility complex, class II, DR beta 1  0,653
 FGFR1OP 
(includes 
EG:11116)  FGFR1 oncogene partner  0,646
 MAPK14  mitogen-activated protein kinase 14  0,642
 KRAS  v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  0,631
 TAF1A
 TATA box binding protein (TBP)-associated factor, RNA polymerase I, A, 
48kDa  0,630
 SUMO4  SMT3 suppressor of mif two 3 homolog 4 (S. cerevisiae)  0,627
 PPP3CB  protein phosphatase 3 (formerly 2B), catalytic subunit, beta isoform  0,615
 CCNH  cyclin H  0,611
 PPP2CA  protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform  0,595
Top Up-regulated
C vs Control Symbol Entrez Gene Name Log Ratio
 FCGR1A  Fc fragment of IgG, high affi  nity Ia, receptor (CD64)  2,126
 CXCL10  chemokine (C-X-C motif ) ligand 10  1,944
 CSTA  cystatin A (stefi n A)  1,810
 BCL2L1  BCL2-like 1  1,578
 S100P  S100 calcium binding protein P  1,522
 IL1R2  interleukin 1 receptor, type II  1,382
 KAT2B  K(lysine) acetyltransferase 2B  1,278
 CCL2  chemokine (C-C motif ) ligand 2  1,215
 IFNGR1  interferon gamma receptor 1  1,210
 IFI44  interferon-induced protein 44  1,189
 TLR5  toll-like receptor 5  1,180
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Table 2A (continued)
 PBX1  pre-B-cell leukemia homeobox 1  1,173
 SLC22A4 
(includes 
EG:6583)
 solute carrier family 22 (organic cation/ergothioneine transporter), 
member 4  1,167
 POLR2K  polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa  1,163
 CCL8  chemokine (C-C motif ) ligand 8  1,118
 FKBP5  FK506 binding protein 5  1,104
 MAPK14  mitogen-activated protein kinase 14  1,094
 SRGN  serglycin  1,087
 ITLN1  intelectin 1 (galactofuranose binding)  1,078
 ANXA1  annexin A1  1,061
 WDR92  WD repeat domain 92  1,058
 JAK2  Janus kinase 2  1,010
 LYZ  lysozyme (renal amyloidosis)  0,994
 CD163  CD163 molecule  0,972
 S100A9  S100 calcium binding protein A9  0,972
 TLR4  toll-like receptor 4  0,965
 GYPB  glycophorin B (MNS blood group)  0,960
 IL1RN  interleukin 1 receptor antagonist  0,942
 MMP9
 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV 
collagenase)  0,869
 STAT1  signal transducer and activator of transcription 1, 91kDa  0,868
 NAT1  N-acetyltransferase 1 (arylamine N-acetyltransferase)  0,823
 CA4  carbonic anhydrase IV  0,819
 SLPI  secretory leukocyte peptidase inhibitor  0,804
 HMGB1 
(includes 
EG:3146)  high-mobility group box 1  0,791
 SELENBP1  selenium binding protein 1  0,755
 MXI1  MAX interactor 1  0,749
 IL15  interleukin 15  0,712
 SOS2  son of sevenless homolog 2 (Drosophila)  0,712
 CHP  calcium binding protein P22  0,700
 SOD2  superoxide dismutase 2, mitochondrial  0,694
 FHL2  four and a half LIM domains 2  0,671
 MT1H  metallothionein 1H  0,668
 TAF7
 TAF7 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
55kDa  0,636
 LRRK2  leucine-rich repeat kinase 2  0,633
 STAT5B  signal transducer and activator of transcription 5B  0,632
 GTF2H5  general transcription factor IIH, polypeptide 5  0,631
 MAP3K1  mitogen-activated protein kinase kinase kinase 1  0,620
 IL18RAP  interleukin 18 receptor accessory protein  0,606
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Table 2A (continued)
 TTLL3  tubulin tyrosine ligase-like family, member 3  0,602
Table 2B, Top down-regulated genes IBD vs Control
A vs 
Control Symbol Entrez Gene Name Log Ratio
 NFATC2  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2  -1,072
 TRA@  T cell receptor alpha locus  -0,931
 TRD@  T cell receptor delta locus  -0,908
 CD3G  CD3g molecule, gamma (CD3-TCR complex)  -0,889
 GNAS  GNAS complex locus  -0,878
 SLC26A2  solute carrier family 26 (sulfate transporter), member 2  -0,864
 PIK3C2A  phosphoinositide-3-kinase, class 2, alpha polypeptide  -0,845
 C11ORF30  chromosome 11 open reading frame 30  -0,839
 HLA-DQA1  major histocompatibility complex, class II, DQ alpha 1  -0,825
 ZNF91  zinc fi nger protein 91  -0,790
 NFATC3  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3  -0,769
 CCL5  chemokine (C-C motif ) ligand 5  -0,760
 EP300  E1A binding protein p300  -0,759
 TAF3
 TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
140kDa  -0,745
 MUC8  mucin 8  -0,699
 CD247  CD247 molecule  -0,663
 TGFBR1  transforming growth factor, beta receptor 1  -0,645
 CCR5  chemokine (C-C motif ) receptor 5  -0,609
 SMARCA4
 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4  -0,606
 KAT2B  K(lysine) acetyltransferase 2B  -0,597
 CUX1  cut-like homeobox 1  -0,591
 SLC20A1  solute carrier family 20 (phosphate transporter), member 1  -0,589
Top Down-regulated
B vs 
Control Symbol Entrez Gene Name Log Ratio
 HLA-DQA1  major histocompatibility complex, class II, DQ alpha 1  -1,745
 HLA-DQB1  major histocompatibility complex, class II, DQ beta 1  -0,882
 NFATC2  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2  -0,870
 MUC8  mucin 8  -0,790
 CCL5  chemokine (C-C motif ) ligand 5  -0,756
 GNAS  GNAS complex locus  -0,726
 NFATC3  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3  -0,714
 POU2F1  POU class 2 homeobox 1  -0,712
 SMARCA4
 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4  -0,698
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Table 2B, continued
 MAP2K7  mitogen-activated protein kinase kinase 7  -0,692
 C11ORF30  chromosome 11 open reading frame 30  -0,662
 ATG16L1  ATG16 autophagy related 16-like 1 (S. cerevisiae)  -0,647
 STAT3
 signal transducer and activator of transcription 3 (acute-phase response 
factor)  -0,633
 NCOR2  nuclear receptor co-repressor 2  -0,615
 NFATC1  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1  -0,600
 NCOA1  nuclear receptor coactivator 1  -0,592
 TAF11
 TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
28kDa  -0,587
Top Down-regulated
C vs 
Control Symbol Entrez Gene Name Log Ratio
 NFATC2  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2  -1,459
 NFATC3  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 3  -1,395
 CD3G  CD3g molecule, gamma (CD3-TCR complex)  -1,225
 GNAS  GNAS complex locus  -1,219
 CCL5  chemokine (C-C motif ) ligand 5  -1,141
 C11ORF30  chromosome 11 open reading frame 30  -1,117
 CD247  CD247 molecule  -1,112
 PIK3C2A  phosphoinositide-3-kinase, class 2, alpha polypeptide  -1,081
 SMARCA4
 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4  -1,068
 TAF3
 TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
140kDa  -1,025
 TGFBR1  transforming growth factor, beta receptor 1  -1,008
 TRA@  T cell receptor alpha locus  -0,978
 UBE2I  ubiquitin-conjugating enzyme E2I (UBC9 homolog, yeast)  -0,944
 EP300  E1A binding protein p300  -0,942
 SLC26A2  solute carrier family 26 (sulfate transporter), member 2  -0,922
 NCOR2  nuclear receptor co-repressor 2  -0,916
 SLC20A1  solute carrier family 20 (phosphate transporter), member 1  -0,916
 TAF11
 TAF11 RNA polymerase II, TATA box binding protein (TBP)-associated factor, 
28kDa  -0,888
 NFATC1  nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1  -0,883
 ZNF91  zinc fi nger protein 91  -0,874
 TRD@  T cell receptor delta locus  -0,861
 IL16  interleukin 16 (lymphocyte chemoattractant factor)  -0,860
 HLA-DQA1  major histocompatibility complex, class II, DQ alpha 1  -0,839
 IGL@  immunoglobulin lambda locus  -0,808
 HLA-DQB1  major histocompatibility complex, class II, DQ beta 1  -0,803
 NCOA1  nuclear receptor coactivator 1  -0,803
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Table 2B, continued
 POU2F1  POU class 2 homeobox 1  -0,801
 CFD  complement factor D (adipsin)  -0,798
 PIK3C2B  phosphoinositide-3-kinase, class 2, beta polypeptide  -0,792
 C5ORF56  chromosome 5 open reading frame 56  -0,782
 HSP90AB1  heat shock protein 90kDa alpha (cytosolic), class B member 1  -0,767
 MUC8  mucin 8  -0,763
 MED1  mediator complex subunit 1  -0,762
 IGH@  immunoglobulin heavy locus  -0,743
 CDKN1C  cyclin-dependent kinase inhibitor 1C (p57, Kip2)  -0,733
 CXCL5  chemokine (C-X-C motif ) ligand 5  -0,712
 SMAD4  SMAD family member 4  -0,701
 CUX1  cut-like homeobox 1  -0,698
 HLA-DRB1  major histocompatibility complex, class II, DR beta 1  -0,698
 JAK1  Janus kinase 1  -0,679
 PIK3CD  phosphoinositide-3-kinase, catalytic, delta polypeptide  -0,669
 NOLC1  nucleolar and coiled-body phosphoprotein 1  -0,668
 RAC1
 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding 
protein Rac1)  -0,665
 GUSB  glucuronidase, beta  -0,661
 SMAD3  SMAD family member 3  -0,660
 IL12RB1  interleukin 12 receptor, beta 1  -0,647
 MAP3K14  mitogen-activated protein kinase kinase kinase 14  -0,635
 IL32  interleukin 32  -0,633
 HLA-DOA  major histocompatibility complex, class II, DO alpha  -0,628
 SMARCA2
 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2  -0,627
 SPARC  secreted protein, acidic, cysteine-rich (osteonectin)  -0,622
 CREBBP  CREB binding protein  -0,621
 CCR5  chemokine (C-C motif ) receptor 5  -0,618
 CD14  CD14 molecule  -0,601
 SCAP  SREBF chaperone  -0,589
 POLR2A  polymerase (RNA) II (DNA directed) polypeptide A, 220kDa  -0,587
 ZGPAT  zinc fi nger, CCCH-type with G patch domain  -0,586
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Table 3A, Top up-regulated genes Group vs Control AND Groups
A vs Control 
AND Group B,C Symbol Entrez Gene Name Log Ratio
 FCGR1A  Fc fragment of IgG, high affi  nity Ia, receptor (CD64)  0,799
 CSTA  cystatin A (stefi n A)  0,634
Top Up-Regultated
B vs Control 
AND Group A,C Symbol Entrez Gene Name Log Ratio
 POLR2K  polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa  2,424
 IL8  interleukin 8  2,352
 IFI44  interferon-induced protein 44  2,254
 IFNGR1  interferon gamma receptor 1  1,857
 ANXA1  annexin A1  1,815
 HMGB1 (includes 
EG:3146)  high-mobility group box 1  1,786
 NAT1  N-acetyltransferase 1 (arylamine N-acetyltransferase)  1,752
 PIK3C2A  phosphoinositide-3-kinase, class 2, alpha polypeptide  1,665
 LRRK2  leucine-rich repeat kinase 2  1,526
 TGFBR1  transforming growth factor, beta receptor 1  1,515
 IL15  interleukin 15  1,510
 ATP2B1  ATPase, Ca++ transporting, plasma membrane 1  1,460
 TAF7
 TAF7 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 55kDa  1,428
 PTPN22
 protein tyrosine phosphatase, non-receptor type 22 
(lymphoid)  1,388
 NRIP1  nuclear receptor interacting protein 1  1,372
 PRKACB  protein kinase, cAMP-dependent, catalytic, beta  1,336
 MAP3K7  mitogen-activated protein kinase kinase kinase 7  1,332
 HSP90AA1
 heat shock protein 90kDa alpha (cytosolic), class A member 
1  1,308
 TAF9
 TAF9 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 32kDa  1,295
 ZNF91  zinc fi nger protein 91  1,287
 MAPK6  mitogen-activated protein kinase 6  1,248
 SLC26A2  solute carrier family 26 (sulfate transporter), member 2  1,246
 NR3C1
 nuclear receptor subfamily 3, group C, member 1 
(glucocorticoid receptor)  1,202
 NRAS  neuroblastoma RAS viral (v-ras) oncogene homolog  1,197
 HSPA14  heat shock 70kDa protein 14  1,139
 CREB1  cAMP responsive element binding protein 1  1,122
 HLTF  helicase-like transcription factor  1,119
 GTF2B  general transcription factor IIB  1,050
 TAF2
 TAF2 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 150kDa  0,953
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Table 3A, continued
 ACAT1  acetyl-Coenzyme A acetyltransferase 1  0,948
 PTGER4  prostaglandin E receptor 4 (subtype EP4)  0,934
 RRAS2  related RAS viral (r-ras) oncogene homolog 2  0,912
 GTF2A1  general transcription factor IIA, 1, 19/37kDa  0,909
 POLR2B  polymerase (RNA) II (DNA directed) polypeptide B, 140kDa  0,897
 MAPK8  mitogen-activated protein kinase 8  0,887
 SMAD4  SMAD family member 4  0,862
 MED14  mediator complex subunit 14  0,838
 GTF2E1  general transcription factor IIE, polypeptide 1, alpha 56kDa  0,831
 TAF5
 TAF5 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 100kDa  0,827
 TAF9B
 TAF9B RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 31kDa  0,826
 PTPN2  protein tyrosine phosphatase, non-receptor type 2  0,826
 TAF1
 TAF1 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 250kDa  0,796
 HLA-DRA  major histocompatibility complex, class II, DR alpha  0,728
 FEZ2  fasciculation and elongation protein zeta 2 (zygin II)  0,715
 SRI  sorcin  0,711
 PIK3CA  phosphoinositide-3-kinase, catalytic, alpha polypeptide  0,701
 BTN2A1  butyrophilin, subfamily 2, member A1  0,690
 TAF12 (includes 
EG:6883)
 TAF12 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 20kDa  0,664
 HLA-DRB1  major histocompatibility complex, class II, DR beta 1  0,653
 MAP2K4  mitogen-activated protein kinase kinase 4  0,638
 TAF1A
 TATA box binding protein (TBP)-associated factor, RNA 
polymerase I, A, 48kDa  0,630
 SMAD2  SMAD family member 2  0,606
 C11ORF30  chromosome 11 open reading frame 30  0,605
 PPP2CA
 protein phosphatase 2 (formerly 2A), catalytic subunit, alpha 
isoform  0,595
Top Up-Regultated
C vs Control 
AND Group A,B Symbol Entrez Gene Name Log Ratio
 IL1R2  interleukin 1 receptor, type II  1,382
 CCL2  chemokine (C-C motif ) ligand 2  1,215
 IFNGR1  interferon gamma receptor 1  1,210
 IFI44  interferon-induced protein 44  1,189
 TLR5  toll-like receptor 5  1,180
 PBX1  pre-B-cell leukemia homeobox 1  1,173
 POLR2K  polymerase (RNA) II (DNA directed) polypeptide K, 7.0kDa  1,163
 FKBP5  FK506 binding protein 5  1,104
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Table 3A, continued
 ITLN1  intelectin 1 (galactofuranose binding)  1,078
 ANXA1  annexin A1  1,061
 CD163  CD163 molecule  0,972
 MMP9
 matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 
92kDa type IV collagenase)  0,869
 NAT1  N-acetyltransferase 1 (arylamine N-acetyltransferase)  0,823
 HMGB1 (includes 
EG:3146)  high-mobility group box 1  0,791
 MXI1  MAX interactor 1  0,749
 TGFBR1  transforming growth factor, beta receptor 1  0,749
 IL15  interleukin 15  0,712
 TAF7
 TAF7 RNA polymerase II, TATA box binding protein (TBP)-
associated factor, 55kDa  0,636
 LRRK2  leucine-rich repeat kinase 2  0,633
Table 3B, Top down-regulated Group vs Control AND Groups
Top Down-
regulated
A vs Control AND Group B,C Symbol Entrez Gene Name Log Ratio
None 
detected
Top Down-
regulated
B vs Control AND Group A,C Symbol Entrez Gene Name Log Ratio
 HLA-DQA1  major histocompatibility complex, class II, DQ alpha 1  -1,745
Top Down-
regulated
C vs Control AND Group A,B Symbol Entrez Gene Name Log Ratio
 HLA-DQA1  major histocompatibility complex, class II, DQ alpha 1  -0,839
 TRA@  T cell receptor alpha locus  -0,978
 NFATC3
 nuclear factor of activated T-cells, cytoplasmic, 
calcineurin-dependent 3  -1,395
Ingenuity pathway analysis reveals group-specifi c involvement of 
immunological pathways
In our IBD population multiple IBD-associated genes showed a signifi cantly diff erent 
expression as compared with controls as well as between groups (table 2 and 3). In order 
to investigate the possible interaction of these diff erent immunological genes, we ana-
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lyzed which related immunological pathways were associated with the immunological 
genes for each group. Therefore, IBD associated genes that were expressed diff erently 
between groups (A,B and C) and controls (table 2) were analyzed by Ingenuity pathway 
analysis. Pathways for each group that were distinct from controls are depicted in table 
4 and involved immunological pathways at all levels of the immune cascade.
In all groups, genes of the glucocorticoid receptor signalling pathway showed diff erent 
expression compared with controls. In the two groups B and C, IL-4 signalling was one of 
the pathways that diff ered strongly from the control group.
Next, to study which pathways were most distinctive for each group individually, we 
analyzed the associated immune pathways from table 3. Associated immunological 
pathways that were distinct between the three IBD groups are listed in table 5. Again, 
the glucocorticoid receptor signalling pathway was one of the signifi cant pathways that 
was distinct for each group.
This in depth Ingenuity pathway analysis indicated that in clinical IBD remission pa-
tients, active immune processes are still present that can be clustered into two diff erent 
subsets.
Table 4 Top canonical pathway Group A/B/C vs Control
Name p-value ratio
A vs Control Glucocorticoid Receptor Signaling 1.01E-23 16/280 (0,057)
Role of NFAT in Regulation of the Immune Response 1.75E-16 11/194 (0,057)
Systemic Lupus Erythematosus Signaling 1.11E-15 10/150 (0,067)
iCOS-iCOSL Signaling in T Helper Cells 6.51E-13 8/115 (0,07)
T Cell Receptor Signaling 7.77E-13 8/110 (0,073)
B vs Control Glucocorticoid Receptor Signaling 9.26E-92 61/280 (0,218)
Estrogen Receptor Signaling 1.46E-42 29/121 (0,24)
Colorectal Cancer Metastasis Signaling 3.56E-22 22/247 (0,089)
IL-4 Signaling 2.63E-21 15/72 (0,208)
B Cell Receptor Signaling 1.97E-20 18/155 (0,116)
C vs Control Glucocorticoid Receptor Signaling 5.66E-72 52/280 (0,186)
IL-4 Signaling 2.65E-19 14/72 (0,194)
Dendritic Cell Maturation 1.60E-18 17/173 (0,098)
RAR Activation 1.26E-17 17/178 (0,096)
Systemic Lupus Erythematosus Signaling 1.41E-16 15/150 (0,1)
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IBD patient variation of RNA gene expression patterns involved in drug 
responsiveness
As we found diff erences in immunological genetic pathways between patients and 
medication-responsiveness varies widely between patients, we wanted to investigate 
whether heterogeneity existed in the patient group treated with a particular anti-
infl ammatory drug. For this purpose we analyzed RNA expression profi les of patients 
treated with azathioprine or mesalazine (Table 6, 7). The two drugs are widely used in 
the treatment of CD and UC respectively.
Table 6 Azathioprine associated genes
Gene Title Gene Symbol
Chromosomal 
Location
ATP citrate lyase ACLY chr17q12-q21
ATPase, class II, type 9A ATP9A chr20q13.2
calreticulin CALR chr19p13.3-p13.2
CD1c molecule CD1C chr1q22-q23
CD27 molecule CD27 chr12p13
GTPase activating protein (SH3 domain) binding protein 2 G3BP2 chr4q21.1
hypoxanthine phosphoribosyltransferase 1 (Lesch-Nyhan syndrome) HPRT1 chrXq26.1
integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) ITGA4 chr2q31.3
Table 5 Top canonical pathways Group A/B/C vs Group and Controls
Name p-value ratio
A vs B,C and 
controls
Role of PKR in Interferon Induction and Antiviral Response 4.05E-3 1/46 (0,022)
Fcg Receptor-mediated Phagocytosis in Macrophages and 
Monocytes 9.21E-3 1/104 (0,01)
Systemic Lupus Erythematosus Signaling 1.24E-2 1/150 (0,007)
Dendritic Cell Maturation 1.44E-2 1/173 (0,006)
Role of NFAT in Regulation of the Immune Response 1.59E-2 1/194 (0,005)
B vs A,C and 
controls
Glucocorticoid Receptor Signaling 1.89E-51 34/280 (0,121)
Estrogen Receptor Signaling 9.51E-28 18/121 (0,149)
Colorectal Cancer Metastasis Signaling 4.28E-14 13/247 (0,053)
HMGB1 Signaling 8.82E-14 10/98 (0,102)
LPS-stimulated MAPK Signaling 3.98E-13 9/80 (0,112)
C vs A,B and 
controls
Glucocorticoid Receptor Signaling 5.41E-18 12/280 (0,043)
Hepatic Fibrosis / Hepatic Stellate Cell Activation 2.37E-7 5/135 (0,037)
Communication between Innate and Adaptive Immune Cells 5.03E-5 3/90 (0,033)
LXR/RXR Activation 5.51E-5 3/86 (0,035)
Colorectal Cancer Metastasis Signaling 9.92E-5 4/247 (0,016)
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Table 6 (continued)
Gene Title Gene Symbol
Chromosomal 
Location
interleukin 21 receptor IL21R chr16p11
lactate dehydrogenase A LDHA chr11p15.4
lactate dehydrogenase B LDHB chr12p12.2-p12.1
lactate dehydrogenase B LDHB chr12p12.2-p12.1
lactate dehydrogenase C LDHC chr11p15.5-p15.3
MYC-associated zinc fi nger protein (purine-binding transcription factor) MAZ chr16p11.2
Phosphoribosyl pyrophosphate amidotransferase PPAT chr4q12
platelet-derived growth factor alpha polypeptide PDGFA chr7p22
tumor necrosis factor (ligand) superfamily, member 10 TNFSF10 chr3q26
Table 7, Mesalazine associated genes
Gene Title Gene Symbol Chromosomal Location
acyl-CoA synthetase short-chain family member 2 ACSS2 chr20q11.22
alkaline phosphatase, intestinal ALPI chr2q37.1
alkaline phosphatase, liver/bone/kidney ALPL chr1p36.12
alkaline phosphatase, placental (Regan isozyme) ALPP /// ALPPL2 chr2q37
alkaline phosphatase, placental-like 2 ALPPL2 chr2q37
arachidonate 12-lipoxygenase ALOX12 chr17p13.1
arachidonate 5-lipoxygenase ALOX5 chr10q11.2
cartilage intermediate layer protein 2 CILP2 chr19p13.11
cartilage intermediate layer protein, nucleotide 
pyrophosphohydrolase
CILP chr15q22
conserved helix-loop-helix ubiquitous kinase CHUK chr10q24-q25
gamma-glutamyltransferase 1 GGT1 chr22q11.23
gamma-glutamyltransferase 2/3 GGT1 /// GGT2 /// GGT3P /// 
GGTLC2 /// GGTLC3
chr22q11.21 /// 
chr22q11.22 /// 
chr22q11.23
gamma-glutamyltransferase 5 GGT5 chr22q11.23
gamma-glutamyltransferase 6 GGT6 chr17p13.2
gamma-glutamyltransferase 7 GGT7 chr20q11.22
gamma-glutamyltransferase light chain 1 GGTLC1 chr20p11.1
inhibitor of kappa light polypeptide gene enhancer in 
B-cells, kinase beta
IKBKB chr8p11.2
nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha
NFKBIA chr14q13
peroxisome proliferator-activated receptor gamma PPARG chr3p25
prostaglandin-endoperoxide synthase 1 
(prostaglandin G/H synthase and cyclooxygenase)
PTGS1 chr9q32-q33.3
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Table 7 (continued)
Gene Title Gene Symbol Chromosomal Location
prostaglandin-endoperoxide synthase 2 
(prostaglandin G/H synthase and cyclooxygenase)
PTGS2 chr1q25.2-q25.3
superoxide dismutase 2, mitochondrial SOD2 chr6q25.3
V-rel reticuloendotheliosis viral oncogene homolog 
A, nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 3, p65 (avian)
RELA chr11q13
First we included patients with azathioprine from our cohort. 21 patients were included 
which were treated with azathioprine. As in fi gure 2, we performed a Pearson’s correla-
tion plot, revealing two subsets (fi gure 3a). This indicated that there is heterogeneity 
between patients treated with azathioprine.
Next, using Ingenuity pathway analysis, we analyzed the expression of genes that 
are known to be responsive to azathioprine (Table 6, fi gure 3a). These known genes 
are depicted in a treescape fi gure next to the correlation plot. Up-regulated genes as 
compared to the mean are shown in red, down-regulated genes are shown in green. 
Although all patients were treated with azathioprine, associated genes showed diff er-
ences in expression, indicating variation in drug responsiveness between groups.
We performed an identical analysis for patients with mesalazine. Figure 3b shows the 
Pearson correlation plot of 16 patients with mesalazine. Known genes involved in the 
working mechanism of mesalazine are depicted in a treescape fi gure on the left and 
in table 7. As with azathioprine, patients with mesalazine form two groups. Again, the 
genetic responsiveness on mesalazine showed signifi cant diff erent response patterns 
between patients (fi gure 3b). These data indicate that while in remission, patients have 
detectable diff erences in therapy responsiveness.
DISCUSSION
To date treatment of IBD is regarded successful if clinical remission is achieved. This 
clinical remission is determined by low scores on the PCDAI and PUCAI for CD and UC 
respectively. Although clinical remission is achieved, macroscopic as well as micro-
scopic infl ammatory markers can still be present and potentially contribute to future 
relapse.20-22 Therefore, clinical remission cannot merely be regarded as the absence of 
disease activity.
Bioinformatics based integration of molecular and clinical information has proven to 
be a crucial for the discovery of new disease pathways relevant to identify formation 
of subclasses of various diseases.18 Using gene expression arrays in IBD, multiple genes 
have been discovered which are associated with activity of disease, phenotype (e.g. CD 
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Figure 3. RNA gene responsiveness to mediation diff ers between IBD patients
A,B, right panel: The correlation visualization displays pair wise correlations between patients with 
azathioprine (A) and mesalazine (B). The colors of the cells relate to Pearson’s correlation coeffi  cient 
values, with deeper colors indicating higher positive (red) and negative (blue) correlations. This Pearson’s 
correlation plot revealed two distinct groups. Left panel: treescape fi gure for SAM signifi cant azathioprine 
(A) and mesalazine (B) targeted genes. The level of gene expression is shown from red (increase) to green 
(decrease) by a factor of at least 4 relative to the geometric means of the control samples. 
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and UC) and adult and pediatric IBD.23-28 However, most of these studies were performed 
using supervised analyzes in order to fi nd associated genes for CD vs UC or disease activ-
ity. This study is, to our knowledge, the fi rst to study paediatric quiescent IBD patients 
including unsupervised analyses that revealed substantial diff erences between patients 
and controls.
Using gene expression arrays of PBL, we have shown that although quiescent pedi-
atric IBD patients display a clinical remission phenotype, the gene expression profi le is 
diverse and distinct from controls in the majority of patients (fi gure 1). Interestingly, CD 
patients as well as UC patients did not form separate clusters within the PCA, suggesting 
overlap of gene expression between these two subsets in this phase of disease.
Using unsupervised analysis on the genes with a three-fold expression form the geo-
metric mean, quiescent pediatric IBD patients could be divided into three groups (fi gure 
2). Diff erences in gene expression between groups revealed multiple signifi cant records. 
Although non-immune genes were overrepresented in these three groups, signifi cant 
diff erences in immunological gene expression and consequent pathways were present 
between controls as well as between groups (table 2-5).
We established that immune pathways are still involved in IBD patients with inactive 
disease. We found diff erences between IBD patients groups and associated pathways 
(table 4, 5). Genes involved in the glucocorticoid receptor signalling pathway were 
abundantly expressed in group B and C. As these groups were most distinct from con-
trols (fi gure 2), this suggests that this pathway plays an important role in the distinction 
between controls and IBD patients.
Due to the limited number of patients and the heterozygous phenotype of IBD, we could 
not establish correlations with clinical characteristics or duration of disease. Therefore, 
we are unable to tell whether these groups will result from diff erences in earlier disease 
activity or may help predict the course of clinical disease including exacerbations. A 
larger prospective study has to be performed in order to answer these questions.
However, we did observe specifi c diff erences in gene responsiveness upon medication 
(fi gure 3). Patients with azathioprine as well as patients with mesalazine, two important 
anti-infl ammatory drugs in the treatment of CD and UC respectively, could be divided 
into two groups based upon the expression of medication-associated genes. As our 
patient groups are limited, we were unable to link these data to clinical responsiveness 
at this stage.
Given the ethical limitations of performing biopsies in paediatric IBD patients with qui-
escent disease. we decided to focus on expression arrays of peripheral blood cells. Nu-
merous studies have shown potential immunological diff erences in peripheral derived 
immune cells from IBD patients in the active stages of the disease.26,  29-33 Continuous 
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monitoring of our IBD patients did not reveal a correlation between group subset and 
clinical phenotype (e.g. relapse) (data not shown). However, as shown in fi gure 3, by 
analyzing the RNA expression levels of the target specifi c genes for azathioprine and 
mesalazine, we were able to detect diff erences in medication responsiveness between 
patients. Whether these diff erences may help predict potential relapses and subse-
quently give rise to specifi c therapeutic interventions remains to be elucidated.
This study indicates that remission in IBD is associated with, gene expression profi les 
that can be separated from controls. We conclude that in spite of clinical remission 
various pathways are still active that include genes involved in infl ammatory responses. 
Finally, subsets of expression profi les exist in the genes involved in azathioprine and 
mesalazine responses.
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Supplementary table 1, Groups - Patient characteristics
Group A Group B Group C
# % # % # %
18 12 15
Male 11 61.1 6 50 2 13.3
Female 7 38.9 6 50 13 86.7
CD 10 55.6 6 50 8 53.3
UC 8 44.4 6 50 7 46.7
Mean 
(SD) SD
Mean 
(SD) SD
Mean 
(SD) SD
PCDAI/PUCAI 2.2 3.6 8.9 3.1 7.5 3.5
ESR (mm/h) 10.9 2.6 10.6 4.2 15.9 2.1
CRP (mmol/l) 2.6 0.6 2.0 0.5 4.0 1.2
Age (y) 16.2 0.3 15.0 0.4 15.7 0.2
Age onset (y) 13.5 0.7 11.7 1.4 12.7 0.5
Supplementary table 2
Please link to: http://snuif.com/tabellen.pdf
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SUMMARY AND DISCUSSION
The human intestine contains about 1014 micro-organisms that critically contribute to 
tissue homeostasis, host metabolism and other benefi cial processes. Despite a continu-
ous microbial exposure within in the intestine, the mucosal immune system is able to 
maintain a state of tolerance to the microbiota. An aberrant immune response of the 
intestinal immune system results in a defective tolerance in the intestine, which leads to 
a breakdown of intestinal homeostasis. This in turn, can lead to chronic intestinal infl am-
mation or infl ammatory bowel disease (IBD).
IBD includes two disease entities: Crohn’s disease (CD) and ulcerative colitis (UC). To 
date, CD and UC are distinguished based upon clinical and histopathological diff er-
ences. CD is characterized by a transmural granulomatous infl ammation, which can 
occur throughout the gastrointestinal tract. In contrast, in UC the colon is aff ected by a 
superfi cial continuous ulcerative infl ammation.
From an immunological perspective, exaggerated responses by mucosal T and B cells 
(the adaptive immune system) have traditionally been regarded as the key contributors 
to the pathogenesis of IBD. However, discoveries of innate defects that are associated 
with IBD have refocused the attention to this arm of the immune system.
Two hypotheses could explain how a defective innate immune system could lead 
to IBD. An aberrant innate immune response can result from a loss of function, which 
leads to sub-optimal recruitment and function of innate cells. Consequently, harm-
less commensal microbiota will increasingly penetrate and translocate the intestinal 
mucosa. In turn, this will lead to chronic attraction and activation of adaptive immune 
cells. On the other hand, gain of function of the innate immune response may lead to 
hyper-responsiveness upon microbial stimulation. In this case, excessive chemokine 
production of innate immune cells will directly cause infl ammation by recruited innate 
and adaptive cells.
Is has become clear that IBD represents a plethora of disease entities that result from 
a large range of defects, including aberrant innate immune responses.
In this thesis we try to answer some of the open questions concerning the pathogenesis 
of IBD and defects in the innate immune system. In chapter 1, we give an overview on 
the recent literature of the role of the innate immune system in the pathogenesis of 
IBD. Specifi cally, we describe how exaggerated as well as a defective innate immune 
responses by various immune cells can lead to IBD.
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As the pathogenesis of IBD is complex, we argue in chapter 2 that results from one study 
cannot be extrapolated to IBD in general. Macrophages of adult CD patients were found 
to produce less of the pro-infl ammatory cytokine IL-8 upon microbial (LPS) stimulation.1 
However, we have shown previously an enhanced production of this chemokine by buc-
cal epithelial cells of pediatric IBD patients2, which illustrates the immune diff erences 
between various immune cells within an individual IBD patient.
Although innate defects play a crucial role in the pathogenesis of IBD, drugs that aff ect 
the adaptive immune system are widely used in the treatment of IBD. Inhibition of T-cell 
function leads to remission in the majority of IBD patients. As the innate immune system 
is strongly implicated in the pathogenesis of IBD, we hypothesized that T-cell suppres-
sors may not only inhibit T-cell-dependent production of pro-infl ammatory mediators, 
but also – indirectly – aff ect innate immune cell function.
In chapter 3 we describe the extent of the T-cell inhibiting drug tacrolimus on the 
function of the innate immune system. The usage of a murine model for CD, TNBS-
induced colitis, enabled us to characterize the various immune cells during the early 
development of colitis. Within 24 hours after the induction of colitis, recruitment of 
innate immune cells, specifi cally neutrophils and monocytes, into the intestinal lamina 
propria was observed. At the same time, numbers of T- and B-cells (adaptive immune 
cells) remained stable. However, by inhibiting T-cell function by the administration of 
tacrolimus, we could diminish colitis to almost control levels. This eff ect of tacrolimus 
was T-cell dependent, as we did not observe any eff ect of this drug in TNBS colitic mice 
without an adaptive immune system.
This study illustrated that at the early phases of colitis development, adaptive immune 
cells play an important role in the recruitment of innate immune cells. As described in 
chapter 1, the innate immune system is crucial in the establishment of intestinal ho-
meostasis. As patients with IBD are being treated with T-cell inhibiting drugs during 
remission, the side eff ect of these drugs could be a diminished recruitment of innate 
immune cells. In turn, this loss of function could lead to bacterial overgrowth and im-
mune activation.
Although we did not study the eff ect of tacrolimus in human IBD, the question remains 
whether the recruitment or function of innate immune cells should be restored during 
the remission phases of IBD.
Resident lamina propria dendritic cells (DC) play an important role in maintenance of 
tolerance to harmless antigens. However, it is unclear whether subtypes of these DC or 
newly recruited infl ammatory antigen presenting cells (APC) drive intestinal infl amma-
tion upon loss of tolerance. In chapter 4 we characterized the role of DC subtypes dur-
ing TNBS-induced colitis. In the establishment of colitis development we observed an 
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infl ux of Ly6c+ monocytes in the lamina propria. Hereafter, an increase in the percentage 
of monocyte-derived Ly6c+CD11b+ DC in the mucosal draining lymph nodes occurred. 
These DC were capable of presenting antigens from the intestine to adaptive immune 
cells in the draining lymph nodes. In accordance to our study described in chapter 3, 
these data indicate that monocytic infi ltration during intestinal infl ammation gives rise 
to a new subtype of monocyte-derived DC that can present antigens and may support T-
cell division. In mice, blocking of migration of CD11b+ cells ameliorates colitis. Whether 
this treatment could be applied in human IBD remains to be investigated.
DC play an important role in the diff erentiation of naive T-cells to T-helper cells (e.g. 
Th1, Th2 and Th17) and regulatory T-cells. Formerly, CD was known as a Th1 disease, 
while UC was characterized by a Th2 immuno-type. Nowadays, this sub-classifi cation is 
not as strict. It is unknown what exactly determines the diff erentiation between these 
phenotypes. The diff erential expression of a subset of T-cell receptors as well as specifi c 
cytokine production by antigen presenting cells may be involved in the proliferation 
and diff erentiation of various subtypes of pro-infl ammatory T-cells.
In chapter 5, we analyzed the cytokine responses of monocyte-derived DC from 
pediatric IBD patients. The production of the pro-infl ammatory cytokines IL-12 and IL-23 
was analyzed and varied widely within the group of patients. We did not fi nd any cor-
relation between disease activity, disease location, medication and the production of 
IL-12 or IL-23. Specifi cally, we found no relation between early and late onset of IBD or 
whether the patients were diagnosed with CD or UC. However, we found a clear dose-
dependent relationship between the production of these two cytokines and the type of 
microbial ligand that was used. In conclusion we hypothesized that the diff erences in 
T-cell subsets originate from the local amount of specifi c microbial ligands and expres-
sion of receptors such as IL-12b2 and IL-23R on the T cells.
Both augmented as well as diminished responsiveness of innate cells have been pro-
posed as contributors to the mucosal infl ammation in IBD. Indeed as indicated in chap-
ter 2, we found that buccal epithelial cells derived from pediatric CD patients, showed 
enhanced responsiveness. However, as we described in chapter 5, DC derived from the 
same group of patients displayed no diff erence in response patterns between controls 
and IBD patients. Moreover, we showed that absolute concentrations of cytokines were 
not directly associated with disease activity.
In chapter 6 we developed an assay using chronic stimulation of peripheral blood-
derived monocytes to represent a more physiological condition of chronic microbial 
exposure within the intestinal mucosa. In this study we showed that monocytes from 
IBD patients and controls that were stimulated with a single challenge of LPS, produced 
comparable amounts of the pro-infl ammatory cytokine TNF-α, confi rming our obser-
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vations in chapter 5. When we challenged these monocytes a second time with high 
dose LPS, these cells became tolerant. This process is known as endotoxin tolerance and 
operates as a self-protective mechanism during phases of excessive infl ammation.
Interestingly, we showed that pediatric IBD patients with inactive disease – both 
CD and UC patients –displayed enhanced endotoxin tolerance compared to controls. 
As these patients showed no clinical sign of active disease, our data suggest that this 
enhanced endotoxin tolerance results from intrinsic aberrancies in the mechanisms that 
regulate innate tolerance. Indeed, IBD has been associated with various mutations in 
genes that play a particular role in innate microbial sensing that could be extrapolated 
to the mechanisms of innate tolerance.3-5
Augmented tolerance could potentially lead to a net defi cit in antimicrobial defense 
upon repetitive exposure, which may result in disturbed homeostatic interactions be-
tween the intestinal microbiota and the mucosal immune system. Subsequently, this 
may result in enhanced local microbial pressure and the activation of adaptive immune 
cells, ultimately leading to chronic infl ammation.
Paneth cells (Pc) play an important role as innate immune cells in the regulation of 
intestinal microbial homeostasis in the small intestine. When stimulated, Pc release 
anti-microbial peptides (e.g. lysozyme and defensins) in order to limit bacterial invasive-
ness in the intestinal crypts. Pc dysfunction leads to impaired production and release of 
these peptides and has been associated with bacterial overgrowth and infl ammatory 
intestinal diseases. TNF-α, a key pro-infl ammatory cytokine in the pathogenesis of IBD, 
is expressed by Pc as well. In hematopoietic cells, TNF-α is induced by microbial stimula-
tion and tightly regulated via anti-infl ammatory molecules, including IL-10. However, 
the role and regulation of this cytokine in Pc is not known.
In chapter 7 we analyzed the regulation of Pc-derived TNF-α expression and compared 
it to the expression of lysozyme. We showed that over-expression of Pc-derived TNF-α 
is associated with IBD and celiac disease, while lysozyme was constitutively expressed. 
Further in vitro research indicated a direct regulation of TNF-α by microbial stimulation 
(via LPS) and IL-10. These factors had no eff ect on lysozyme production, indicating dif-
ferential regulation of TNF-α and lysozyme. We confi rmed these results in two mouse 
models, IL10-defi cient (IL-10-/-) and LPS-sensitive mice. IL-10-/- mice showed enhanced 
expression of Pc-derived TNF-α, confi rming a role for IL-10 in the regulation of Pc-derived 
TNF-α. Dependency of microbial stimulation was confi rmed in germfree IL-10-/- mice 
and LPS insensitive mice. These mice showed no TNF-α (germfree) or less TNF-α (LPS 
insensitive) expression in the Pc, while lysozyme was constitutively expressed in these 
conditions. Enhanced production of TNF-α by Pc may contribute to the establishment of 
chronic intestinal infl ammation.
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In chapter 8 we analyzed RNA gene expression profi les of peripheral blood cells from 
pediatric IBD patients with inactive disease. First we showed that pediatric IBD patients 
with inactive disease displayed altered gene expression profi les compared to controls. 
Moreover, we did not detect a sub-classifi cation for CD and UC patients, indicating 
genomic overlap between these two phenotypes. Further analysis revealed three 
subclasses based upon RNA expression profi les. Diff erent immunological genes were 
transcribed in each of these groups, indicating that IBD-associated genes were still ac-
tive and signifi cantly diff erent from controls, despite the fact that the majority of IBD 
patients were in clinical remission. This diff erential gene expression could refl ect base-
line immunological diff erences between IBD patients and controls, as well as between 
individual IBD patients.
Most CD patients are treated with azathioprine, whereas the majority of UC patients 
is treated with mesalazine. In the majority of patient, these two types of drugs are ef-
fi cient in establishing and maintaining remission. However, drug responsiveness varies 
between patients. We investigated the basis for variations in drug responsiveness by 
analyzing the expression levels of the target-specifi c genes for azathioprine and mesala-
zine. Based on specifi c gene expression profi les of the pediatric IBD patients that were 
treated with azathioprine and/or mesalazine we were able to identify two specifi c clus-
ters. Whether these diff erences may help predict potential relapses and subsequently 
give rise to specifi c therapeutic interventions remains to be elucidated.
CONCLUSIVE REMARKS & FUTURE STUDIES
The discoveries of defects in IBD that are typically associated with innate immune cells 
have refocused research to this arm of the immune response. In spite of the abundant 
evidence that T- and B-cells contribute to the IBD pathogenesis, it is conceivable that 
future IBD therapies will specifi cally aim at targeting specifi c bacteria or molecules 
involved in microbial sensing. In this respect, it is of particular interest that pediatric or 
early onset IBD seems to be specifi cally associated with defects of the innate immune 
system.6 Finally, many of the proposed mechanisms may only apply for certain subsets 
of patients or occur simultaneously in the same patient. The real challenge therefore, 
will be to develop novel (molecular) tools that will enable us to subcategorize patients 
into more specifi c IBD subsetss of IBD other than just CD or UC. Tools for the identifi ca-
tion of the specifi c disease subtype in a certain patient and at a specifi c phase of disease 
will eventually generate a range of novel patient-tailored interventions.
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S AMENVATTING EN DISCUSSIE
In de darm bevinden zich circa 1014 micro-organismen die een belangrijke bijdrage leve-
ren aan de homeostase, het metabolisme en andere gunstige processen. Ondanks dat de 
darm permeabel is voor verschillende voedingstoff en en bacteriële producten, leidt dit 
normaal gesproken niet tot chronische ontsteking. De complexe immuunregulatie die 
voorkomt dat het mucosale immuunsysteem overreageert op de in de darm aanwezige 
commensale bacteriën staat bekend als mucosale tolerantie. Een disfunctionerende 
immuunrespons kan resulteren in een verbreking van de tolerantie. Uiteindelijk kan dit 
leiden tot een chronische ontsteking in de darm en tot een infl ammatoire darmziekte 
(IBD).
Binnen IBD wordt onderscheid gemaakt tussen twee fenotypes: de ziekte van Crohn 
(CD) en colitis ulcerosa (UC). Dit onderscheid wordt gemaakt op basis van klinische en 
histopathologische gronden. CD wordt gekarakteriseerd door een transmurale granulo-
mateuze ontsteking, welke door de gehele darm kan voorkomen. Daarentegen is bij UC 
alleen het colon aangedaan door een oppervlakkige continue ulceratieve ontsteking.
Vanuit een immunologisch perspectief werden overreacties van mucosale T- en B-cellen 
(het verworven immuunsysteem) gezien als de belangrijkste oorzaken in de patho-
genese van IBD. Echter, door de ontdekking van defecten in het aangeboren (innate) 
immuunsysteem die geassocieerd zijn met IBD, is de aandacht van het verworven im-
muunsysteem verlegd naar dit aangeboren immuunsysteem.
Op twee manieren kan een disfunctionerend aangeboren immuunsysteem leiden tot 
IBD. Een verzwakte functie van het aangeboren immuunsysteem heeft een suboptimale 
aantrekking en functie van aangeboren immuuncellen tot gevolg. Dit kan leiden tot een 
overgroei en penetratie van bacteriën in de darm, hetgeen resulteert in de aantrekking 
en activatie van cellen van het verworven immuunsysteem en zo tot een chronische 
ontsteking in de darm.
Ook een versterkte functie van het aangeboren immuunsysteem kan uitmonden in een 
disfunctionerende immuunrespons op microbiële stimulatie. In dit geval zorgt een over-
productie van chemokines door de cellen van het aangeboren immuunsysteem direct 
voor ontsteking door versterkte aantrekking en activatie van aangeboren en verworven 
immuuncellen.
Het is duidelijk geworden dat IBD uit een veelvoud van ziektetypen bestaat die elk 
het gevolg zijn van een meervoud van defecten, inclusief die van het aangeboren im-
muunsysteem.
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In dit proefschrift proberen wij een antwoord te vinden op enkele van de nog openstaan-
de vragen met betrekking tot de pathogenese van IBD en defecten van het aangeboren 
immuun systeem. In hoofdstuk 1 geven wij een overzicht van de literatuur waarin de 
rol wordt beschreven van het aangeboren immuunsysteem in de pathogenese van IBD. 
Wij beschrijven hoe een versterkte als ook een verzwakte functie van de verschillende 
aangeboren immuuncellen kan leiden tot IBD.
Aangezien de pathogenese van IBD complex is, bediscussiëren wij in hoofdstuk 2 dat 
gevonden studieresultaten niet zonder meer mogen worden geëxtrapoleerd naar IBD in 
zijn algemeenheid. In dit specifi eke geval produceerden macrofagen van volwassenen 
met CD minder interleukine (IL)-8 na stimulatie.1 Echter, onze groep liet zien dat epitheli-
ale cellen van het wangslijmvlies van kinderen met CD dit chemokine juist in verhoogde 
mate produceerden.2 Dit voorbeeld illustreert de verschillen in immuunrespons tussen 
verscheidene immuuncellen en tussen patiënten met IBD.
Ondanks dat defecten van het aangeboren immuunsysteem een belangrijke rol spelen 
in de pathogenese van IBD worden medicijnen die aangrijpen op het verworven im-
muunsysteem in veelvoud gebruikt bij de behandeling van dit ziektebeeld. Inhibitie van 
de functie van T-cellen leidt tot remissie in een groot deel van de patiënten met IBD. 
Aangezien het aangeboren immuunsysteem een cruciale rol speelt in de pathogenese 
van IBD, was onze hypothese dat suppressie van T-cellen niet alleen resulteert in een 
inhibitie van de productie van pro-infl ammatoire mediatoren door deze cellen, maar 
dat ook – indirect – aangegrepen wordt op de functie van aangeboren immuuncellen.
In hoofdstuk 3 beschrijven we de reikwijdte van het T-cel inhiberende medicijn tacro-
limus op de functie van het aangeboren immuunsysteem. Door gebruik te maken van 
een muismodel voor CD, TNBS colitis, konden wij de verschillende immuuncellen die 
betrokken zijn bij het ontstaan van colitis karakteriseren. Binnen 24 uur na de inductie 
vond er rekrutering plaats van aangeboren immuuncellen (neutrofi elen en monocyten) 
in de lamina propria van de darm, hetgeen resulteerde in colitis. Tegelijkertijd bleven 
T- en B-cellen (het verworven immuunsysteem) in aantallen gelijk. Inhibitie van de T-
celfunctie door het geven van tacrolimus zorgde voor een zeer sterke reductie van de 
infl ux van monocyten en neutrofi elen en leidde hiermee tot een reductie van colitis. 
Dit eff ect van tacrolimus was T-cel afhankelijk, aangezien we geen eff ect zagen van dit 
medicijn op TNBS colitis in muizen zonder verworven immuunsysteem.
Deze studie illustreerde dat in de vroege fase van de ontwikkeling van colitis ook 
verworven immuuncellen een belangrijke rol spelen in de aantrekking van aangeboren 
immuuncellen. Zoals beschreven in hoofdstuk 1 is het aangeboren immuunsysteem cru-
ciaal voor het in stand houden van de intestinale homeostase. Aangezien IBD patiënten 
behandeld worden met T-cel inhiberende medicijnen, ook ten tijde van remissie, zou 
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een bijwerking van deze medicatie kunnen zijn dat de aantrekking van aangeboren im-
muuncellen wordt verminderd. Deze verzwakte functie van het aangeboren immuun-
systeem zou kunnen leiden tot bacteriële overgroei, immuunactivatie en exacerbatie 
van colitis. Hoewel we het eff ect van tacrolimus niet hebben bestudeerd in humane 
IBD, is de vraag of ten tijde van remissie de rekrutering of activatie van aangeboren 
immuuncellen in zekere mate zouden moeten worden gewaarborgd.
Dendritische cellen (DC) zijn aangeboren antigeen presenterende cellen en van groot 
belang in de totstandkoming van tolerantie tegen de commensale microben. Ondui-
delijk is of ten tijde van het verbreken van tolerantie intestinale infl ammatie gedreven 
wordt door een subtype van de in de darm aanwezige DC of door nieuw gerekruteerde 
antigeen presenterende cellen. Om een antwoord op deze vraag te vinden, bestudeer-
den wij in hoofdstuk 4 de rol van DC tijdens TNBS colitis.
Bij het ontstaan van colitis zagen wij een infl ux van Ly6c+ CD11b+ monocyten in de 
lamina propria. Hierna volgde een toename van DC in de drainerende lymfklieren, welke 
gevormd waren uit deze Ly6c+ CD11b+ monocyten. Deze DC waren in staat antigenen 
vanuit de darm op te pikken en aan te bieden aan T-cellen in de lymfklier. Deze studie, 
volgend op de data van hoofdstuk 3, laat zien dat ten tijde van infl ammatie monocyten 
de darm infi ltreren en uitgroeien tot nieuwe DC in de lymfklier. Vanuit eerdere studies 
in muizen is bekend dat blokkade van monocyten en macrofagen kan leiden tot een 
vermindering van colitis. Of deze behandeling ook zou kunnen worden toegepast bij 
IBD moet echter nog worden onderzocht.
DC spelen een belangrijke rol in de diff erentiatie van naïeve T-cellen naar T-helper cellen 
(zoals Th1, Th2 en Th17) en regulatoire T-cellen. Vroeger werd CD beschouwd als een 
ziekte van Th1 cellen, terwijl UC gekarakteriseerd werd door een Th2 fenotype. Tegen-
woordig is deze classifi catie minder stringent. Het is onduidelijk wat de diff erentiatie 
van deze twee fenotypes bepaalt. Zowel de diff erentiële expressie van een subset van T-
celreceptoren, als ook productie van specifi eke cytokines door antigeen presenterende 
cellen kunnen zorgen voor de proliferatie en diff erentiatie van verschillende subtypes 
van pro-infl ammatoire T-cellen.
Om de rol van cytokines die door DC worden geproduceerd te onderzoeken, analy-
seerden wij in hoofdstuk 5 de cytokine-respons van DC van pediatrische IBD patiënten. 
De productie van interleukine (IL)-12 en IL-23 werd gerelateerd aan het type IBD, de 
ziekteduur en de behandeling.
De productie van deze twee cytokines kende een grote spreiding binnen onze patiën-
ten. Er was geen relatie tussen ziekteactiviteit, lokalisatie van de ontsteking of medicatie 
en de productie van IL-12 en IL-23. Bovendien vonden we voor zowel CD als UC geen 
relatie tussen korte of langdurige ziekteactiviteit. We vonden echter wel een duidelijke 
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dosis-respons relatie tussen de productie van deze twee cytokines en het type gebruikte 
microbiële ligand.
Dit onderzoek toonde aan dat noch CD, noch UC is geassocieerd met een predispositie 
in de productie van een van deze cytokines. Daarbij was het vermogen van de DC om 
IL-12 of IL-23 te produceren niet gecorreleerd met de ziekteactiviteit. Bovendien konden 
we geen verband aantonen tussen IL-12 en IL-23, hetgeen suggereert dat deze twee 
cytokines diff erentieel gereguleerd worden.
Concluderend is onze hypothese dat de verschillende T-cel subsets voortkomen 
vanuit de lokale hoeveelheid van specifi eke microbiele liganden en de expressie van 
receptoren op de T-cel, zoals IL-12β2 en IL-23R.
Zoals in beschreven hoofdstuk 1 en 2 kunnen zowel een verzwakte als ook een versterkte 
functie van het aangeboren immuunsysteem bijdragen aan de mucosale infl ammatie 
in IBD. In hoofdstuk 2 beschreven wij dat epitheelcellen van het wangslijmvlies van 
kinderen met CD een versterkte immuunreactie lieten zien. Echter, zoals in hoofdstuk 
5 beschreven, lieten DC afkomstig van dezelfde groep patiënten geen verschil zien in 
responspatronen tussen controles en IBD patiënten. De vraag is nu of een enkele mi-
crobiële stimulatie wel te vergelijken is met de fysiologische conditie van chronische 
microbiële blootstelling in de intestinale mucosa.
In hoofdstuk 6 hebben wij een assay ontwikkeld waarin chronische stimulatie van 
uit bloed afkomstige monocyten kan worden geanalyseerd. Voor iedere patiënt afzon-
derlijk berekenden wij de verschillen in reactie op deze chronische stimulatie. In dit 
onderzoek lieten wij zien dat monocyten van pediatrische IBD patiënten in vergelijking 
met controles een vergelijkbare hoeveelheid van het pro-infl ammatoire cytokine TNF-α 
produceerden op een enkele bacteriële stimulus (LPS), waarmee we onze bevinding in 
hoofdstuk 5 bevestigden.
Monocyten die wij voor een tweede maal stimuleerden met hoge dosis LPS werden 
tolerant voor deze stimulus. Dit proces, dat bekend staat als endotoxine tolerantie, is 
bekend sinds de vijftiger jaren van de vorige eeuw en werkt als een zelfbeschermings-
mechanisme tijdens fases van excessieve infl ammatie, zoals sepsis.
Interessant genoeg zagen wij dat pediatrische IBD patiënten met een inactieve 
ziekteactiviteit een versterkte tolerantie lieten zien in vergelijking met controles. Aan-
gezien deze patiënten geen ziekteactiviteit hadden, suggereert dit dat deze versterkte 
tolerantie het gevolg is van intrinsieke defecten in het mechanisme dat zorg draagt voor 
aangeboren tolerantie.3-5
Een versterkte tolerantie zou kunnen leiden tot een verminderde verdediging tegen 
de continue blootstelling aan micro-organismen in de darm. De daaropvolgende bac-
teriële overgroei en penetratie leidt vervolgens tot een verstoorde homeostase en tot 
activatie van T- en B-cellen en chronische infl ammatie.
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Panethcellen (Pc) spelen een belangrijke rol als aangeboren immuuncellen in de 
regulatie van intestinale microbiële homeostase in de darm. Door de secretie van anti-
microbiële peptiden door Pc, zoals lysozym en defensines, wordt de intestinale crypt en 
de daar aanwezige stamcel beschermd tegen bacteriële invasie. Disfunctie van de Pc 
leidt tot verminderde productie en secretie van deze peptiden en is geassocieerd met 
bacteriële overgroei en intestinale infl ammatoire ziekten.
Ook produceren Pc TNF-α, een belangrijk pro-infl ammatoir cytokine betrokken in de 
pathogenese van IBD. In hematopoietische cellen wordt TNF-α geproduceerd na micro-
biële stimulatie en wordt productie gereguleerd via anti-infl ammatoire cytokines, zoals 
IL-10. De rol en de regulatie van TNF-α in de Pc is echter niet bekend.
In hoofdstuk 7 analyseerden wij de regulatie van Pc-TNF-α. In dit hoofdstuk lieten 
we zien dat overexpressie van TNF-α in de Pc geassocieerd is met IBD en coeliakie. In 
vitro analyse liet een directe regulatie zien van TNF-α door microbiële stimulatie (LPS) en 
IL-10. Deze twee factoren hadden geen invloed op de productie van lysozym, hetgeen 
suggereert dat TNF-α en lysozym diff erentieel gereguleerd worden.
Wij bevestigden deze resultaten in twee muismodellen. TNF-α in de PC kwam tot 
verhoogde expressie in IL-10 defi ciënte (IL-10-/-) muizen, hetgeen de regulerende rol 
van IL-10 bevestigd. Door gebruik te maken van steriele (bacterie-vrije) IL-10-/- muizen 
konden wij de initiërende rol van de microbiota op de productie van TNF-α door Pc 
bevestigen. Steriele muizen produceerden geen TNF-α in de Pc, terwijl lysozym onder 
dezelfde condities tot normale expressie kwam.
Een overproductie van TNF-α door Pc zou kunnen bijdragen tot het ontstaan van 
ontsteking in de darm, zoals wordt gezien bij onze pediatrische IBD patiënten.
In hoofdstuk 8 analyseerden wij de RNA-expressieprofi elen van pediatrische IBD pa-
tiënten met een inactieve ziekteactiviteit. Als eerste lieten wij zien dat deze patiënten 
een ander genetisch profi el hadden in vergelijking met controle patiënten. Daarbij was 
er geen subclassifi catie zichtbaar tussen CD en UC, hetgeen duidt op een genetische 
overlap tussen deze twee fenotypes. Verdere analyse, gebaseerd op RNA-expressiepro-
fi elen, liet drie subgroepen zien. Ondanks dat de patiënten in remissie waren, kwamen 
in elke groep verschillende immunologische genen tot expressie. Dit betekent dat 
IBD-geassocieerde genen nog steeds actief zijn ten tijde van remissie en de expressie 
verschilt van controle patiënten en tussen patiënten met IBD. Basale immunologische 
verschillen tussen IBD patiënten en controle patiënten, als ook tussen IBD patiënten 
onderling, kunnen op deze manier verder worden onderzocht.
Behandeling van CD en UC vindt in een groot aantal gevallen plaats met respectieve-
lijk azathioprine en mesalazine. Bij de meeste patiënten zijn deze twee medicijnen ef-
fectief voor de inductie en het in stand houden van remissie. De mate van responsiviteit 
verschilt echter tussen patiënten.
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Wij onderzochten de basis voor variatie in de responsiviteit door analyse van de 
RNA-expressieprofi elen van de specifi eke aangrijpingsgenen voor azathioprine en me-
salazine. Op basis van deze specifi eke genexpressieprofi elen van onze pediatrische IBD 
patiënten, konden wij twee specifi eke clusters onderscheiden. Het is de vraag of deze 
verschillen in de toekomst mogelijk potentiële exacerbaties kunnen voorspellen en zo 
kunnen leiden tot meer specifi eke therapeutische interventies.
CONCLUSIE EN TOEKOMSTIGE STUDIES
De ontdekking van defecten in het aangeboren immuunsysteem die geassocieerd zijn 
met IBD heeft de aandacht van het verworven immuunsysteem verlegd naar het aange-
boren immuunsysteem.
Ondanks het overvloedige bewijs dat T- en B-cellen een belangrijke rol spelen in de 
pathogenese van IBD, is het voorstelbaar dat toekomstige therapieën voor IBD vooral 
zullen aangrijpen op specifi eke bacteriën of op de moleculen die de microben herken-
nen. In dit licht is het van belang om te weten dat pediatrische IBD specifi ek geassocieerd 
is met defecten van het aangeboren immuun systeem.6
Tenslotte kunnen de hierboven beschreven mechanismen mogelijk alleen van 
toepassing zijn op specifi eke groepen van patiënten of kunnen meerdere van deze 
mechanismen tegelijkertijd binnen één patiënt aanwezig zijn.
De uitdaging ligt er daarom in om nieuwe moleculaire technieken te ontwikkelen 
die het mogelijk maken om patiënten beter te classifi ceren dan alleen in CD of UC. 
De technieken die onderscheid maken in fenotypes van verschillende patiënten op 
verschillende fases van de ziekte zullen uiteindelijk leiden tot nieuwe methodes om IBD 
beter te behandelen.
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Hoewel er op de omslag van dit proefschrift maar een auteur staat vermeld, zouden 
dit er velen moeten zijn. Zonder de hulp van de hieronder genoemde personen zou 
het zonder twijfel onmogelijk geweest zijn om dit promotieonderzoek te beginnen, laat 
staan af te krijgen.
Allereerst wil ik graag alle patiënten bedanken die hebben geparticipeerd in de onder-
zoeken van dit proefschrift. Iedereen veel dank voor jullie medewerking. Hopelijk helpt 
dit onderzoek mede tot de ontwikkeling van betere behandelingen voor IBD.
Zonder leiding gebeurt er echter helemaal niets.
Hooggeleerde professor E.E.S. Nieuwenhuis, beste Edward, ha E., het is fantastisch om 
onder jouw te kunnen promoveren! Heel veel dank voor vier ontzettend leuke, leerzame 
en inspirerende jaren. Jouw visie, gekoppeld aan het gegeven dat je vaker gelijk hebt, 
dan je op grond van toeval mag verwachten, zorgde voor een unieke tijd. “Just do it” 
is een wijze les (net als die andere), die ik zeker in mijn oren knoop. Ik ben blij dat ik je 
goed heb leren kennen en hoop dan ook dat we in de toekomst nog veel samen kunnen 
werken (met af en toe een bier met Hankje). Gr, P.
Beste professor A.J. van der Heijden, graag wil ik u bedanken voor uw rol als tweede 
promotor van dit proefschrift. Dank voor uw ondersteuning en uw beoordeling van dit 
proefschrift.
Ook mijn twee copromotoren zijn zeer belangrijk geweest in de totstandkoming van 
dit proefschrift.
Beste Janneke, zonder je supervisie als copromotor was ik zeker in zeven (acht) sloten 
tegelijk gelopen. Jouw grondigheid heeft ervoor gezorgd dat er altijd een goed funda-
ment was voor alle experimenten. Je kennis van de immunologie is verbazend en je zorg 
voor ieder op het lab heel bijzonder. Heel veel dank voor al je ondersteuning!
Beste Hankje, veel dank voor alle hulp met alle patiënten. Jouw klinische blik was heel 
belangrijk voor de studies. Daarbij zorgde de door jou opgezette IBD-poli voor de best 
toegankelijke patiëntenpopulatie die ik me kon wensen. En zeker niet onbelangrijk, met 
jou in de familie kan er nog een bier worden gedronken! Ik ben benieuwd wat er nog 
gaat volgen.
Graag wil ik ook de leescommissie bedanken voor hun samenwerking en de beoorde-
ling van dit proefschrift.
Beste Professor van de Spek, beste Peter. Veel dank voor je enthousiasme en vertrou-
wen in ons gezamenlijk project. Het is zeer inspirerend om met iemand met zoveel 
energie samen te kunnen werken. Dit smaakt naar nog veel meer.
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Beste Professor Lambrecht, beste Bart. Toen ik in het begin van mijn onderzoek op 
je kamer kwam en jij begon te vertellen over DC’s begreep ik er niets van. Door jouw 
expertise nu een beetje. Veel dank voor je al hulp.
Beste Professor Tibboel, beste professor, nadat ik onder u als AGNIO begonnen ben 
in het Sophia, is het voor mij extra leuk dat u in de commissie zit. Veel dank voor de 
geboden kansen en het vertrouwen.
Minstens even belangrijk was alle hulp die ik van de analisten op het lab en personen 
daarbuiten kreeg. Zonder de ondersteuning van de deze mensen waren de experimen-
ten in dit proefschrift nooit gelukt. Lieve Dicky, in het kort: Je bent onmisbaar! Heel veel 
dank voor alle hulp met alle, alle projecten en niet in de laatste plaats voor je enge-
lengeduld. Lieve Ytje, Lilian, Rolien, Kit-Yeng en Lisette, dank voor al jullie expertise en 
hulp gedurende de afgelopen vier jaar met muizenexperimenten, FACS, PCR, celkweek 
en stimulatie, koffi  e drinken, DNA/RNA extractie, immunohistochemie en wie weet wat 
meer. Beste Ingrid, als echte lab-moeder zorg jij ervoor dat het lab niet aan zichzelf ten 
onder gaat. Dank voor al je hulp.
Beste Henk Dronk en dierverzorgers van het EDC, veel dank voor jullie zorg voor de 
muizen tijdens alle experimenten.
Lieve Sigrid, ik ken niemand die zoveel excel-snelkoppelingen kent als jij. Zonder jou 
bestond Infl ammatics niet. Denk dat we een goed team vorm(d)en. Heel veel dank voor 
al je analyses. Tijd voor Baileys!
Lieve Merel, veel dank voor je ondersteuning en gezelligheid gedurende de laatste 
jaren. Het was een grote steun om een persoon als jij betrokken bij dit onderzoek te 
hebben zodat alles ook organisatorisch klopt.
Beste kamergenoten en collega’s, veel dank voor een gezellige tijd met veel humor en 
af en toe ook wat wetenschap. Lieve Sabine, buurvrouw, veel dank voor al je hulp door 
dit hele project heen. Je kritische houding was erg fi jn als ik weer eens dingen wilde 
schrijven die kant nog wal raakten. Heel leuk om nu in Utrecht weer de draad te kunnen 
oppakken.
Beste Colin, hoewel met staart, je was als man de redding tegen het overschot aan 
vrouwen. Ik vond het erg leuk om met ons tweeën de colitis letterlijk tot een goed einde 
te brengen. Dank voor al je hulp en goede intensieve samenwerking. Beste Sylvia, veel 
dank voor al je humor, tegenwicht en gezelligheid. Tot snel weer in Utrecht. Beste Fleur 
en Jeroen, als collega AIO’s was het altijd fi jn om ervaringen uit te wisselen. Veel dank 
voor jullie interesse, samenwerking en veel succes met het afronden van jullie promo-
tieonderzoeken. Beste Jolanda, veel dank voor al je hulp. Ik vond het erg gezellig om 
met je samen te werken. Denk dat we heel goed samen koffi  e kunnen drinken. Beste 
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Gerard, dank voor de goede en vruchtbare samenwerking. Lieve Charlotte, veel dank 
voor je hulp. Jouw oog voor detail was en is zeer belangrijk. Veel succes met je eigen 
promotietraject. Erg leuk om te weten dat een gedeelte van het werk wordt doorgezet.
Beste collega’s Apeldoorn, dank voor jullie begrip als ik er weer eens niet was om te 
schrijven aan “ dat boekje”.
Ook buiten de medische wereld heb ik veel hulp gekregen.
Lieve ouders, heel veel dank voor alle steun (natuurlijk ook voor alle keren oppas-
sen zodat er weer wat regels konden worden geschreven) en interesse. Niet alleen nu 
tijdens dit promotieonderzoek, maar ook in de tijden hiervoor en nu erna. Ik vind het 
heel bijzonder en prijs me gelukkig met twee zulke ouders.
Lieve Antoon en Nicolaas, super dat jullie naast me staan als paranimf. Antoon, veel 
dank voor de fantastische omslag. Succes met je eigen promotieonderzoek. Ik zal zeker je 
dankwoord en stellingen lezen. Nicolaas, ontzettend veel dank voor alle keren oppassen 
en je andere hulp. Lieve Geerteke, veel dank voor je interesse, je hulp en je gezelligheid.
En natuurlijk:
Allerliefste Elseline,
Wat is het leven heerlijk met jou! Wat is nu leuker dan met jou en Siebren & Feiko (en 
H&K) te zijn. Zo’n promotieonderzoekje stelt dan ook eigenlijk niets voor. Liefste, heel 
veel dank voor je steun, hulp, begrip en vooral voor al je geduld (lees: een volmaakte 
echtgenote). En voor je kaptafeltje als bureau.
Vind je grenzeloos lief. Vind je echt de liefste, daarom heet je ook allerliefste!
P.S. Voor degenen die alleen het dankwoord en de stellingen lezen: probeer ook eens de Nederlandse 
samenvatting!
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